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Abstract 
 
CDCA7, or cell division cycle associated protein A7, was described in 2001 by Prescott and 
colleagues as a target of Myc-dependent transcriptional regulation (Prescott et al., 2001). We have 
identified CDCA7 as associating with the transcription factor Myc and is the target of 
phosphorylation by the prosurvival serine/threonine kinase Akt. Phosphorylation by Akt at 
threonine 163 disrupts CDCA7 association with Myc, promotes binding to 14-3-3 and 
sequestration in the cytoplasm. Coexpression of CDCA7 and Myc in fibroblasts potentiates Myc-
dependent apoptosis upon serum withdrawal. In contrast, knockdown of CDCA7 by shRNA 
abrogated Myc-dependent apoptosis. Myc induced transformation of fibroblasts was reduced in 
the presence of CDCA7 and significantly inhibited by the expression of the non-Myc binding 
mutant ∆(156-187) CDCA7. We have shown that CDCA7 enhances the activation of an E-box in 
a Myc-binding dependent manner. CDCA7 increases Myc occupancy of the proapoptotic BAX 
promoter, elevates BAX and Cyclin B1 mRNA levels while reducing p15INK4B mRNA levels. This 
data points to a novel mechanism which implicates Akt phosphorylation of CDCA7 as 
participating in the dual signal model of Myc of function and thus affecting Myc-dependent growth 
and transformation.  
In this study, we have also shown that expression of CDCA7 reduces proliferation rates and shifts 
cell cycle distribution towards G2/M phase and that phosphorylation of CDCA7 at T163 occurs 
strictly in G2/M. CDCA7 phosphorylated at threonine 163 colocalizes with the centrosomal 
protein marker γ-Tubulin and activated Akt (phospho-serine 473) in mitotic cells. Finally, we have 
shown that CDCA7 co-associates with monomers of itself which is dependent on amino acids 187-
234, adding to the possible mechanisms by which CDCA7 function may be regulated.  
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Chapter 1: Introduction and Research Objectives 
Introduction 
The long road to oncogenesis is often hastened by deregulated oncogenes or tumor suppressors 
which otherwise carefully work to balance the scale between cellular proliferation and apoptosis. 
This delicate balance is best exemplified by the oncogene Myc, which has been the subject of 
intense cancer research since its discovery thirty years ago. In its infancy, Myc was described as a 
transcription factor involved in the expression of genes involved in metabolism, adhesion, cell 
cycle progression, development and malignant transformation; qualities well suited for a powerful 
oncogene (Oster et al., 2002, Askew et al., 1991). Myc has been estimated to be active in nearly 
70% of human cancers, with mechanism of activation including amplifications, translocations, 
deregulated translation or protein turnover (Nilsson and Cleveland, 2003). Most notably, Myc has 
been deemed essential in the progression of Burkitt’s lymphoma due to a translocation event which 
puts Myc under the control of the immunoglobulin heavy locus regulatory element (Spencer and 
Groudine, 1991). By the early ‘90s it was becoming obvious that Myc would be a central player 
in our understanding of cancer, as 1485 papers were published on Myc within ten years of its 
discovery. However, in 1992 the Myc paradigm would be turned on its head when Evan and 
colleagues published their seminal paper describing Myc’s critical role in apoptosis upon serum 
withdrawal from constitutive Myc expressing Rat1 fibroblasts. The group showed that as Myc 
levels increased, Rat1 cells became proportionally prone to apoptosis upon serum withdrawal. 
Thus, a paradox was born: how could two diametrically opposed functions be controlled by the 
same protein? When and how would the scales be tipped towards proliferation or apoptosis in this 
precarious balance (Evan et al., 1992)?  In 1997, Kauffmann-Zeh and colleagues provided a clue 
when they showed that Myc induced apoptosis could be suppressed by Phosphoinositide-3 kinase 
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(PI-3K) and Akt activation (Kauffmann-Zeh et al., 1997). These findings were supported by the 
fact that simultaneously dysregulated Myc and Akt (via overactive receptor tyrosine kinases) can 
provide the necessary environment to promote oncogenesis (Stambolic et al., 1999). A hypothesis 
began to emerge which suggested that a built-in safety mechanism was in place to prevent aberrant 
Myc related proliferation by inducing apoptosis in the absence of survival signals (Evan et al., 
1992). This lead to the ‘dual-signal’ model of Myc activity which postulates that Myc sensitizes 
cells to apoptosis but prevents their ultimate demise via signaling by survival factors such as 
platelet-derived growth factor (PDGF) or insulin (Harrington et al., 1994). Since the birth of the 
dual-signal model, it has become an accepted principle of cancer biology that apoptotic pathways 
mediated by oncogenes must be sidestepped during tumorigenesis, and only then can a transformed 
cell outgrow its environment (Schmitt et al., 2002). Therefore, the coupling of apoptotic and 
proliferative activities by a single oncogene presents a unique opportunity for therapeutic 
intervention to promote the death of tumor cells. 
How Akt prevents Myc induced apoptosis remains a long-standing mystery. Akt may influence 
pro-apoptotic effectors such as Bad or increase Myc protein levels by indirectly stabilizing it via 
inhibition of T58 phosphorylation by glycogen synthase kinase 3 (GSK3), a Myc residue which is 
known to promote its degradation when phosphorylated (Welcker et al., 2004). Adding to the 
mystery, to date there have been no studies implicating Akt in directly acting upon the Myc/Max 
transcriptional heterodimer. The recent discovery of a Myc and E2F responsive gene known as 
cdca7, the subject of this thesis, may shed some light on the interplay between Myc and Akt and 
how this interaction affects apoptosis. 
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MYC    
The transcription factor Myc is a part of the family of basic-helix-loop-helix-leucine zipper 
(bHLH-LZ) transcription factors and is known to both repress and activate target genes by DNA 
recognition of E box motifs (CACGTG) (Spencer and Groudine, 1991). Myc is encoded by an 
immediate early response gene which is transactivated by the stimulation of any number of 
upstream membrane-ligand receptor complexes (Kelly et al., 1983). Expression levels of Myc are 
faithfully controlled by a host of mechanisms that converge on the transcriptional regulatory motifs 
found within its promoter region (Levens, 2010). Peak levels of Myc expression occur at the G0-
G1 transition of quiescent cells, but remains constant through out the phases of the cell cycle in 
proliferating cells (Thompson et al., 1985; Rabbitts et al., 1985). Therefore, Myc activity in cycling 
cells is mediated by mechanisms that are not confined to mRNA or protein levels.  
Myc has been associated with the regulation of 15% of all genes, many of which influence 
functions such as the control of apoptosis, cell growth and cell division (Gearhart et al., 2007). 
Transactivation via Myc is promoted by heterodimerization with its partner Max (also a bHLH-
LZ protein) and recruitment of coactivators along with histone acetyltransferases and 
ATPase/helicase among others (Nilsson and Cleveland, 2003). Repression is thought to occur 
when Mad heterodimerizes with Max and competes for identical E box motifs, displacing Myc 
and recruiting transcriptional corepressors and histone deacetylases (Rottman and Luscher, 2006). 
Myc activity is also controlled by keeping protein levels transient, as it is indirectly targeted by 
Akt for proteolytic degradation (Hann and Eisenman, 1984).  There is no surprise that healthy cells 
exert such fine control over Myc activity, as it is often suggested that Myc is at the heart of the cell 
cycle progression engine. Many of the positive regulators of the cell cycle are encoded by gene 
targets of Myc, including cyclins, Cdks and the transcription factor E2F. Unsolicited expression 
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of any number of these regulators could prove to be detrimental. In addition to being directly 
responsible for the expression of these regulators, Myc can also exert its influence indirectly by 
hyperactivating cyclin/Cdk complexes by expressing Cdk activating kinase (CAK) and Cdc25 
phosphatase. Completion of the cell cycle at mitosis is also influenced by Myc as it is known to 
bind to origins of replication and expresses genes that are vital to replication initiation (Bretones 
et al., 2015). 
Perhaps the most intriguing discovery from Myc’s sphere of influence is the role it plays in the 
production of induced pluripotent stem cells (iPSC). In 2006, Yamanaka and his colleagues 
identified Sox2, Oct4, KLF4 and Myc as the four critical factors (dubbed Yamanaka factors) 
required in reverting fibroblasts back into a pluripotent stem-cell-like state. A feat which would 
earn the group a Noble Prize. By retroviral integration of the corresponding coding sequences into 
the genome of terminally differentiated fibroblasts, the Yamanaka lab recapitulated the four 
hallmarks of pluripotent stem cells: spontaneous differentiation in cell culture, embryoid body 
formation, teratoma formation and contribution to embryo development (Takahashi et al., 2006). 
Although a very exciting prospect for regenerative medicine, the contribution of Myc to iPSC 
generation should come as no surprise as its expression is required for vertebrate development 
(Stanton et al., 1990).   
Molecular Profile of Myc 
 
The transcription factor Myc is encoded by the MYC gene which produces a polypeptide that is 
57-65 kDa in size. Transcription can initiate at one of three start codons: a canonical AUG, an 
upstream CUG or a downstream AUG (Blackwood et al., 1994). Expression from the non-
canonical start codons results in versions of Myc for which there is little information regarding 
form or function. Myc transcribed from the canonical AUG has been thoroughly investigated and 
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is the subject of the review here. This isoform of Myc contains an N-terminal transcriptional 
regulatory domain located up stream of a nuclear localization signal (NLS). This domain has been 
shown to form complexes with a variety of proteins including GCN5, TBP and TRRAP, all of 
which promote transcriptional activity primarily via epigenetic modifications such as histone 
acetylation (Dang, 2012).  The C-terminus contains a basic DNA-binding domain followed by a 
helix-loop-helix-leucine zipper (bHLH-LZ) motif that is critical for Myc’s ability to 
heterodimerize with Max (Spencer and Groudine, 1991). Monomers of the Myc-Max heterodimer 
make contact with target genes via their DNA binding domains at E-box motifs (5’-CACGTG3’) 
(Park et al., 2004). Both the basic DNA-binding domain and bHLH-LZ region have been shown 
to be required for transformation (Dang et al., 1989; Stone et al., 1987). Although Myc seems 
committed to binding Max in order to interact with DNA, Max has the ability to heterodimerize 
with other members of the Mxd family via their bHLH-LZ domains. For example, Mad can 
compete with Myc for Max binding, thereby forming Mad-Max heterodimers which bind DNA at 
E-boxes and repress activation by recruitment of histone deacetylases (Ayer et al., 1993).  
Myc and Cell Proliferation 
 
In normal tissue, Myc is abundantly expressed during development and it is ubiquitous in adult 
tissues which have high proliferative potential, such as the gut and epidermis (Schmid et al., 1989). 
On the contrary, Myc is not detected in cells which have left the cell cycle (Davis et al., 1993). 
Current estimates suggest that activation of Myc occurs in approximately 70% of cancers, 
indicating this lesion is a perquisite for tumorigenesis. Myc activation can occur through all 
conceivable means including translocations, increased translation, amplification and improved 
protein stability (Sears et al., 1999). Elevated expression of Myc has been detected in various types 
of cancer including myeloid leukaemia, melanoma, glioblastomas, osteosarcomas, small lung 
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carcinomas, colon, cervical and breast (Khan and Pelengaris, 2007). Gain of function mutations 
within Myc have been reported, however most examples of Myc activation are a result of 
unsolicited errors within the signalling pathways that control Myc transcription (Bhatia et al., 
1993). Aware of the ubiquitous nature of Myc expression in tumors, early Myc researchers focused 
on the correlation between elevated levels of Myc and the risk of transformation and neoplasia. 
Investigations using transgenic mice models for Myc-induced tumorigenesis have shown that brief 
inactivation of Myc causes regression of tumors and induction of apoptosis. This suggests that 
sustained expression of Myc is required to preserve the transformed state (Jain et al., 2002). 
Finally, Myc expression has been shown to be essential in angiogenesis during proper development 
and during tumorigenesis (Baudino et al., 2002). The sum of this data, although only a cross 
section, helped shed light on why Myc activation was so prevalent in cancer. 
Initial research revealed that constitutive expression of Myc was adequate to induce and maintain 
cell proliferation that was independent of mitogen stimulation (Cavalieri and Goldfarb, 1987). 
Enforced expression was also shown to be sufficient to inhibit terminal differentiation and enforce 
unchecked proliferation (Maruyama et al., 1987). Activated Myc has been shown to shorten the 
length of G1 phase, while studies knocking out or repressing Myc expression suggest that the 
oncogene is critical for entry into S phase (Heikkila et al, 1987). Since these studies, Myc has been 
shown to regulate the cell cycle by both positive and negative means. For example, Myc can 
directly repress the expression of cyclin-dependent kinases (Cdk) inhibitors, or indirectly 
inactivate them by sequestration and degradation. Myc can promote cell cycle progression by 
positive means through transcription of cyclins D1, D2, E1 and A2, in addition to Cdk4, CDC25A, 
E2F1 and E2F2 (Meyer and Penn, 2008). 
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Myc and Apoptosis 
 
The legacy of Myc as an oncogene contributing to malignancy was fully cemented in the first ten 
years of its study. It was in 1987 when Wyllie and his colleagues produced a study which would 
implicate Myc in apoptosis, an unexpected result of a transcription factor associated with 
proliferation and cell cycle progression. When the group expressed ras and Myc in rat fibroblasts 
they observed an increased rate of cell death compared to cells expressing ras alone (Wyllie et al., 
1987). In 1991, Neiman and his associates would corroborate Myc’s role in apoptosis when they 
showed that premalignant B lymphocytes expressing ectopic viral Myc were more susceptible to 
cell death via radiation compared to cells not expressing Myc. However, this Myc-mediated 
sensitivity to apoptosis was not observed in cells after malignant transformation, suggesting the 
existence of a mechanism by which cancerous cells side step Myc’s role in apoptosis (Neiman et 
al., 1991). Three months later, the Askew lab broadened our mechanistic understanding of Myc’s 
contribution to apoptosis with their studies of interleukin 3 (IL-3) dependent myeloid cells. Upon 
IL-3 withdrawal, these cells undergo a downregulation of Myc, arrest in G1 phase and eventually 
apoptosis. When these cells constitutively expressed Myc, removal of IL-3 resulted in a rapid 
initiation of programmed cells death independent of cell cycle status (Askew et al., 1991). These 
early investigations revealed some surprising insights into the dual nature of Myc, most notably 
the cell’s binary response to elevated Myc levels based on environmental cues: a) Cells cultured 
in the presence of growth factors will rapidly proliferate when Myc is over expressed or b) these 
same cells will undergo apoptosis upon depletion of growth factors. This binary nature of the most 
infamous pro-proliferative transcription factor was codified by Evan in 1992. The research group 
recapitulated Myc’s affect on apoptosis in Rat1 cells constitutively expressing Myc, resulting in a 
propensity to undergo apoptosis when cultured in low serum conditions. The study also revealed 
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that the region of Myc required for its apoptotic function directly overlaps with regions that are 
vital for cotransformation, autoregulation and inhibition of differentiation (Evan et al., 1992). 
Early results from these seminal investigations into Myc’s apoptotic function gave rise to the 
notion that oncogenes may possess dormant tumor suppressor traits as a safety mechanism against 
unwarranted cell proliferation (Lowe et al., 2004). Our understanding of cell death enhanced by 
Myc expression has grown to include apoptosis via chemotherapy, radiation, DNA damage, 
hypoxia, glucose starvation, heat shock and chemotoxins (Soucie et al., 2001). Since elevated 
levels of Myc are a normal occurrence in most human cancers, a vast amount of interest as been 
devoted to the development of treatments which hope to tip the scales of oncogenic Myc activity 
from cell proliferation to cell death (Schmitz et al., 2014).    
Our understanding of the dual nature of Myc has grown to encompass the interplay between the 
oncoprotein and various effectors of the apoptotic machinery. Key to that understanding is 
unravelling the events that occur at the arbiter of cell death, the mitochondrion. As with Myc, 
mitochondria have assumed a monolithic legacy, often being dubbed the ‘powerhouse of the cell’, 
tasked with simply producing ATP. However, with time we have come to realize that mitochondria 
also lead a dual existence, primed to secrete an array of proapoptotic factors that are critical in 
committing the cell to programmed death (Harris and Thompson, 2000). The apoptotic program 
which converges on the mitochondria can be categorized into three phases: induction, decision and 
execution. Apoptosis is initiated via a variety of inducers such as extrinsic mechanisms 
independent of death receptors including survival factor withdrawal, chemotherapeutics and 
metabolic inhibitors. Intrinsic inducers include activation of death receptors such as CD95 and 
tumor necrosis factor receptor. The subsequent signal cascades lead to the decision phase of 
apoptosis which is in large part managed by the Bcl-2 family of pro and anti-apoptotic regulators 
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(Bcl-2, Bad, Bax, Bak among others). Members of this family use protein-protein interactions and 
subcellular localization to decide whether the apoptotic program will proceed or not. Briefly, 
inhibition of proapoptotic Bak and Bax is lifted when their heterodimeric partner Bcl-2 is 
sequestered by Bad, allowing Bak and Bax to localize at the mitochondrial outer membrane where 
they form pores that allow the secretion of cytochrome c. The execution phase is defined by the 
activation of caspases upon compromise of the mitochondrial membrane, formation of the 
apoptosome and eventual indiscriminate proteolysis of cellular proteins (Soucie et al., 2001). 
Within this signalling axis, the mitochondrial secretion of the proapoptotic factor cytochrome c 
has become a node of great interest because stimulation of which is stimulated by the activation of 
Myc (Juin et al., 1999).   
Many efforts have been made to find a means by which Myc can influence apoptosis via the Bcl-
2 family of pro and anti-apoptotic proteins. For example, human germinal center B-cell 
lymphomas, supraglottic squamous cell carcinoma and acute lymphoblastic leukemia contain 
elevated Myc levels and are often accompanied by overexpression of Bcl-2, a potent oncoprotein 
and mediator of pro-survival (Martin-Subero et al., 2005; Ozdek et al., 2004; Berger et al., 1996). 
This genetic environment has been replicated in bcl-2/Myc double transgenic mice which die 
within a few days of birth due to immature lymphoblastic leukemia (Strasser et al., 1990). On the 
contrary, transgenic mice expressing only Myc have a better prognosis and develop lethal 
lymphomas within five months of birth (Harris et al., 1988). Finally, researchers have reported 
significant levels of apoptosis in transgenic mice expressing Myc in a Bcl-2 -/- background. These 
studies support the notion that overexpression of Bcl-2 is required for cells to overcome the 
apoptotic affects of oncogenic Myc (Letai et al., 2004). The affects seen here also extends to other 
members of the Bcl-2 pathway, including BAG-1, which is a chaperone of Bcl-2 with prosurvival 
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functions. Loss of a single BAG-1 allele results in decreased tumor formation in animal models, 
hypothesized to be the result of increased levels of apoptosis (Takayama et al., 1995). Zhang and 
colleagues have shown that Myc-dependent induction of BAG-1 is crucial in diminishing the 
dormant apoptotic effects of oncogenic Myc (Zhang et al., 2011). 
Despite the informative results linking Myc to known members of the apoptotic machinery, what 
remains unclear is how cells differentiate between Myc that is stimulated by normal mitogenic 
cues and oncogenic Myc. In normal cells, Myc is required for cell proliferation and cell cycle 
progression. Therefore, Myc’s dormant tumor suppressor activity can only be prompted when Myc 
signalling has become oncogenic in normal cells. In the context of cancer prevention, these 
dormant tumor suppressor activities must be initiated to prevent damaged cells from propagating. 
Only when these tumor suppressor pathways are repressed can cancer begin to develop. Therefore, 
cells must initiate apoptotic programs as a response to oncogenic, rather then normal growth cues 
(Murphy et al., 2008). What complicates the situation is the means by which Myc contributes to 
oncogenesis, either by overexpression or dysregulation. In the case of overexpression, tumors with 
elevated Myc levels are often identified as more advanced and aggressive. This has been 
hypothesised to be a result of forced Myc occupancy of low affinity promoters resulting in the 
transactivation of novel genes. However, dysregulation of Myc not concurrent with overexpression 
is often adequate to side-step a cell’s requirement for mitogens during normal proliferation while 
simultaneously abrogating tumor suppressor responses. This scenario could be a result of ill-
sustained transactivation of the standard subset of Myc target genes (Fernandez et al., 2003). 
Although there is some uncertainty regarding Myc expression and dysregulation, it is known that 
apoptosis induced by Myc depends on dimerization with Max, Myc’s N-terminal transcriptional 
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activation domain and subsequent DNA binding. This suggests that Myc induces apoptosis as a 
product of variations in target gene expression (Shiio et al., 2006).  
In 2008, Murphy and colleagues set out to decouple the effects of dysregulated and overexpressed 
Myc using genetic models that allows for the controlled expression of a constitutively active form 
of Myc. The group’s results indicate that low level expression of dysregulated Myc is sufficient to 
drive proliferation and is tumorigenic. However, overexpression of dysregulated Myc beyond a 
certain threshold was required to activate apoptosis and the ARF/p53 tumor surveillance pathway. 
This would indicate that maintaining low levels of oncogene expression is critical in avoiding the 
activation of tumor supressing pathways during the onset of tumorigenesis (Murphy et al., 2008). 
These results threaten the concept of Myc as a monolithic driver of cell proliferation and point to 
an intrinsic safety mechanism that aims to balance proliferation with antiproliferative programs. It 
is this balance which is now commonly thought to prevent spontaneous tumorigenesis (Lowe et 
al., 2004).  
The binary nature of Myc activity and the complexities involved in a cell’s decision to live or die 
would suggest that Myc is most likely working in concert with other oncogenes/tumor suppressors 
to tip the scales. One of these candidate proteins is the tumor suppressor p53, which is recruited 
during one of many stress response pathways to induce apoptosis (Levine and Oren, 2009). One 
such response occurs during genotoxic threats that increase the likelihood of transformation if 
apoptosis is not initiated. Although the p53 response to DNA damage has been of great interest to 
researchers, the elucidation of p53’s contributions to apoptosis effector mechanisms has garnered 
considerable attention. p53 influences apoptosis by regulating the transcription of members of the 
BCL family of proapoptotic proteins, specifically BAX, BAK and PUMA. BCL family members 
can also be functionally regulated by p53 via protein-protein interactions which has the affect of 
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altering their prosurvival to proapoptotic ratio (Haupt et al., 1997). The result is targeting of 
proapoptotic BCL family members to the mitochondrial outer membrane, leading to a breakdown 
of mitochondrial membrane permeability and release of caspase activating molecules. The 
proteolytic activity of caspase molecules has earned them the title of ‘executioners’ of the apoptotic 
program as they indiscriminately cleave proteins. The signalling pathways leading to p53 
stimulated apoptosis can also be initiated by the activation of oncogenes such as Myc. For example, 
growth signalling by oncogenic Myc results in p53 activation by enhancing the function of the 
tumor suppressor ARF, which abrogates the p53 inhibitor MDM2. The compounding effects of 
the loss of p53 and oncogenic Myc signalling are of substantial interest since the apoptotic 
functions of Myc heavily depend on the activation of p53 (Zindy et al., 1998). This is obvious in 
the case of Eµ-Myc transgenic mice which serve as a model for B cell lymphoma which develop 
tumors resulting in the death of 90% of mice within 5 months of birth (Harris et al., 1988). Young 
mice show evidence of high apoptosis rates in their B-lymphocyte compartment, possibly as a 
means of preventing tumorigenesis. This would suggest that within the 5 month incubation period, 
a second genetic lesion must be acquired to inhibit Myc induced apoptosis. It turns out that in Eµ-
Myc mice, 28% of tumors harbor a p53 loss of function and 24% sustain loss of ARF function, 
while others expressed MDM2 at elevated levels (Eischen et al., 1999). Although only one of many 
examples, the Eµ-Myc model convincingly shows that the apoptotic qualities of Myc are 
intimately linked to the ARF/p53 pathway. Research into Myc activated apoptosis via p53 has 
ironically sparked interest in apoptotic programs that do not rely on p53. For example, in 
transformed cells with activated Myc and loss of p53 function, there maybe an opportunity to rouse 
Myc’s dormant apoptotic qualities outside of the ARF/p53 signalling axis. This has been observed 
in myeloid cells from p53 null mice with deregulated Myc expression. These cells undergo 
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apoptosis upon IL-6 treatment independent of p53 function (Amanullah et al., 2000). This is of 
considerably interest since many human cancers are a product of the loss of p53 function, and yet 
they may still poses potent apoptotic potential via dysregulated Myc. Therefore, the potential for 
therapeutic intervention is an exciting prospect.  
The obvious question that arises from the data presented here is whether cell cycle progression or 
apoptosis is the primary result of Myc activation. Considering that apoptosis is overcome and 
tumors flourish only when changes to the apoptotic machinery arise, there is evidence to suggest 
our classical understanding of Myc is severely flawed. As presented here, some of these changes 
include upregulation of the oncogenes BCL-2, BAG-1 and MDM2 or loss of p53 and ARF 
function. Recent advances in the targeted inhibition of BCL-2 and MDM2, coupled with our 
understanding of apoptosis and Myc thresholds in tumors, may allow us to intelligently restore the 
apoptotic potential of affected cells (Vassilev, 2004; Tse et al., 2008; Murphy et all 2008). By the 
same token, inhibition of Myc by small molecule inhibitors should give pause for concern 
considering the potent apoptotic potential of overexpressed Myc (Mertz et al., 2011). This is of 
considerable note when inhibition of Myc may be coupled with treatments intended to induce cell 
death, such as radiation and chemotherapy.  
Notwithstanding the volume of data produced by investigations into Myc induced apoptosis, its 
exact mechanistic details have not been fully elucidated. As a consolation, three possible scenarios 
describing Myc’s involvement in cell death have been proposed; they are the conflict, dual signal 
and modified dual signal models of Myc function. The conflict model is a default definition of 
Myc function that does not extend beyond a role in cell proliferation and hypothesizes that 
apoptosis is indirect downstream response to oncogenic Myc. The dual signal model suggests that 
Myc is simultaneously executing distinct proliferation and apoptosis programs, with the later being 
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suppressed by survival signals (Harrington et al., 1994). This is well illustrated in the case of 
apoptosis upon serum withdrawal from Rat1 cells overexpressing Myc (Evan et al., 1992).  
However, there is evidence to suggest that apoptosis and proliferation via Myc can not be 
completely separated as independent and distinct programs. For example, both apoptosis and 
proliferation rely on DNA binding upon Max association with Myc (Amati et al., 1993). Therefore, 
we are forced to consider the hypothesis that Myc concurrently primes both proliferation and 
apoptosis. This notion is at the heart of the modified dual signal model which proposes that priming 
of apoptosis and proliferation are a result of a single pathway, while triggering of apoptosis is 
achieved via a second pathway. Priming of apoptosis would be achieved by transcriptional 
regulation of target genes, and triggering would be a product of death signaling converging on the 
primed target gene products (Prendergast, 1999).  In both iterations of the dual signal model of 
Myc, apoptosis is kept at bay by the availability of survival factors such as those found in serum 
or cytokines such as insulin-like growth factor (IGF-1). There has been limited research devoted 
to categorizing the subset of survival factors, cytokines and their respective signalling pathways 
which are directly implicated in preventing Myc driven apoptosis. One such study by Rohn and 
colleagues points to activation of Akt kinase by IGF-1 stimulation as a potent suppressor of Myc 
induced apoptosis via the CD95 death receptor pathway (Rohn et al., 1998). Although Akt’s 
influence on apoptosis is well documented, the exact mechanisms by which it prevents Myc 
specific apoptosis is unknown. There is some indication that Akt may directly target pro-apoptotic 
BAD for phosphorylation, resulting in binding of BAD to 14-3-3 and sequestering of BAD away 
from Bcl-2 (Du and Montminy, 1998). Other studies have shown that activation of the PI3k/Akt 
pathway by insulin stimulation up regulates Myc-mediated transcription by phosphorylation and 
degradation of Mad1 (Zhu et al., 2008).  
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In the thirty years since Myc’s discovery, an enormous volume of data has been collected which 
describes the many functions of this prolific oncogene. A deep understanding of this pleiotropic 
transcription factor will arm researchers and clinicians of the future with powerful, novel 
opportunities to treat afflictions associated with Myc; not the least of which is cancer. Although 
there have been advances in targeted small molecule inhibitors, targeting of oncogenes with latent 
apoptotic abilities deserves extra attention. Exploiting these apoptotic abilities cannot come at the 
expense of silencing the very oncogene which sensitizes the cell to apoptosis. Myc has certainly 
earned its reputation as a powerful oncogene, but in many cases additional lesions are required for 
tumorigenesis to take hold. Next, we turn our attention to Akt kinase, a powerful mediator of 
survival, growth and apoptosis, and is often dysregulated in Myc-tumors (Zhu et al., 2008). 
Phosphoinositide-3 Kinase and Akt 
 
Akt kinase is a serine/threonine kinase that mediates crucial cellular functions in response to 
extracellular stimuli and growth factors. These functions include cell cycle progression, gene 
expression, differentiation and cell growth by transducing signals from the plasma membrane to 
the nucleus. Akt belongs to a family of serine/threonine kinases that include Akt1, Akt2 and Akt 
3, all of which are highly homologous in mammalian cells (Jones et al., 1991; Cheng et al., 1992; 
Brodbeck et al., 1999). Akt activation occurs downstream of phosphoinositide-3 kinase (PI3K), 
which is tasked with phosphorylating the membrane lipid phosphatidylinositol-4,5-P2 (PIP2) at the 
3’ position of the inositol ring to generate PI(3,4,5)P3 (PIP3). Generation of PIP3 allows for the 
serine/threonine protein kinase Akt to be targeted to the membrane via its Pleckstrin Homology 
domain, where it can be subsequently activated by phosphorylation via phosphoinositide 
dependent kinase 1 (PDK1) (Stephens et al., 1998). Activated Akt is free to act upon over 50 
known substrates, many of which influence processes such as proliferation, angiogenesis, motility, 
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metabolism and survival. It is known that the dysregulation of any of these cellular processes, via 
oncogenes such as Akt, can be a primary contributing factor in the pathogenesis of various 
diseases, including type-2 diabetes and cancer (Fresno Vara et al., 2004). For example, upon 
survival-factor stimulation, Akt promotes the survival of cells by inhibiting the function of the pro-
apoptotic protein BAD. The up regulation of Akt could thus prove to be a critical step in 
oncogenesis (Datta et al., 1997). Akt can also be dysregulated by the tumor suppressor PTEN 
which dephosphorylates PIP3 at the 3’ position, converting the PI3K product back to PIP2 
(Maehama and Dixon, 1998). In cases where this gene is inactivated, high levels of PIP3 cause the 
aberrant activation of Akt as seen in many advanced human cancers (Lin et al., 1998) and is 
correlated with neoplasia (Haas-Kogan et al., 1998). 
Molecular Profile of Akt 
 
Akt kinases 1, 2 and 3 are members of the AGC kinase family which include protein kinase A, G 
and C. All three members of the Akt family share a conserved structure which includes an N-
terminal pleckstrin homology (PH) domain, a kinase domain and a C-terminal hydrophobic motif 
which serves as a regulatory domain. The 100 amino acid PH domain found in Akt allows the 
kinase to be targeted to the cell membrane by interacting with membrane bound 
phosphatidylinositol (3, 4, 5) triphosphate (PIP3). This membrane targeting ability is shared by 
other signaling molecules that interact with 3-phosphoinositides (Lietzke et al., 2000), including 
the domain’s namesake found in plecsktrin, which is a target of phosphorylation by PKC in 
platelets (Tyers et al., 1988).  
The centrally located kinase domain is conserved between members of the AGC kinase family and 
contains a threonine residue at position 308 which can partially activate Akt upon phosphorylation 
(Alessi et al., 1996). Full activation of Akt requires phosphorylation of T308 and serine 473 which 
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is located down stream of the kinase domain and within the C-terminal regulatory domain. This 
region of approximately 40 amino acids contains the F-X-X-F/Y-S/T-Y/F hydrophobic motif, 
which is a hallmark of the AGC kinase family. Phosphorylation of the serine or threonine residue 
within this motif is required for full activation and is a requites shared by all AGC kinases. Deletion 
of the hydrophobic motif eliminates enzymatic activity of all Akt isoforms (Peterson and 
Schreiber, 1999; Andjelkovic et al., 1997).  
Phosphorylation of T308 and S473 occurs as a response to stimulation by growth factors and is 
dependent on a PI3K and PH domain mediated membrane translocation event. Translocation of 
Akt to the membrane follows activation of PI3K by G protein-coupled receptors and tyrosine 
kinase receptors (Wymann et al., 2003). Akt is targeted to the membrane by high affinity binding 
to PIP3 via its PH domain resulting in a conformational change that precipitates phosphorylation 
of T308 by the phosphoinositide-dependent kinase-1 (PDK1) (Andjelkovic et al., 1997; Stephens 
et al., 1998). Phosphorylation of T308 depends on co-localization of Akt and PDK1 at membrane 
(Anderson et al., 1998). 
The source of S473 phosphorylation has not been unanimously agreed upon, however it is known 
that its phosphorylation is dependent on both PI3K and T308. Because of this relationship, PDK1 
has been suggested to be the kinase responsible for S473 phosphorylation (Balendran et al., 1999). 
Disagreement stems from studies using PDK1 -/- ES cells which showed that S473 
phosphorylation in these cells was similar to wild-type cells, while T308 phosphorylation was 
absent (Williams et al., 2000). This result was countered by researchers that showed an increase 
in S473 phosphorylation when they transiently overexpressed PDK1 in HEK293 cells (Hill et al., 
2001). Phosphorylation of S473 has also been linked to the mammalian target of rapamycin 
complex 2 (mTORC2) following growth factor stimulation (Sarbassov et al., 2005). DNA damage 
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has also been shown to result in S473 phosphorylation via DNA-dependent protein kinase (DNA-
PK) (Bozulic et al., 2008)). Finally, there have been studies suggesting that Akt has an innate 
ability to autophosphorylate S473 (Toker and Newton, 2000).  
Complete activation of Akt by phosphorylation of T308 and S473 allows Akt to transmit signals 
from the plasma membrane to various effectors of the PI3K pathway. Substrates of Akt are subject 
to inhibitory and stimulatory phosphorylation with implications on cell survival and apoptosis. 
Akt and Cell Survival 
 
Cell survival is commonly discussed in terms of a cell’s ability to balance apoptosis with 
proliferation. This balancing act is at the heart of the Akt signaling pathway, allowing cells to 
tolerate apoptotic stimuli by engaging cell survival signals via activated Akt (Yao and Cooper, 
1995). As a downstream effector of the PI3K pathway, Akt can influence cell survival either by 
direct means, via transcriptional control or by metabolic regulation (Song et al., 2005).  
Direct control of cell survival is carried out by Akt primarily via the blocking of apoptosis. This is 
accomplished by Akt mediated phosphorylation of some of the critical regulators and effectors of 
the apoptotic process. For example, upon receptor tyrosine kinase activation, Akt is stimulated to 
directly phosphorylate the pro-apoptotic protein BAD at S136 (del Peso et al., 1997). 
Phosphorylation of Bad disrupts BAD/Bcl-2 heterodimers by promoting the binding of BAD to 
the 14-3-3 adapter protein. As a result, Bcl-2 is free to inhibit apoptosis by heterodimerizing with 
pro-apoptotic Bax or Bak which are otherwise responsible for the formation of pores in the outer 
mitochondrial membrane. Therefore, phosphorylation of BAD at S136 by Akt can inhibit the 
release of cytochrome c which when allowed, is a critical step in committing a cell towards 
apoptosis (Datta et al., 1997).  
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Akt can phosphorylate direct effectors of the apoptotic cascade as a means of survival. This is 
evident in the case of pro-caspase-9, which is considered an initiator caspase and is activated upon 
the release of cytochrome c from the mitochondria. Akt has been shown to phosphorylate pro-
caspase-9 at S196, thereby minimizing its activity by unknown means (Cardone et al., 1998). 
Although inhibition of pro-caspase-9 by Akt has been seen in human cells, this residue is not 
conserved in monkey, mouse or rat despite evidence suggesting that Akt has a means to abrogate 
apoptosis down stream of cytochrome c release. This would suggest the existence of other Akt 
targets yet to be identified (Allan and Clarke, 2009).  
Influence on cell survival can also come in the form of transcriptional regulation by way of Akt 
phosphorylation of transcription factors. For example, Akt is known to phosphorylate all four 
isoforms of the FoxO family of transcription factors whose target genes code for pro-apoptotic 
proteins such as CD95 ligand (CD95L) and TNF-related apoptosis inducing ligand (TRAIL). Both 
of these ligands activate the apoptosis program upon binding with their death receptors (CD95 is 
discussed above in regard to Myc). Phosphorylation of FoxO transcription factors results in 14-3-
3 binding and sequestration in the cytoplasm, thereby inhibiting the effects of apoptosis mediated 
by these target genes (Burgering and Medema, 2003). A reoccurring theme within Akt function is 
the association of 14-3-3 proteins with targets of Akt phosphorylation. The genesis of this 
correlation has not yet been determined, however it can be attributed in part to overlap between 
14-3-3 binding and Akt phosphorylation consensus sites. 14-3-3 is known to bind at 
phosphorylated serine or threonine residues within what is known as the mode I motif: R-S-X-
pS/pT-X-P (where X is any amino acid, A is arginine, R is serine, T is threonine, P is proline and 
p indicates a phosphorylated residue). This conforms well with the minimal Akt motif which 
requires A-X-X-S/T to be present in order to produce the phosphorylated serine/threonine residue 
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required for 14-3-3 binding (Smith et al., 2011). Both motifs share an arginine at -3 relative to their 
respective pS/T residues. As we shall see in the data presented at the heart of this thesis, Akt and 
14-3-3 binding will once again implicate themselves in mediating apoptosis.  
Another example of Akt’s ability to influence transcription is by its impact on the transcription 
factor p53, albeit indirect in this case. p53 is a critical player in DNA damage-induced apoptosis 
and is partly regulated by the E3 ubiquitin ligase Mdm2, which targets the transcription factor for 
degradation. Activation of the PI3K pathway results in phosphorylation of Mdm2 at ser166 and 
186 by Akt, resulting in its targeting to the nucleus and upregulation of its ubiquitin ligase activity. 
As a consequence, p53 levels are reduced, which lead to an inhibition of p53 mediated transcription 
and apoptosis (Mayo and Donner, 2001; Gottileb et al., 2002; Ogawara et al., 2002). 
The Akt Signalling Pathway and Cancer 
 
The examples above illustrate the extent to which Akt plays a role in critical cell processes that 
promote cell survival. With Akt’s great power comes great responsibility, which when unchecked, 
often contributes to tumorigenesis. Perturbations in Akt and PI3K signalling pathway activity can 
result in uncontrolled cell growth by a variety of means. These include amplification and 
overexpression of Akt, hyperactivation of Akt or unsolicited activity of members of the PI3K 
pathway upstream or downstream of Akt (Altomare and Testa, 2005). Because of the ubiquitous 
nature of these lesions in human cancers, members of the PI3K pathway are an attractive target of 
therapeutic intervention. However, as with the case of Myc outlined above, careful consideration 
must be placed in avoiding off target effects that can render these efforts useless (Thorpe et al., 
2015).  
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The very first examples of lesions to the Akt gene came in 1992 when Cheng and colleagues 
identified an amplification and overexpression of Akt2 in a relatively small sample of ovarian 
carcinoma cell lines and tumors (Cheng et al.,1992). Overexpression of Akt2 mRNA has also been 
reported in ovarian carcinomas in the absence of Akt2 amplification, although the means of this 
mRNA overexpression has not been identified. The amplification and/or overexpression of Akt2 
has been hypothesized to contribute to tumorigenesis by sensitizing cells to negligible levels of 
growth factors (Bellacosa et al., 1996). 
Amplification and overexpression of Akt2 has also been observed in pancreatic carcinomas and 
pancreatic cell lines such as PANC1. In this cell line, 50-fold amplification of Akt2 was reported, 
most likely contributing to the abnormally high levels of Akt2 protein and mRNA in these cells. 
In an attempt to investigate the possibility of therapeutic intervention of abnormal Akt2, the Cheng 
lab transfected PANC1 cells with antisense Akt2 RNA. Expression of Akt2 in cells transfected 
with Akt2 antisense RNA was significantly lower when compared to control transfections. The 
tumorigenicity of these cells in nude mice was significantly reduced as was their invasiveness in 
rat tracheal xenotransplant assays (Cheng et al., 1996). These results were some of the first to 
highlight the possibility of intervening in tumor progression driven by dysregulated Akt2.  
Amplification of the Akt1 isoform has not been observed as commonly as Akt2. The first example 
occurred in early investigations by Stephen Staal of gastric carcinomas which revealed only one 
instance of Akt1 amplification in 225 samples (Staal, 1987). Likewise, only a single example of 
amplification and overexpression of Akt1 was reported in a screen of 103 malignant gliosarcomas 
(Knobbe and Reifenberger, 2003). Despite few examples of Akt1 amplification, there have been 
reports of elevated Akt1 protein levels in some types of tumors. In the case of 
22 
 
immunohistochemical analysis of 280 breast tumors, elevated Akt1 staining was observed in 24% 
of tumors while only 4% were markedly positive for Akt2 (Stål et al., 2003).  
The effects of overexpressed Akt on transformation has also been demonstrated in cell culture. 
Retroviral overexpression of Akt2 in NIH3T3 cells results in transformation as per growth in soft 
agar and tumor formation in nude mice (Cheng et al., 1997). Overexpression of wild-type Akt1 
failed to recapitulate this result in NIH3T3 cells. Only when constitutively active Akt1 was 
expressed in these cells were they able to grow in soft agar and produce tumors in nude mice (Sun 
et al., 2001).  
Dysregulation of Akt has also been reported as a product of hyperactivation and has been 
documented in various human cancers including thyroid, gastric, pancreatic, ovarian and breast 
carcinomas (Bellacoas et al., 2005). This is of considerable importance since Akt activation has 
been correlated with poor prognosis and advanced disease in some cancers. This was pointed out 
in a study by Sun and colleagues who showed that of tumors with activated Akt1, 80% of them 
were high grade and stage III/IV carcinomas (Sun et al., 2001). Despite these alarming statistics, 
phosphorylated and active Akt expression has been reported in precancerous conditions such as 
bronchopulmonary dysplasia. This would suggest that activation of Akt in some cases may precede 
tumorigenesis and therefore might be a target for early intervention as a means of preventing tumor 
formation (Tsao et al., 2003).  
The nature of Akt as a transducer of PI3K signalling means that any number of perturbations 
upstream of Akt could result in dysregulated signalling. This could manifest as a loss of PTEN 
activity resulting in an abundance of PIP3 and therefore hyperactivation of Akt. This was found to 
be the case in 35% of endometrial cancers studied by Terakawa and colleagues (Terakawa et al., 
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2003).  PI3K can also generate a surplus of PIP3 via overstimulation of receptor tyrosine kinases 
(Di Cristofano and Pandolfi, 2000; Altomare and Testa, 2005). Similarly, overexpression of wild-
type growth factor receptors may sensitize cells to otherwise negligible levels of growth factors 
(Hanahan and Weinberg, 2000). Examples of mutant receptors have also been reported to result in 
constitutive activation of PI3K signalling (Sordella et al., 2004). In one of the most intriguing 
examples of a mutant protein activating Akt occurs in over 95% of chronic myeloid leukemia 
(CML) cases. A reciprocal translocation between chromosome 9 and 22 generates a fusion gene 
known as BCR-ABL that codes for a constitutively active tyrosine kinase. This mutant tyrosine 
kinase activates PI3K via binding of its p85 regulatory subunit, which consequently results in the 
aberrant activation of Akt (Skorski et al., 1997). This same p85 regulatory subunit of PI3K has 
been found to be mutated in T-cell lymphoma cell lines, colorectal and ovarian tumors, colon 
cancer cell lines, colon carcinoma, ovarian cancer cell lines and ovarian carcinomas. In each case, 
a truncated form of the p85 regulatory subunit results in constitutively active PI3K (Jucker et al., 
2002; Philip et al., 2001) 
PI3K and Akt Inhibitors as Therapeutic Intervention 
 
Interest in inhibiting PI3K and Akt as a means of cancer treatment has resulted in three generations 
of compounds targeting these potent oncogenes. Despite these efforts, none of these inhibitors 
have been introduced into clinical use, while hopes of more advance compounds are driving 
progress in next generation inhibitors of PI3K and Akt.  
Early attempts in inhibiting PI3K resulted in the development of compounds like Wortmannin and 
LY294002. These compounds are considered ‘pan-inhibitors’ because of their ability to inhibit all 
isoforms of class I PI3Ks. Despite this, neither Wortmannin or LY294002 have been approved for 
clinical use due to their poor pharmacodynamics. The utility of these compounds has not been lost 
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on researchers as they have become critical in helping us develop our understanding of the PI3K 
pathway (Martini et al., 2013). Attempts to create a second generation of PI3K inhibitors has 
focused on increasing isoform selectivity. These are currently being tested in clinical trials on 
patients with genitourinary cancers and include PI3Kα specific GDC-0032 and PI3Kβ specific 
GSK2636771 (Porta and Figlin, 2009; Laplante and Sabatini, 2012). Finally, the third and most 
recent generation of compounds has been dubbed the ‘dual PI3K/mTOR inhibitors’ which seeks 
to leverage the high degree of sequence homology within the catalytic sites of PI3K and Akt. 
Although efficacy of compounds such as NVP-BEZ235 have yet to be proven in vivo, there is hope 
that simultaneous targeting of PI3K and mTOR may improve outcomes for cancer patience in 
which both of these molecules are dysregulated (Martelli et al., 2012).  
Compounds specifically targeting Akt have focused on its ATP binding site, pleckstrin homology 
domain and substrate site as a means of inhibition. The number of Akt inhibiting compounds that 
have entered clinical development is far outweighed by those targeting PI3K and mTOR (Pal et 
al., 2010). The most promising of Akt inhibitors is Miltefosine, however its use has not been 
approved for the treatment of cancer. However, the compound has completed phase III trials and 
has been approved in India, Columbia and Germany for treatment in patients co-infected with 
visceral or cutaneous leishmaniasis and HIV (Leonard et al., 2001; Dorlo et al., 2012). Visceral 
leishmaniasis (VL) is the most severe form of black fever which is caused by a single celled 
protozoan of the Leishmania genus and is the second most lethal parasite after malaria (Desjeux, 
2001). VL often occurs in patience afflicted with HIV, and requires specific treatment strategies 
to overcome resistance to other drugs. Miltefosine inhibits Akt in macrophages expressing HIV 
viral Tat protein, which is a potent activator of the pro-survival PI3K pathway. Apoptosis can then 
be specifically induced in these cells upon treatment with secondary compounds, thereby 
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preventing viral production without harming healthy cells (Chugh et al., 2008). Although VL and 
HIV are obviously not implicated in uncontrolled cell growth, the development of Miltefosine is a 
wonderful example of how our knowledge of signaling transduction can be of benefit to 
researchers and clinicians outside the sphere of oncology.  
Although promising breakthroughs abound in small molecule inhibitors of PI3K/Akt, none of the 
drugs described here have been able to achieve the gold standard of complete remission in cancer 
patients. The inability to do so is usually attributed to the onset of resistance, the molecular basis 
of which has been hypothesized to include activation of redundant yet latent pathways, secondary 
target lesions or amplification of downstream effectors in the same pathway (Tan and Yu, 2013). 
The ability for cancer to adapt in the face of treatment is just one of many obstacles that needs to 
be overcome if we are to successfully treat this disease the way we have treated other diseases in 
the 21st century.  
CDCA7 – MYC Associated Protein and Target of Akt 
In the onset of our investigation into CDCA7, very little was known about this novel cell cycle 
associated protein. Prior to our publication in 2013, CDCA7 was the focus of only three articles, 
two of which were published by the same group. Bellow is a summary of what was known prior 
to 2013 which served as the foundation for our initial investigation, followed by a review of the 
latest literature regarding CDCA7.  
CDCA7 – 2001-2006 
 
In 2001 Prescott and colleagues identified JPO1/CDCA7 as a novel Myc target gene, which 
encodes a nuclear protein 47 kDa in size, consisting of 371 amino acids and is conserved across 
many species including human, mouse, rat and Xenopus. CDCA7 mRNA is highly expressed in 
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human colon, thymus and small intestinal tissue, in contrast to bone marrow, spleen and peripheral 
leukocytes where it is marginally detected. When stably overexpressed in Rat1a cells, CDCA7 has 
limited transforming ability and does increase the clonogenicity of CB33 human lymphoblastoid 
cells, although not to the same extent as Myc. However, Prescott was able to establish that CDCA7 
is involved in transformation and anchorage-independent growth by demonstrating its 
complementation with a transformation-defective Myc Box II mutant. The data presented by this 
group suggests that CDCA7 is one of many Myc target genes that synergistically work with Myc 
towards tumorigenesis (Prescott et al., 2001).  
Investigations into the relationship between CDCA7 and Myc were consequently probed by 
Osthus and colleagues in 2005, which was the same group to first shed light on CDCA7. Using 
hybridization arrays containing a variety of solid tumor and blood samples, the group showed that 
elevated CDCA7 levels are correlated with high levels of Myc in solid tumors, while increased 
mRNA levels were detected in patients with acute myeloid leukemia (AML) and blast crisis-staged 
chronic myeloid leukemia (CML). Osthus and colleagues were the first to probe the effects of 
CDCA7 in an animal model. Their results showed that transgenic mice expressing CDCA7 have 
elevated incidences of blood and solid tumors over their control littermates. Consequently, the 
group hypothesized that their observations, in light of the data presented by Prescott et al., indicate 
that CDCA7 may be implicated in Myc-mediated tumorigenesis (Osthus et al., 2005).  
In 2006, a group led by Yuya Goto at Meiji University in Tokyo would shed light on the 
transcriptional regulation of CDCA7 as well as its own transcriptional abilities. In addition to being 
a Myc responsive gene, Goto and colleagues showed that CDCA7 is a direct transcriptional target 
of the transcription factor E2F1. CDCA7 was also able to induce transcriptional activity in 
mammalian one-hybrid assays. This was not surprising as the C-terminal cysteine rich region of 
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CDCA7 is homologous to the transcriptional regulatory domain of the closely related JPO2.  E2F1 
is known to be involved in pathways regulating DNA replication and cell cycle progression (Goto 
et al., 2006), therefore it is important to note that CDCA7’s expression peaks at the G1 to S phase 
transition (Osthus et al., 2005). CDCA7 has thus been characterized as an E2F1-mediated member 
of the cell division cycle-associated family of genes (CDCA), whose members exhibits expression 
patterns correlating with those of cell cycle genes such as CDC2/7 and cyclins (Goto et al., 2006).  
CDCA7 – Gill, Gabor, Couzens and Scheid (2013) 
 
Although there have been no studies probing the nature of a possible physical interaction between 
CDCA7 and Myc, Penn and colleagues have shown that JPO2 (a related family member of 
CDCA7) binds Myc at its N-terminal domain, an association which promotes Myc-dependent 
transformation (Huang et al., 2005). At the amino acid level, JPO2 and CDCA7 share a C-terminal 
cysteine rich region (Goto et al., 2006) which may confer DNA binding and promoter specificity 
of Myc-CDCA7 complexes. Figure 1.1 and 2.1 outlines various conserved motifs within CDCA7 
and their proposed functions, including a consensus Akt substrate site, a 14-3-3 binding domain 
as well as a bi-partite nuclear localization sequence (Obenauer et al., 2003; Madiera et al., 2015). 
In light of CDCA7’s novel role in Myc-mediated oncogenic pathways and its E2F1-mediated 
expression, it is becoming increasingly clear that CDCA7 may play an important role in cancer. In 
2013 our research group published a report (Gill et al., 2013; Chapter 2 of this thesis) that 
implicated CDCA7 as a Myc binding protein, whose interaction with Myc is mediated by 
phosphorylation at T163 by Akt, promoting dissociation from Myc and binding of 14-3-3, resulting 
in its sequestration to the cytoplasm. Knockdown of cdcA7 abrogated Myc-dependent apoptosis, 
while over expression repressed growth rates and promoted Myc-dependent apoptosis. Our 
research was the first to suggest that CDCA7 may be directly involved in the Myc-apoptosis 
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paradox. Chapters 3 and 4 of this thesis further explore the mechanistic details contributing to the 
phenotypes described in our 2013 publication. 
CDCA7 – 2014-2017 
 
In the years following our 2013 publication, four articles explicitly focusing on CDCA7 have been 
published, yet none of them address the relationship between CDCA7 and Myc. For the most part, 
these investigations have focused on CDCA7’s contribution to development or its role in a 
condition known as Immunodeficiency, Centromeric Instability and Facial Anomalies (ICF) 
syndrome. Although not completely related to the topic of Myc-mediated apoptosis, below is a 
review of these most recent findings regarding CDCA7, some of which sheds light on CDCA7’s 
role in DNA-centric activities.  
ICF is a heterogeneous autosomal recessive disorder whose hallmarks include facial anomalies, 
developmental delay and immunodeficiency often leading to respiratory and gastrointestinal 
infections that are frequently lethal. All ICF patients present with hypomethylated 
juxtacentromeric heterochromatin and centromeric instability. The disease was initially 
characterized by mutations in two ICF genes, although only 50% of cases were explained by 
mutations in ICF1 (DNA methyltransferase 3B or DNMT3B) and 30% were attributed to 
mutations in ICF 2 (zinc-finger and BTB domain containing 24 or ZBTB24). While mutations to 
DNMT3B resulted in reduced methyltransferase activity, the function of ZBTB24 was unknown 
until recently. Therefore, approximately 20% of ICF cases cannot not be explained by mutations 
in one of these two ICF genes. In 2015, Thijssen and colleagues combined homozygosity mapping 
with whole-exome sequencing to identify novel homozygosity in five patients who do not harbour 
mutations in DNMT3B or ZBTB24. The group identified 4 homozygous variants of CDCA7 in 
these patients, each containing missense mutations within the c-terminal z-finger domain. These 
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include R274C, R274H, G294V and R304H. The group subsequently knocked down CDCA7 in 
mouse embryonic fibroblasts, resulting in hypomethylation of CpG centromeric repeats the likes 
of which is found in all human cases of ICF (Thijssen et al., 2015). 
In 2016, a study by Wu and colleagues focused on ZBTB24 and its contributions to ICF etiology. 
The group found that CDCA7 expression is significantly reduced in mouse embryonic stem cells 
that are homozygous for a loss of function ZBTB24 mutant. Expression of CDCA7 was restored 
in these cells upon ectopic expression of wild-type ZBTB24. Furthermore, CDCA7 expression 
was also shown to be reduced in ICF patients harbouring ZBTB24 nonsense mutations. Finally, 
the group demonstrated that ZBTB24 occupies the CDCA7 promoter and may function as a 
regulator of CDCA7 expression (Wu et al., 2016). The results published by Thijssen et al. and Wu 
et al. establish a relationship between two of the four ICF genes at the transcriptional level and 
sheds some light on the activity of CDCA7 outside of cell survival paradigm we have largely 
focused on thus far. 
In studies unrelated to ICF, CDCA7 has been identified as a major transcriptional target of Notch 
signalling during human embryonic stem cell hematopoietic differentiation (Guiu et al., 2014). 
Conversely, repression of CDCA7 expression by the transcription factor Pax6 has been shown to 
be critical for normal corticogenesis (Huang et al., 2017). Although research into CDCA7 is still 
very early in its infancy, the publications summarized here indicate that CDCA7 most likely plays 
an important role in normal cell survival and development. The influence of any protein on Myc-
mediated functions is usually justification for substantial investments of time and research funds. 
Our research group is not an exception to this line of thinking. The research presented here is a 
product of eight years of research, culminating in voluminous data that has been distilled down to 
the most pertinent results.     
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Significance of Research and Research Objectives 
 
The evidence presented by Prescott et al., Osthus et al. and Goto et al. suggests that CDCA7 may 
play an important role in Myc-mediated transformation. This is enforced by the following: 
- CDCA7 is a Myc and E2F1 target gene. 
- CDCA7 rescues a transformation deficient mutant of Myc  
- Elevated levels of CDCA7 are correlated with elevated levels of Myc in solid tumors 
- CDCA7 has transcriptional activity 
- CDCA7 expression peaks at the G1-S transition  
- CDCA7 contains an Akt consensus site, 14-3-3 binding site and a nuclear localization signal 
In light of these results and the importance of Myc in many critical cellular processes, it would be 
prudent to develop a molecular profile of CDCA7 to define the nature of CDCA7’s relationship 
with Myc. The possibility that CDCA7 may be a target of Akt phosphorylation is intriguing 
because of the fact that simultaneously dysregulated Myc and Akt (via overactive receptor tyrosine 
kinases) have been shown to provide the necessary environment to promote oncogenesis 
(Stambolic et al., 1999). This molecular profile of CDCA7 may also shed light on the Myc-
apoptosis paradox as Kauffmann-Zeh and colleagues have demonstrated that Myc induced 
apoptosis could be suppressed by Phosphoinositide-3 kinase (PI-3K) and Akt activation 
(Kauffmann-Zeh et al., 1997). The following research objectives have been addressed in the thesis 
presented here: 
Research Objective 1: Investigate Consensus Sites within CDCA7’s Amino Acid Sequence 
Figure 1 shows some of the interesting consensus sites found within the CDCA7 amino acid 
sequence, such as an Akt phosphorylation site, 14-3-3 binding site and bi-partite nuclear 
localization sequence (NLS) (Obenauer et al., 2003; Madiera et al., 2015). These sites should be 
31 
 
investigated and confirmed or rejected as conforming to the consensus sites in question. These 
consensus sites are of particular interest because they are localized in and around threonine 163, 
making way for the possibility that phosphorylation by Akt mediates 14-3-3 binding and alters 
sub-cellular localization. This paradigm has been observed in the case of the transcription factor 
FoxO4 (Obsilova et al., 2005) and if confirmed, would shed light on CDCA7’s post-translational 
regulation and /or function.  
Research Objective 2: Does CDCA7 Interact with the Oncogene Myc? 
 
Huang and colleagues have shown that JPO2 (a related family member of CDCA7) can associate 
directly with Myc, resulting in its transforming abilities in medulloblastoma cells (Huang et al., 
2005). Investigating if CDCA7 also interacts with Myc could shed light on any contributions this 
novel protein might have in Myc-dependent cellular processes, including proliferation, apoptosis 
or gene expression. This can be approached using in vivo association assays via co-
immunoprecipitation or in vitro association assays using bacterially expressed and purified 
proteins. The exact region of CDCA7 interaction with Myc can be determined using targeted 
deletion mutants that focus on areas of interest within CDCA7. Lack of association upon deletion 
of a region may suggest its involvement in direct protein-protein interactions.  
Research Objective 3: Map the Subcellular Localization of CDCA7 
 
Subcellular localization of a protein can help us understand the function and regulation thereof. 
Using immunohistochemistry will allow us to investigate where CDCA7 is located during various 
phases of the cell cycle and how a multitude of treatment conditions may affect subcellular 
localization. The presences of a consensus bipartite NLS suggests that CDCA7 subcellular 
localization may be confined to the nucleus. However, research objective 1 may reveal a 
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mechanism which can mediate nuclear localization by means of T163 phosphorylation and 
therefore contribute to a potential dynamic means of controlling CDCA7 function.  
Research Objective 4: How Does CDCA7 Affect Apoptosis and Proliferation? 
 
Since 1992 it has been well known that Myc plays an important role not only in proliferation, but 
apoptosis as well (Evan et al., 1992). The mechanism behind Myc’s non-mutually exclusive 
influence on proliferation and apoptosis has remained a mystery. Investigating whether CDCA7 
contributes to this paradox may help explain how Myc can contribute to two diametrically apposed 
cellular processes.   
Research Objective 5: Does CDCA7 Exist as a Monomer or a Homodimer? 
 
Within the highly conserved C-terminal region of CDCA7 there is a potential zinc-finger, which 
in many cases allows proteins to either homo or heterodimerize (Ou et al, 2006). Determining 
whether CDCA7 exists natively as a dimer or monomer will help develop the overall molecular 
profile of CDCA7 in addition to learning more about how its function may be regulated.   
Research Objective 6: How Does CDCA7 Affect Gene Expression? 
 
The CDCA7 family member JPO2 has been shown to associate with Myc; an association which 
promotes Myc-dependent transformation (Huang et al., 2005). CDCA7 and JPO2 share a C-
terminal cysteine rich region (Goto, et al., 2006), which may allow for DNA binding and promoter 
specificity of a Myc-CDCA7 complex. Identifying the potential subset of genes which are affected 
by CDCA7 may allow for the dissection of CDCA7’s influence on a genetic level. The most 
notable genes to probe would be those involved with proliferation and apoptosis, such as cyclins, 
CDKs or members of the Bcl-2 family of pro/anti-apoptotic proteins.   
33 
 
Research Objective 7: How Does CDCA7 Affect the Cell Cycle? 
 
Goto and colleagues have shown that CDCA7 is a gene target of the transcription factor E2F1. It 
is important to note that E2F1 plays a regulating role in cell cycle progression and DNA 
replication, perhaps contributing to the temporal expression of CDCA7 at the G1 to S phase 
transition. How this temporal expression affects progression through the cell cycle is yet to be 
seen. 
 
Research objectives 1-4 have been addressed in a manuscript published in 2013 by Molecular and 
Cellular Biology and is appended in the following section. Research objectives 5-7 are addressed 
in chapters 3 and 4.  
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Figure 1.1 CDCA7 conserved areas and regions of interest. The area around T163, 158-181, 
contains three notable consensus motifs: a Akt substrate site, a 14-3-3 binding motif and a bi-
partite nuclear localization sequence. The c-terminal portion of CDCA7 also contains a putative 
zinc-finger. Areas in red show a greater then 90% conservation amongst species (Obenauer et al., 
2003; Madiera et al., 2015). 
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Figure 1.2 PI3K pathway activation and Akt function. Akt activation occurs downstream of 
phosphoinositide-3 kinase (PI3K), which is tasked with phosphorylating the membrane lipid 
phosphatidylinositol-4,5-P2 (PIP2) at the 3’ position of the inositol ring to generate PI(3,4,5)P3 
(PIP3). Generation of PIP3 allows for the serine/threonine protein kinase Akt to be targeted to the 
membrane via its Pleckstrin Homology domain, where it can be subsequently activated by 
phosphorylation via phosphoinositide dependent kinase 1 (PDK1) (Stephens et al., 1998). 
Activated Akt is free to act upon over 50 known substrates, many of which influence processes 
such as proliferation, angiogenesis, motility, metabolism and survival. 
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Abstract 
 
Cell division control protein A7 (CDCA7) is a recently identified target of MYC-dependent 
transcriptional regulation. We have discovered that CDCA7 associates with MYC and that this 
association is modulated in a phosphorylation-dependent manner. The pro-survival kinase Akt 
phosphorylates CDCA7 at threonine 163, promoting binding to 14-3-3, dissociation from MYC, 
and sequestration to the cytoplasm. Upon serum-withdrawal, induction of CDCA7 expression in 
the presence of MYC sensitized cells to apoptosis, whereas CDCA7 knockdown reduced MYC-
dependent apoptosis. Transformation of fibroblasts by MYC was reduced by co-expression of 
CDCA7, while the non-MYC interacting protein (156-187)-CDCA7 largely inhibited MYC-
induced transformation. These studies provide insight into a new mechanism by which Akt 
signaling to CDCA7 could alter MYC-dependent growth and transformation, contributing to 
tumorigenesis. 
Introduction 
 
The transcription factor MYC is a proto-oncogene that regulates the expression of hundreds of 
genes involved in cell cycle progression, adhesion, metabolism, and apoptosis (24, 35, 36, 40). 
Over-expression of MYC is a hallmark of human cancer, contributing to the expression of 
numerous groups of genes involved in transformation, metastasis, and overall poor prognosis (58, 
59). MYC has been estimated to be active in nearly 70% of human cancers, with the mechanisms 
of activation including amplification, translocation, deregulated translation, and protein turnover 
(1, 39). As such, MYC has been the subject of extensive study in the search for treatment 
modalities (reviewed in (23, 36, 53)).  
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Activation of MYC is induced by mitogenic stimuli to promote cell cycle progression (2, 5, 9, 20, 
25, 33, 49). To prevent aberrant MYC expression from driving unsafe proliferation in the animal, 
a safeguard has evolved whereby MYC activation in the absence of mitogenic survival signals is 
opposed by cellular responses of apoptosis and/or cell cycle arrest, depending on the cellular 
context and p53 status (3, 17, 18, 26, 27, 45, 46, 61). Despite these observations of almost 20 years 
ago, and the realization that other growth-promoting transcription factors, such as E1A and E2F1 
act similarly (38, 47, 48, 60), the mechanism of MYC-induced apoptosis and cell cycle arrest is 
still poorly understood.  
Expression of pro-survival oncogenes, with the earliest example being Bcl-2, have previously been 
shown to counteract the death function of MYC (4, 19, 55). Additionally, activation of PI3K and 
its downstream target Akt can protect against apoptosis induced by MYC (29). PI3K and Akt were 
shown in the mid-1990’s to convey a strong pro-survival signal downstream of receptor tyrosine 
kinases (15, 30, 31) by impacting the apoptosis machinery directly (11, 12, 50, 62), and by 
regulating FOXO transcription factors (6-8, 13, 51). Furthermore, loss of the tumor suppressor 
MMAC1/PTEN results in constitutive PI3K signals (32, 54) and can lead to tumors in humans (10, 
14). Thus, aberrant MYC activation together with overactive Akt, a condition that is often achieved 
in tumor cells, can provide the cooperative growth and anti-apoptotic signals necessary to promote 
tumorigenesis. 
A recently identified protein, CDCA7 (also called JPO1), is expressed from the MYC- and E2F-
responsive gene cdca7 (22, 41, 44). MYC and E2F1 bind to the promoter of cdca7 to drive CDCA7 
expression (22, 44), causing CDCA7 mRNA to be widely expressed with high levels in the colon, 
thymus and small intestine, and lower levels in the testis, stomach and bone marrow (44). High 
levels of CDCA7 mRNA have been found in patients with AML and blast crisis-staged CML (41), 
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while solid tumors displaying high levels of MYC were also shown to be positive for CDCA7 (41). 
While CDCA7 had weak transformation properties when expressed alone, co-expression rescued 
transformation of a transformation-defective MYC with a MYC-Box II deletion (44). Furthermore, 
recent work by Penn and colleagues have shown that JPO2, a protein with some homology with 
CDCA7, can directly associate with MYC, and this increases MYC-dependent transformation 
(28). Both CDCA7 and JPO2 contain a highly conserved carboxyl-terminal cysteine rich region 
that might allow binding to DNA (22). However, it is unknown if CDCA7 also associates with 
MYC. 
In the present study, we show that CDCA7 and MYC physically interact. We have mapped the 
domains of interaction and have discovered that Akt phosphorylates CDCA7 near this contact 
region, leading to loss of its association with MYC, binding to 14-3-3 proteins and exclusion from 
the nucleus. Co-expression of CDCA7 with MYC sensitized cells to serum-withdrawal induced 
apoptosis and this pro-apoptotic activity required the MYC-binding region. Short hairpin RNAi-
mediated knockdown of CDCA7 rescued cells from MYC-dependent apoptosis following removal 
from serum. These finding point to a feed-forward loop whereby MYC activation up-regulates 
CDCA7, with Akt activity controlling the accessibility of CDCA7 to nuclear MYC proportionate 
to growth factor signaling. 
Methods and materials 
 
Cell lines and cell culture 
HEK 293 and Rat1 cells were obtained from the American Type Culture Collection and maintained 
in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum and 
antibiotics at 37°C and 5% CO2.  Akt 1/2 null mouse embryonic fibroblasts (52) were a gift from 
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Dr. Veronique Nogueira of the University of Illinois at Chicago. Rat1-MYC cells were obtained 
by stable transfection of Myc and selection in 600 g/ml G418 and 20% fetal bovine serum. Clones 
expressing both wild-type and mutant CDCA7 were established using the Tet-ON advanced 
inducible gene expression system from Clontech. Specifically, stable clones expressing a tet-
induced transactivator (rtTA) were obtained by stable transfection of Rat1 and Rat1-MYC cells, 
respectively, with pIREShyg3-rtTA, followed by selection in 200g/ml hygromycin. 
Subsequently the rtTA-Rat1 and rtTA-Rat1-MYC cells were co-transfected with a 100:1 ratio of 
pTRE-tight-3xFLAG-CDCA7 plasmid and linearized puromycin plasmid, followed by selection 
in 2g/ml puromycin.  All Rat1-MYC derived inducible lines were maintained in 20% fetal bovine 
serum while Rat1-CDCA7 derived inducible lines were maintained in 10% fetal bovine serum.   
Antibodies and Reagents 
Mouse monoclonal M2 anti-flag (A2220) and rabbit polyclonal anti-CDCA7 (HPA005565) were 
purchased from Sigma-Aldrich.  Rabbit polyclonal anti-CDCA7 (Ab69609) was purchased from 
Abcam.  Mouse monoclonal anti-14-3-3 (SC-1657) and 9E10 mouse monoclonal anti-MYC (SC-
40) were purchased from Santa Cruz. Rabbit polyclonal anti-Myc (5605), rabbit polyclonal anti-
pan Akt (9272) and mouse monoclonal anti p-Ser473 Akt (4051) were purchased from Cell 
Signaling Technologies.  An anti-p-Thr163 CDCA7 rabbit polyclonal antibody was generated by 
Genscript Corporation (California). Akt inhibitor VIII  (A6730) and LY294002 (L9908) were 
purchased from Sigma-Aldrich. 
Cloning 
The CDCA7coding region was ligated into the p3XFLAG-CMV10 mammalian expression vector 
(Sigma-Aldrich) to introduce an amino terminal FLAG epitope. Mutagenesis of p3XFLAG-
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CMV10-CDCA7 was performed using the QuikChange kit (Stratagene), and the various mutations 
were sequence-verified. Amino-terminal and internal deletions were created by introducing silent 
mutations coding for unique restriction sites, followed by digestion and re-ligation.  Carboxyl 
terminal deletions were created by introducing stop codons.  All deletions were sequence verified. 
CDCA7 containing the 14-3-3-binding R18-peptide PHCVPRDLSWLDLEANMCLP or the 
control non-14-3-3-binding peptide PHCVPRDLSWLKLKANMCLP were created by ligating a 
double-stranded oligonucleotide to replace amino acids 139-164 of CDCA7 in the 3XFLAG-
CMV10 vector. The C-terminal His-tagged Myc plasmid was created by cloning the Myc coding 
region into pEcoli-C-terminal 6xHN (Clontech).  
For transient and stable expression of cDNA in cells, HEK 293, mouse 3T3, or Rat1 cells were 
plated onto 100-mm-diameter dishes at 80% confluency and transfected with 5 g of plasmid using 
Lipofectamine 2000 (Invitrogen) following the manufacturer’s protocol. Transfection medium was 
removed and replaced with complete Dulbecco’s modified Eagle’s medium overnight. 
For retroviral expression of CDCA7 in Rat1 cells, 3X-FLAG-CDCA7 or CDCA7 with various 
mutations were cloned into the pQCXIH retroviral vector (Clontech) upstream of an IRES 
sequence and the hygromycin resistance gene. Either empty pQCXIH or pQCXIH-CDCA7-IRES-
Hygro retroviral vectors were transfected into the ecotropic-envelope protein packaging cell line 
EcoPack 2-293 (Clontech). Viral particles were collected 48 hours later and concentrated using 
Retro-X concentrator (Clontech).  
shRNA Cloning and qRT-PCR 
Oligonucleotides   
(5’-GATCCCCAATGAAGTTCCCAGCACGATTCAAGAGATCGTGCTGGGAACTTCATTTTTTTA-3’),  
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(5’-GATCCCCAGTTCCCAGCACGAAATACTTCAAGAGAGTATTTCGTGCTGGGAACTTTTTTA-3’)  
(5’-GATCCCCCTGTGGACGGCTATATGAATTCAAGAGATTCATATAGCCGTCCACAGTTTTTA-3’) 
targeting rat CDCA7 at nucleotides 212, 220 and 658 respectively, were annealed, ligated into 
the pSuper vector, and transfected into Rat1-MYC cells. Several colonies of each targeting 
region were isolated following puromycin selection. 
Total RNA was purified and cDNA synthesized using NEB’s ProtoScript® M-MuLV First 
Strand cDNA Synthesis Kit. Quantification of shRNA knockdown and screening of clones was 
performed using SA Bioscience’s RT² SYBR® Green qPCR Master mix and Applied 
Biosystems’ 7500 Fast RT-PCR system.  
Cell Lysis, Immunoprecipitation, and Immunoblotting 
Cells were lysed in either RIPA lysis buffer (10mM NaPO4, pH 7.6, 150mMNaCl, 5mM EDTA, 
0.1% sodium dodecyl sulphate, 0.25% deoxycholic acid, 1% triton X-100, plus protease and 
phosphatase inhibitors) or Triton X-100 lysis buffer (50mMHepes, pH 7.9, 250mMNaCl, 0.1% 
Triton X-100, 10% glycerol, plus protease and phosphatase inhibitors). Ten l of anti-FLAG M2 
agarose conjugated beads (Sigma Aldrich) were added to lysates and incubated overnight at 4°C. 
The beads were washed five times with lysis buffer, and proteins were eluted with 200 l of lithium 
dodecyl sulfate sample buffer and heated to 70°C for 10 min. Portions of the lysates prior to 
immunoprecipitation were also reserved and boiled with lithium dodecyl sulfate-containing 
sample buffer. Lysates and immunoprecipitations were fractionated by SDS-PAGE, transferred to 
a PVDF membrane, blocked in 5% skim milk for 30 min, and probed with the appropriate antibody 
overnight at room temperature.  Primary antibodies were decorated with IR700 anti-mouse and/or 
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IR800 anti-rabbit secondary antibodies (Li-Cor Biosciences) for 3 hours at room temperature and 
visualized using the infrared laser scanning (Odyssey, Li-Cor Biosciences).  
Microscopy 
Rat1, NIH3T3 or HEK 293cells were plated at 80% confluency on no. 1 glass coverslips. 
Following the desired treatment, the coverslips were washed twice in PBS and then fixed and 
permeabilized in 3:1 methanol:acetic acid for 25 minutes. The coverslips were then washed three 
times in PBS followed by blocking in 1% BSA in PBS. Primary antibodies at varying 
concentrations were applied for 1.5 hours in a humidified chamber at room temperature.  
Coverslips were washed three times in PBS prior to applying secondary antibodies for 2 hours in 
a humidified chamber at room temperature and in the dark. The slips were washed three times in 
PBS before mounting with Invitrogen’s ProLong Gold antifade reagent with DAPI. The slides 
were viewed on an Olympus microscope and images were taken via a QImaging 2000R camera 
and Q-Capture pro software.  
Live cell imaging was performed on an inverted Olympus microscope equipped with an Ultraview 
ERS spinning disc unit, 37C heated stage and 60X heated objective. NIH 3T3 cells were 
transfected on number-1 coverslip chambers overnight, serum starved for 4 hours, and stimulated 
with PDGF. Confocal images were taken every 5 minutes for the duration of the time course and 
analyzed with Perkin Elmer Ultraview ERS software. 
Peptide Competition Assay 
The Thr163 peptide (CDSKSPRRRTFPG) and phosphopeptide (CDSKSPRRR(p)TFPG) 
corresponding to the sequence surrounding Thr163 were synthesized by Genscript.  Triton-X100 
lysates containing FLAG-CDCA7 were immunoprecipitated with anti-FLAG M2 agarose 
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conjugated beads overnight at 4°C.  Following washing, beads were incubated at 4°C for 1 hour 
with various concentrations of peptide or phosphopeptide where indicated. The beads were washed 
three times, and proteins were eluted and resolved by SDS-PAGE. Co-immunoprecipitated 14-3-
3 was detected using rabbit polyclonal anti-14-3-3β antibody.  
In vitro pull-down assay 
HEK293 cells were transfected overnight with FLAG-CDCA7and various mutants.  Cells were 
lysed in RIPA lysis buffer and immunoprecipitated with FLAG-M2 agarose conjugated beads 
overnight at 4°C.  Agarose beads were washed 3 times with RIPA lysis buffer and then 3 times 
with Triton X-100 lysis buffer.  Immunoprecipitates were then eluted by incubation at 4°C with 
20M FLAG peptide in Triton X-100 lysis buffer. 
For generation of recombinant MYC, 6xHN-MYC-expressing DH5 bacteria were cultured 
overnight in 100ml Terrific broth (TB) at 37C with shaking overnight.  The following day 1L of 
TB was inoculated from the overnight culture.  Cells were stimulated with 1 mM IPTG when the 
OD600 reached 1.0.  The culture was then incubated at 16C overnight.  Cells were pelleted by 
centrifugation and resuspended in 60mL of binding buffer (50mM Tris, pH 7.5, 500mM NaCl, 
5mM Imidazole).  Cells were lysed by sonication at 30% amplitude, 2 seconds on, 3 seconds off, 
for a total of 2 minutes. Insoluble precipitates were removed by centrifugation and the supernatant 
was bound to Ni-Nta beads at 4C, for 20 minutes with gentle rocking.  Ni-Nta beads were washed 
with 10 column volumes of wash buffer (50mM Tris, pH 7.5, 500 mM NaCl, 30 mM Imidazole).  
6xHN-MYC was eluted in 5 mL fractions with elution buffer (50 mM Tris, pH 7.5, 500 mM NaCl, 
250 mM Imidazole). Purified 6xHN-MYC was dialyzed against three changes of HKG buffer (20 
mM HEPES, pH 7.4, 125 mM KCl, 20% (v/v) glycerol). 
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For pull-down experiments, 500 ng of purified His-MYC protein was bound to Ni-NTA agarose 
beads and incubated with purifiedFLAG-CDCA7 protein for 4hoursat 4°C in Triton X-100 lysis 
buffer. Beads were washed 5 times and proteins were proteins were eluted with 200 l of lithium 
dodecyl sulfate sample buffer heated to 70°C for 10 min. Portions of the input protein prior to 
binding were also boiled with lithium dodecyl sulfate-containing sample buffer. Input and bound 
protein were fractionated by SDS-PAGE. 
Apoptosis assays 
For annexin assays, cells were harvested with EDTA-free trypsin and washed twice at 4°C with 
ice cold PBS and stained by resuspension in 200l Annexin binding buffer (10 mM HEPES, pH 
7.4, 140mMNaCl, 2.5 mM CaCl2) containing 5ml Annexin V-alexa488 conjugate and 1g/ml 
propidium iodide.  The proportion of apoptotic cells (Annexin-V positive, propidium iodide 
negative) was determined using a FACScan flow cytometer and Cell-Quest software (Becton 
Dickinson). Caspase assays were performed by scraping approximately 106 cells in caspase assay 
buffer (25 mM HEPES pH 7.4, 5 mM EDTA, 2 mM DTT, 137 mM NaCl, 10% glycerol).  Cells 
were sonicated at low power, and insoluble materials pelleted by centrifugation.  150l of lysate 
was incubated at 37C with 10M DEVD substrate (N-Acetyl-Asp-Glu-Val-Asp-7-amido-4-
methylcoumarin, Sigma).   Samples were read every 15 minutes at 380nm excitation, 450nm 
emission and caspase-3 activity was normalized to total protein as determined by Bradford assay. 
Metabolic Labeling 
HEK293 cells were transfected overnight with FLAG-CDCA7, washed and incubated in 
phosphate free medium containing 1 mCi/ml 32P-labeled orthophosphate for 4 hours.  Cells were 
lysed in 1ml RIPA and FLAG-CDCA7 was immunoprecipitated with pre-bound monoclonal M2 
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anti-Flag beads overnight at 4C.  Immunoprecipitates were fractionated by 8% SDS-PAGE, 
Coomassie stained and 32P-labeled CDCA7 was detected by autoradiography.    
Tryptic mapping 
32P-labeled CDCA7 was isolated as described above, excised from the gel and digested with 
10g/ml tosylphenylalanylchloromethyl ketone-treated trypsin (Promega) in 50mM (NH4)HCO3, 
pH 7.8, overnight at 37C.   Isolation of peptides was performed as described elsewhere (34).  
In vitro Akt phosphorylation assay 
FLAG-tagged CDCA7 was immunoprecipitated from cell lysates with 25 μl FLAG M2 
monoclonal antibody conjugated to agarose (Sigma–Aldrich). Immunoprecipitates were washed 
three times in RIPA buffer, followed by an additional two times in reaction buffer containing 40 
mM MOPS-NaOH pH 7.0, 1 mM EDTA.  The samples were then resuspended in reaction buffer 
plus 0.5 ug of active Akt (S472D) (Millipore). The kinase reaction was started by the addition of 
an ATP mixture containing 8 M magnesium acetate, 10 M ATP and 1μCi of [32P]ATP.  Samples 
were incubated for 20 minutes at 30C, the supernatant was then removed to fresh tubes and 
CDCA7 immunoprecipitates were washed three times with reaction buffer and finally resuspended 
in 1x LDS sample buffer.  The supernatant containing Akt and the CDCA7 immunopreciptates 
were resolved by SDS-PAGE. [32P]CDCA7 was visualized with a phosphoimager (Bio-Rad 
Laboratories). 
Soft-agarose colony formation assay 
Rat1 cells were infected with retrovirus generated by the pQCXIH-CDCA7-IRES-Hygro vector. 
After 5-7 days selection in hygromycin (200 g/ml), resistant pools were counted and plated in 
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complete medium containing 0.3% agarose and hygromycin over a bottom layer of complete 
medium containing 0.7% agarose and hygromycin. Fresh medium with serum was added to the 
plates every two days, and after two weeks plates were stained with crystal violet, destained, and 
visualized by infrared scanning on an Odyssey laser scanner. Macroscopic colonies were counted 
using ImageJ software. 
Results 
 
CDCA7 binds to the carboxyl terminus of MYC 
Figure 2.1A depicts the various regions of CDCA7 and their postulated biological roles, which 
includes a C-terminal zinc finger domain that could interact with DNA, a leucine zipper (LZ) 
region that could promote hetero- and homo-dimerization, and a putative nuclear localization 
signal between amino acids 170 and 190 of human CDCA7. Conservation within this region is 
very high between species. We performed co-precipitation experiments, and deletions of both N-
terminal and C-terminal segments of CDCA7 revealed that a small region of CDCA7, amino acids 
146-170, was essential for interaction with MYC (Figure 2.1B,C). In reciprocal experiments we 
found that CDCA7 lost association with MYC harboring a deletion of the C-terminal region (274-
440), but not MYC lacking the N-terminal MYC Box (MB) I and II domains (5-149), or the 
central region of MYC containing the MBIII domain (151-274) (Figure 2.1D). Finally, 
immunoprecipitation of endogenous MYC led to co-precipitation of endogenous CDCA7, 
indicating interaction of physiological levels of these proteins (Figure 2.1E). 
The region of CDCA7 that associates with MYC is remarkable for several reasons. First, there 
appears to be a putative bipartite NLS domain spanning amino acids 160-190 (Figure 2.1A). 
Secondly, threonine 163 conforms to the consensus Akt phosphorylation site with an arginine at -
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5 and -3, and a bulky hydrophobic at +1. Furthermore, there is a proline at +2, and this same 
arrangement of residues is present in other Akt substrates that bind to the phospho-adapter proteins 
14-3-3, including FOXO3 (7, 8, 51). Based on these initial observations, we formulated the 
hypothesis that MYC and CDCA7 association could be regulated in a transient manner though 
phosphorylation at Thr163 by Akt and binding to 14-3-3. 
To test whether Thr163 is a site of phosphorylation, we performed phosphotryptic mapping of 
CDCA7 isolated from cells labeled with 32P-orthophosphate (Figure 2.2A). One spot co-migrated 
with a synthetic phosphotryptic peptide for this residue, which disappeared upon mutation of 
Thr163 to alanine. Next, we generated a phospho-specific antibody to this site. The anti-phospho-
Thr163 antibody reacted with wildtype CDCA7 but not T163A CDCA7 (Figure 2.2B). Treatment 
of CDCA7 with calf intestinal phosphatase resulted in significant reduction in immunoreactivity 
(Figure 2.2B). These data establish that Thr163 is phosphorylated in cells. 
Next, we immunoprecipitated CDCA7 and found that it co-precipitated endogenous 14-3-3 in a 
phospho-Thr163-dependent manner (Figure 2.2C). Addition of a molar excess of a synthetic 
Thr163-containing phosphopeptide, but not the corresponding unphosphorylated peptide, caused 
a loss of 14-3-3 binding (Figure 2.2D). We mutated each residue surrounding Thr163 starting at -
7 to alanine and examined for 14-3-3 binding and reactivity to the phosphospecific antibody. Both 
the -5 and -3 arginine’s, Arg158 and Arg160, were absolutely required for 14-3-3 binding and 
phosphorylation of Thr163 (Figure 2.2E).  Mutation of phenylalanine 164 and proline 165 resulted 
in loss of phospho-Thr163 reactivity and loss of 14-3-3 binding. Interestingly, mutation of Arg161 
or Arg162 to alanine caused an increase in 14-3-3 binding and an apparent increase in Thr163 
phosphorylation. 
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Binding of 14-3-3 is known to alter numerous biological functions of their target proteins, 
including subcellular localization (21). In cells grown in 10% serum, over-expressed wildtype 
CDCA7 resided primarily in the nucleus and, to a lesser extent, cytoplasm (Figure 2.3A). In 
contrast, T163A CDCA7 was entirely nuclear with no cytoplasmic localization. Conversely, the 
R161A CDCA7 mutation caused both cytoplasmic and nuclear staining, correlating with the 
increased binding to 14-3-3 seen in Figure 2.2E. P165A mutation, which abolished 14-3-3 binding, 
likewise resulted in entirely nuclear localization. We quantified these observations by calculating 
the ratio of the fluorescence intensity of the cytoplasm (Fc) to nucleus (Fn) for each mutation. 
R161A CDCA7, as expected had the highest Fc/Fn ratio, which was similar to wildtype CDCA7 
stimulated with FGF. T163A, F164A and P165A all had low Fc/Fn ratios, consistent with their 
predominantly nuclear staining seen in Figure 2.3A and their low level of 14-3-3 binding seen in 
Figure 2.2E. 
Next, we asked if constitutive 14-3-3 binding independent of Thr163 phosphorylation could 
regulate localization. To test this, we substituted the 20 amino acids surrounding Thr163 with the 
R18 peptide (PHCVPRDLSWLDLEANMCLP). This peptide was isolated from a phage-display 
screen for peptides that bind strongly to 14-3-3, where the underlined D and E residues form 
contacts with 14-3-3 and substitute for phospho-amino acids (56). We found that DE-CDCA7 
bound to 14-3-3, and resulted in cytoplasmic CDCA7 (Figure 2.3C, D). As a control, we generated 
a protein in which the D and E residues were substituted with lysine. KK-CDCA7 did not bind to 
14-3-3 and was entirely nuclear (Figure 2.3C, D). Thus, the binding of 14-3-3 at Thr163 of CDCA7 
appeared to be responsible for its shift to the cytoplasm in cells. 
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Amino Acids 160-176 is a bipartite nuclear localization signal 
To account for the shift in localization due to Thr163 phosphorylation and 14-3-3 binding, we 
searched CDCA7 for a proximal NLS domain that could be influenced by 14-3-3. The presence of 
basic arginine residues at 160, 161, 162, and another cluster at 170, 171, 175 and 176 resembled 
the bipartite NLS domains of RB and SWI5 (Figure 2.4A). To test this, we asked whether the 
isolated region spanning amino acids 157–188 of CDCA7 could import a large cargo protein. We 
juxtaposed our test region between GFP and -galactosidase, which created a 140-kDa protein. A 
bona fide NLS isolated from SV40 caused the GFP--gal fusion protein to localize to the nucleus 
(Figure 2.4B). Introduction of a point mutation within the SV40 NLS resulted in cytoplasmic 
localization, validating this model for testing NLS activity. Insertion of amino acids 157-188 of 
CDCA7 resulted in nuclear localization, similar to the NLS of SV40 (Figure 2.4B). In contrast, 
subdivision of the full 157-188 region into smaller regions surrounding just the 14-3-3 binding 
site, amino acids 157-167, or the second cluster of arginine’s from 167-188, led to entirely 
cytoplasmic localization (Figure 2.4B).  This suggests that the entire region of 157 through 188 is 
needed for the nuclear import of the GFP--galactosidase fusion protein. 
We next tested the importance of the specific arginine residues within the putative NLS. Mutation 
of Arg160, 161 or 162 shifted the localization of the fusion protein to the cytoplasm (Figure 2.4C). 
Similarly, mutation of Arg171 or Arg176 individually to glutamic acid shifted the balance of 
localization from nucleus to cytoplasm, while the double mutation of R171E/R176E led to 
complete nuclear exclusion (Figure 2.4C). Finally, mutation of Arg182 or Arg184 had no effect 
on localization (Figure 2.4C). These results indicate that arginine’s 160, 161, 162, 171 and 176 
compose the critical basic residues of a potential bipartite NLS within CDCA7. 
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Akt phosphorylates Thr163 of CDCA7 
Next, we asked whether Thr163 phosphorylation changed in cells treated with mitogenic stimuli. 
We expressed CDCA7 in 3T3 fibroblast cells followed by stimulation with PDGF, and found that 
Thr163 phosphorylation increased rapidly and remained sustained for several hours (Figure 2.5A). 
Furthermore, we found that PDGF stimulation led to increased cytoplasmic localization that lagged 
behind phosphorylation of Thr163 (Figure 2.5B). Finally, GFP-CDCA7 was visualized in live cells 
over a time course of PDGF stimulation (Figure 2.5C,D). This experiment showed that 
cytoplasmic GFP-CDCA7 signal increased approximately 3-fold, which agreed well with the 
kinetics observed by immunoblotting in Figure 2.5B.  
We then expressed CDCA7 or T163A CDCA7 in 3T3 cells and performed immunofluorescence 
with anti-phospho-Thr163 antibody (Figure 2.5E). This showed that there was a small amount of 
primarily nuclear phospho-Thr163 signal in unstimulated cells. Stimulation with PDGF for 15 and 
60 minutes resulted in an increase in both nuclear and cytoplasmic phospho-Thr163 signal, 
corresponding to the appearance of cytoplasmic CDCA7. Finally, we isolated nuclear and 
cytoplasmic fractions of cells expressing CDCA7 following treatment with LY-294002, a PI3K 
inhibitor (Figure 2.5F). Cytoplasmic CDCA7 was present in cells maintained in serum, but was 
abolished upon treatment with LY-294002. The T163A CDCA7 mutation caused very little 
detectable cytoplasmic CDCA7. 
We were able to detect endogenous CDCA7 in 3T3 cells by immunofluorescence using an 
antibody raised against CDCA7 (Abcam). This experiment showed that under serum-starved 
conditions endogenous CDCA7 was predominantly nuclear with some cytoplasmic staining 
(Figure 2.6A). Stimulation with PDGF for 30 minutes caused a pronounced shift to the cytoplasm. 
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Pre-treatment of cells with LY294002, wortmannin, or Akt inhibitor VIII, each potent inhibitors 
of PI3K and Akt, completely reversed the cytoplasmic localization of endogenous CDCA7 in 
response to PDGF, with pronounced staining of endogenous CDCA7 in the nucleus. Moreover, 
stimulation of cells with PDGF caused an increase in the amount of detectable endogenous Thr163 
phosphorylation (Figure 2.6B). This was different from ectopically expressed CDCA7 and GFP-
CDCA7: rather than being localized to the nucleus and cytoplasm, endogenous phospho-CDCA7 
signal was detected primarily in the cytoplasm at 60 minutes. This might be a result of the lower 
amount of endogenous CDCA7 protein compared with over-expressed CDCA7, which could 
overwhelm the cells resources to shuttle phospho-CDCA7 from the nucleus. Pre-treatment with 
LY-294002 abolished the elevated Thr163 phosphorylation induced by PDGF (Figure 2.6B). 
The observations that LY294002 could block the phosphorylation of endogenous Thr163, and 
reduce the cytoplasmic localization of CDCA7, suggested that a downstream effector of PI3K, 
such as Akt, might phosphorylate CDCA7 at this site. Treatment of cells with LY294002 reduced 
Thr163 phosphorylation (Figure 2.7A). To test if this was a result of loss of Akt activation, we co-
expressed gag-Akt, a membrane bound, constitutively active form with wildtype CDCA7 or 
T163A CDCA7. Gag-Akt caused an elevation of Thr163 phosphorylation of CDCA7 and 14-3-3 
binding (Figure 2.7B) that was lost upon mutation of Thr163 to alanine. Active recombinant Akt 
directly phosphorylated CDCA7, but not T163A CDCA7, in vitro (Figure 2.7C). Inhibition of Akt 
in cells with Akt inhibitor VIII blocked phosphorylation of CDCA7 in cells (Figure 2.7D). Co-
expression of gag-Akt with CDCA7 caused a redistribution of wildtype CDCA7 from the nucleus 
to the cytoplasm, but not T163A CDCA7 (Figure 2.7E). Finally, expression of CDCA7 in mouse 
embryonic fibroblasts in which Akt1 and Akt2 were deleted by homologous recombination 
resulted in diminished Thr163 phosphorylation (Figure 2.7F). PDGF-stimulated phosphorylation 
53 
 
of Thr163 was reduced in Akt1/2 -/- MEFs compared with wildtype MEFs, which was similar to 
the reduction of total Ser473 phosphorylation detected for the remaining endogenous Akt3 (Figure 
2.7G). Together, these experiments provide strong evidence that Akt catalyzes Thr163 
phosphorylation. 
Binding of 14-3-3 regulates CDCA7 – MYC interaction 
Since Akt phosphorylates CDCA7 and promotes 14-3-3 binding very near the residues required 
for MYC interaction, we thought that phosphorylation-dependent 14-3-3 binding could cause a 
change in association between CDCA7 and MYC. When we compared wildtype CDCA7 and 
T163A CDCA7 for their ability to co-immunoprecipitate MYC from cells, we found that more 
MYC bound to T163A CDCA7 than the equivalent amount of wildtype CDCA7 (Figure 2.8A). 
Using purified proteins in pull-down experiments, we found that DE-CDCA7, which binds to 14-
3-3 constitutively, immunoprecipitated less MYC, similar to the loss of MYC interaction seen with 
(156-187)-CDCA7 (Figure 2.8B). On the other hand, the non-14-3-3 interacting control protein, 
KK-CDCA7, did bind to MYC, about as well as wildtype CDCA7.  
If 14-3-3 directly competes with MYC for sites of association on CDCA7, then recombinant 14-
3-3 should compete with MYC for CDCA7 binding. So, we incubated recombinant MYC with 
purified FLAG-CDCA7 stripped of endogenous 14-3-3 by SDS treatment, together in the presence 
or absence of recombinant 14-3-3 (Figure 2.8C). We rationalized that a fraction of the purified 
CDCA7 binding to MYC would be phosphorylated at Thr163, and if 14-3-3 competes with MYC 
then addition of 14-3-3 should break this interaction. This was found to be the case, as 14-3-3 
dramatically reduced the amount of Thr163-phosphorylated CDCA7 co-precipitating with MYC 
(Figure 2.8C). Together, these experiments indicate that 14-3-3 competes with MYC for binding 
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to CDCA7. Furthermore, when co-expressed in Rat1 cells, MYC co-localizes with non-14-3-3 
binding CDCA7 mutants T163A and KK, while MYC co-localized to a lesser degree with wildtype 
CDCA7 and the 14-3-3 binding DE mutant containing the R18 peptide substitution (Figure 2.8D). 
Together these results show that 14-3-3, by competing with MYC, alters CDCA7 location in the 
cell, and therefore its degree of interaction with MYC. 
CDCA7 expression sensitizes cells to serum withdrawal-induced apoptosis 
We next established Rat1 fibroblast cells expressing MYC under a constitutive CMV promoter 
(termed MYC-Rat1). These cells underwent apoptosis following 4-24 hours of serum withdrawal, 
reproducing the findings of Evan et al. (18). In order to investigate if CDCA7 altered MYC-
dependent apoptosis, we expressed CDCA7 under the control of a doxycycline-inducible promoter 
in either parental Rat1-TET-ON or MYC-Rat1-TET-ON fibroblasts. Several independent clones 
were isolated from each and all showed a low level of CDCA7 expression when grown in serum 
supplemented with 10 ng/ml doxycycline (Figure 2.9A). When doxycycline was increased to 1000 
ng/ml, the level of expression of CDCA7 increased approximately 100-fold (Figure 2.9A). 
Interestingly, we were not able to generate T163A-CDCA7-MYC-Rat1 cells. Colonies that were 
isolated were either negative for MYC expression or negative for T163A CDCA7, indicating a 
possible prohibitive condition for co-expression.  
To see if there was an effect on apoptosis upon up-regulation of CDCA7, we pre-treated CDCA7-
Rat1 or CDCA7-MYC-Rat1 with doxycycline for 18 hours, followed by 4 hours of serum 
withdrawal. The CDCA7-MYC-Rat1 cells were sensitized to apoptosis with increasing 
concentration of doxycycline (Figure 2.9C). Only a minor increase in apoptosis was observed with 
up-regulation of CDCA7 in the absence of ectopic MYC expression (Figure 2.9C). Next, we asked 
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if the non-MYC binding CDCA7, (156-187)-CDCA7 would alter MYC-dependent apoptosis 
(Figure 2.9D). Here we treated CDCA7-MYC-Rat1 or (156-187)-CDCA7-MYC-Rat1 cells with 
doxycycline for 18 hours and then serum starved for 4 hours. This result showed that despite a 
high level of MYC expression (Figure 2.9B), the (156-187)-CDCA7-MYC-Rat1 cells were no 
longer susceptible to serum-withdrawal induced apoptosis, suggesting that (156-187)-CDCA7 
was acting as a dominant negative and repressing MYC-induced apoptosis.  
Loss of CDCA7 expression reduces MYC-dependent apoptosis. 
Endogenous CDCA7 mRNA levels in MYC-Rat1 cells were between 2- and 5-fold higher 
compared to Rat1 cells not expressing ectopic MYC (data not shown), consistent with an earlier 
report that the cdca7 promoter is a target of MYC (44). Since we have shown that elevated levels 
of ectopic CDCA7 sensitized MYC-Rat1 cells to apoptosis upon serum withdrawal, we 
hypothesized that the elevated levels of both CDCA7 and MYC in the MYC-Rat1 cells may act 
together to cause the higher levels of apoptosis seen in these cells. In addition, the loss of apoptosis 
as a result of expression of (156-187)-CDCA7 suggested that CDCA7 was necessary for MYC-
sensitized apoptosis. To test this, we created MYC-Rat1 lines expressing shRNA sequences 
targeting endogenous CDCA7. This resulted in a knockdown of endogenous CDCA7 messenger 
RNA compared to a control line expressing scrambled shRNA (Figure 2.10A). These Rat1-MYC-
sh lines maintained high levels of MYC as detected by immunoblot (Figure 2.10B). When cultured 
in 0.2% serum overnight, Rat1-MYC-sh cells exhibited less morphological evidence of apoptosis 
when compared to their MYC-Rat1 parental lines (Figure 2.10D), and experienced less cell death 
measured by trypan blue exclusion (Figure 2.10E), and less apoptosis when measured by Annexin 
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V-binding assay (Figure 2.10C), or by caspase-3 activity (Figure 2.10F, G). Together, these result 
show that CDCA7 is necessary for MYC to promote apoptosis upon serum withdrawal. 
CDCA7 expression alters MYC-dependent transformation 
We next asked whether CDCA7 alters MYC-induced transformation. We assessed this by 
expressing CDCA7 in the MYC-Rat1 cells and evaluating soft agarose colony formation. To 
overcome the negative selection of prolonged expression of T163A CDCA7 and MYC, we 
introduced CDCA7 and mutants into the MYC-Rat1 cells by retroviral infection, followed by a 
short selection period and analysis of the polyclonal pools. These results showed that both wildtype 
and T163A CDCA7 reduced the number of macroscopic colonies resulting from MYC expression, 
indicating that increased expression of CDCA7 interferes with MYC-induced transformation 
(Figure 2.11A,B). Surprisingly, (156-187)-CDCA7 expression largely inhibited MYC-dependent 
colony formation, suggesting that this protein was acting as a dominant negative, similar to its 
effects on MYC-dependent apoptosis. Parental Rat1 cells did not form colonies (Figure 2.11A), 
and we found no effect of CDCA7 expression alone in Rat1 (data not shown), in agreement with 
pervious results of Prescott and coworkers (44). Finally, stable knockdown of CDCA7 also 
reduced the number of macroscopic colonies formed compared to Rat1-Myc cells expressing 
scrambled shRNA (Figure 2.11C,D). Together, these results suggest that CDCA7 is a necessary 
co-factor for Myc-induced transformation and apoptosis. 
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Figure 2.1. Mapping of CDCA7 and MYC association. A. Sequence alignment of CDCA7 
within amino acids 131 and 180 of human CDCA7 and from various other species. The asterisk 
indicates the position of a putative Akt phosphorylation/14-3-3 binding site. B. Purified CDCA7 
or various truncations were incubated with His-MYC and subjected to pulldown with Ni-Agarose, 
followed by immunoblotting with anti-FLAG antibody (upper panel). A reserved portion of the 
input CDCA7 was also immunoblotted with anti-FLAG (lower panel). C. Schematic diagram of 
the region of interaction. D. Purified full length His-MYC or containing various truncations were 
incubated with purified FLAG-CDCA7 or 156-187-CDCA7 and subjected to pull-down with 
Ni-agarose and immunoblotted with anti-FLAG antibody. Input His-MYC was detected with an 
N-terminal anti-MYC antibody (D84C12) or a C-terminal antibody (9E10). E. Endogenous MYC 
was immunoprecipitated from HEK293 cells and endogenous CDCA7 was detected by 
immunoblotting with anti-CDCA7 (Sigma). Anti-FLAG antibody was used as a non-specific 
immunoprecipitation control. 
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Figure 2.2. CDCA7 is phosphorylated at Thr163 and binds to 14-3-3. A. Two-dimensional 
tryptic maps of wildtype and T163A-CDCA7. Dotted circle indicates the position of cold synthetic 
Thr163 tryptic peptide co-migrated with 32P-labelled peptides. B. A phosphor-specific antibody 
raised against phosphor-Thr163 peptide was used to immunoblot CDCA7, CDCA7 pretreated with 
calf intestinal phosphatase, or T163A-CDCA7. C. CDCA7 or T163A-CDCA7 was expressed in 
cells and immunoprecipitated with anti-FLAG-agarose. Co-immunoprecipitated proteins were 
detected with anti-FLAG or anti-14-3-3 immunoblotting to detect endogenous 14-3-3. D. 14-3-3 
bound to CDCA7 was competed with increasing concentrations of the synthetic phospho-Thr163 
peptide or the unphosphorylated peptide. Following several washes, proteins were resolved by 
PAGE and immunoblotted with anti-FLAG or anti-14-3-3 antibodies to detect co-
immunoprecipitated endogenous 14-3-3. E. CDCA7 containing the indicated mutations was 
immunoprecipitated and proteins were immunoblotted with anti-FLAG, anti-phospho-Thr163 or 
anti-14-3-3. 
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Figure 2.3. Thr163 phosphorylation alters CDCA7 localization. A. NIH3T3 cells were 
transfected with FLAG-CDCA7 containing the indicated mutations on coverslips. After 24 hours, 
cells were fixed in methanol and immunofluorescence microscopy was performed to detect 
CDCA7. B. NIH 3T3 cells were transfected with various FLAG-CDCA7 cDNA's for 24 hours, 
followed by stimulation of some samples with FGF for the indicated times. Cells were fixed, 
stained with anti-FLAG and visualized by confocal microscopy. The fluorescence intensity of the 
cytoplasm (Fc) and the nucleus (Fn) were measured in a blind analysis for each sample, and the 
ratio Fc/Fn was calculated. Error bars represent the standard error of the mean for a minimum of 
30 cells for each sample. C. Cells expressing CDCA7, T163A-CDCA7, DE-CDCA7 or KK-
CDCA7 were lysed and CDCA7 was immunoprecipitated with anti-FLAG M2 agarose. Co-
immunoprecipitated endogenous 14-3-3 was detected by anti-14-3-3 immunoblotting. D. NIH 3T3 
cells were plated on coverslips and transfected with FLAG-DE-CDCA7 or FLAG-KK-CDCA7. 
After 24 hours, cells were fixed, stained with anti-FLAG antibody, and immunofluorescence 
microscopy was performed. 
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Figure 2.4. Amino acids 167-188 of CDCA7 comprise a putative bipartite NLS. A. Sequence 
alignment of CDCA7 with the bipartite NLS domains of human RB protein and SWI5 protein. B. 
NIH3T3 cells were transfected on glass coverslips with a vectors expressing pFloc-GFP-SV40--
gal, pFloc-GFP-SV40KE--gal, or pFloc-GFP-CDCA7peptide--gal containing various regions 
of CDCA7 as indicated for 24 hours. The following day GFP signal in live cells were visualized 
by fluorescence microscopy. C. pFloc-GFP-CDCA7peptide--gal containing amino acids 156-188 
of CDCA7 and the indicated mutations were transfected into NIH3T3 cells plated on coverslips. 
The next day, cells were fixed with methanol and visualized by confocal microscopy. 
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Figure 2.5. PDGF stimulates CDCA7 phosphorylation at Thr163 and cytoplasmic 
translocation. A. NIH3T3 cells were transfected with FLAG-CDCA7, and the following day were 
starved of serum for 6 hours and stimulated with PDGF for the indicated times. Cells were then 
solubilized in 0.25% NP-40 buffer and nuclei were removed by centrifugation. Lysates were 
probed with anti-phospho-Thr163 and anti-FLAG and both signals were detected simultaneously 
on an Odyssey infrared scanner. The dual colored image represents the merge of the phospho- (680 
nm) and FLAG- (800 nm) signals with ratios of intensities shown beneath. B. Graphical 
representation of A. C. NIH3T3 cells were transfected with GFP-CDCA7 on a No.1 glass bottom 
chamber. After 24 hours, the cells were starved of serum for 6 hours and visualized on a Spinning 
Disc Confocal microscope. At T=0’, PDGF was added and the cells were captured every 5 minutes 
for one hour. D. Cytoplasmic fluorescent intensity was determined using Ultraview software 
(Perkin Elmer) and plotted against time of PDGF stimulation. The intensity of the nuclei was also 
measured and decreased by approximately 5% over the time period (not shown).  E. NIH3T3 cells 
were transfected on glass coverslips with FLAG-CDCA7 or T163A-CDCA7 for 24 hours. 
Following a 6 hour of serum starvation, cells were stimulated with PDGF for the indicated times, 
fixed with methanol, and visualized with anti-FLAG and anti-phospho-Thr163 
immunofluorescence microscopy. F. NIH 3T3 cells were transfected with CDCA7 or T163A 
CDCA7, and the following day were incubated with 50 mM LY294002 for 1 hour before nuclear 
and cytoplasmic extracts were isolated. CDCA7, endogenous Akt and P-Thr308 Akt were detected 
by immunoblotting with -FLAG , -Akt and -P-Thr308 Akt antibodies. 
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Figure 2.6. Endogenous CDCA7 is phosphorylated at Thr163 and translocates to the 
cytoplasm upon PDGF stimulation. A. NIH3T3 cells were plated on glass coverslips and starved 
of serum for 6 hours. PDGF was added for one hour together with LY294002 (25 M), 
Wortmannin (100 nM), Akt Inhibitor VIII (2.5 M) or vehicle where indicated. Cells were fixed 
in methanol and stained with anti-CDCA7 and DAPI, and visualized by florescence microscopy. 
B. Similar experiment as in A, except that cells were stained with anti-phospho-Thr163. 
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Figure 2.7. Akt phosphorylates CDCA7 at Thr163. A. Cells expressing CDCA7 were treated 
with the PI3K inhibitor LY294002 for 1 hour, lysed and immunoblotting was performed to detect 
Thr163 phosphorylation and total CDCA7. B. 293 cells were transfected with CDCA7 together 
with empty vector or Gag-Akt. 24 hours later CDCA7 was immunoprecipitated and 
phosphorylation of Thr163 and co-immunoprecipitated endogenous 14-3-3 were visualized by 
immunoblotting. C. Purified CDCA7 was phosphorylated in vitro with recombinant active 
(S473D)-Akt and 32P--ATP. Proteins were resolved by PAGE and visualized by autoradiography. 
Total CDCA7 and Akt were detected by immunoblotting. D. Cells expressing CDCA7 were treated 
with the Akt inhibitor VIII (0.5 and 2.5 M) for 20 min, lysed, and phosho-Thr163 and total 
CDCA7 were detected by immunoblotting. E. NIH3T3 cells were transfected with WT CDCA7 
or T163A CDCA7 together with vector or Gag-Akt. The next day cells were fixed and stained with 
anti-FLAG (for total CDCA7) and anti-phospho-S473 (for active Akt). F. Akt 1/2 +/+ and -/- 
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MEFs were transfected with CDCA7 on glass coverslips overnight in the presence of serum, fixed 
with methanol, stained with -FLAG and -P-Thr163 and visualized by immunofluorescence 
microscopy. G. Akt 1/2 +/+ and -/- MEFs were transfected with CDCA7 for 24 hours, starved of 
serum overnight, and then stimulated with PDGF for 1 hour. CDCA7 was detected by 
immunoblotting with -FLAG and -p-Thr163 antibodies. The numbers beneath each lane 
represent the ratio of p-Thr163/FLAG signals obtained by direct immunofluorescence detection 
on an Odyssey infrared imager. Lysates were also probed with -pan-Akt (Cell Signaling 
Technology; which detects Akt 1, 2 and 3; arrow indicates Akt band), and a-P-S-473 Akt (Cell 
Signaling Technology). 
 
 
 
 
 
66 
 
 
Figure 2.8. 14-3-3 competes with MYC for binding to CDCA7. A. 293 cells were transfected 
with MYC together with empty vector, FLAG-CDCA7 or FLAG-T163A CDCA7. Detergent 
solubilized cell extracts were prepared and FLAG-CDCA7 was immunoprecipitated with anti-
FLAG M2 antibody. B. Recombinant His-MYC was purified on Ni-Agarose, and wildtype 
CDCA7, 153-188 CDCA7, DE-CDCA7 or KK-CDCA7 were added, the beads rotated 1 hour, 
washed and boiled in sample buffer. Co-precipitated CDCA7 was detected by FLAG 
immunoblotting. C. CDCA7 was immunoprecipitated from cells and incubated with recombinant 
His-MYC with and without recombinant 14-3-3. CDCA7 bound to MYC was precipitated by Ni-
agarose. 14-3-3 specifically reduced the amount of phospho-Thr163 CDCA7 bound to MYC. D. 
Rat1 fibroblasts were co-transfected with FLAG-CDCA7 and CMV-MYC plasmids, 
immunostained, and localization was visualized by confocal florescence microscopy.  MYC co-
localizes with CDCA7 in the nucleus when Thr163 was mutated to alanine, or with the non-14-3-
3 binding R18 peptide (KK) but not with wildtype CDCA7 or the 14-3-3 binding CDCA7 
containing the R18 peptide (DE).  
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Figure 2.9. CDCA7 increases MYC-induced apoptosis. A. Rat1 cells or Rat1 cells expressing 
MYC were established with CDCA7 expression under the control of a doxycycline-inducible 
promoter as described in Experimental Procedures.  After 24 hours of doxycycline treatment at 
various concentrations, cells were lysed and CDCA7 was detected by immunoblotting. B. Various 
cell lines from A were immunoblotted for the presence of ectopically expressed MYC, indicated 
by arrow. C. CDCA7-Rat1 and CDCA7-MYC-Rat1 cells were treated with the indicated 
concentrations of doxycycline for 18 hours, followed by serum starvation for 4 hours. Apoptosis 
was measured by Annexin-V labeling and flow cytometry. The error bars represent the range of 
duplicate samples, and are representative of three independent experiments. D. MYC-Rat1, 
CDCA7-Rat1, CDCA7-MYC-Rat1 and (156-187)-CDCA7-MYC-Rat1 cells were cultured for 
18 hours in 10 ng/ml doxycycline, followed by serum starvation for 4 hours. Apoptosis was 
determined by Annexin-V labeling and flow cytometry. The error bars represent the range of 
duplicate samples, and are representative of three experiments.  
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Figure 2.10. Knockdown of CDCA7 rescues Rat1-MYC cells from serum-withdrawal 
induced apoptosis. shRNA-expressing Rat1 cell lines in which endogenous CDCA7 was knocked 
down were established in the presence of ectopic MYC as described in Materials and Methods 
(Rat1-MYC-sh1, Rat1-MYC-sh2).  Additionally, control lines were established using a scrambled 
version of the CDCA7 targeting sequence (Rat1-MYC-scrmb). A. Quantitative RT-PCR of ectopic 
MYC (black bars) and endogenous CDCA7 (gray bars) was performed on scrambled shRNA-
expressing Rat1-MYC cells, or Rat1-MYC cells expressing shRNA-targeted CDCA7. 
Quantitative RT-PCR was performed in triplicate for each clone. B. MYC levels of shRNA Rat1-
MYC lines were determined by immunoblotting. C. Rat1-MYC, Rat1-MYC-sh1 and Rat1-MYC-
sh2 cells were serum starved for 4 or 24 hours and apoptosis was measured by Annexin-V labeling 
and flow cytometry. Error bars represent the standard deviation of triplicate samples. D. Rat1, 
Rat1-MYC, or Rat1-MYC-sh1 cells grown to 40% confluency were placed in 0.2% serum 
overnight. DIC images were captured using bright field microscopy. E. Rat1-MYC-Scrmb1 or 
Rat1-MYC-sh1 cells were plated as in D and the following day trypan blue-positive cells were 
counted as a percentage of total cells using a hemocytometer. F. Rat1-MYC cells as well as two 
scrambled lines, and two lines expressing shRNA-targeted CDCA7 were plated in triplicate, 
starved in 0.2% serum for 4 hours, and assayed for caspase-3 activity.  G.  Rat1-MYC-scrmb-1 
cells and Rat1-MYC-sh1cells were plated in triplicate in various serum concentrations for 4 hours, 
and assayed for caspase-3 activity.  
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Figure 2.11. CDCA7 influences MYC-induced transformation. A. Rat1 cells or Rat1 cells 
stably expressing MYC were infected with retrovirus containing either empty vector, wildtype 
CDCA7, (156-187)-CDCA7 or T163A-CDCA7. Hygromycin-resistant pools were isolated after 
5 days of selection and 5 x 103 cells were plated in complete medium containing 0.3% agarose 
over a 0.7% agarose bottom layer, as described in Materials and Methods. Two weeks later 
colonies were stained with crystal violet, destained with water, and imaged on an Odyssey infrared 
scanner using a 4 mm offset and 41 m resolution setting.  B. Colonies were counted using ImageJ 
software, with the error bars representing the standard deviation of 6 individual wells. The * 
indicates a significant difference with WT CDCA7 (p=0.0005), while ** indicates a significant 
difference with vector alone (p=0.0003) and *** indicates a significant difference with vector 
alone (p=0.004). Lysates of the hygromycin-resistant pools were immunoblotted with -FLAG. 
C. Rat1-MYC-scrmb or Rat1-MYC-sh cells were plated as in A, and colonies were stained after 
two weeks with crystal violet.  D. Macroscopic colonies were counted using ImageJ from 4 
individual wells, with error bars representing the standard deviation. The * indicates a significant 
difference with Rat1-MYC-scrmb (P=0.001).  
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Discussion 
 
Aberrant proliferation induced by MYC is opposed by apoptosis and/or cell cycle arrest, providing 
cells with a safety mechanism against the onset of MYC-induced hyper-proliferation and 
tumorigenesis (57). During normal development, proliferative signals result in activation of 
pathways that instruct the cell to co-operate with MYC and divide. Phosphoinositide 3-OH kinase 
is at the apex of one important pathway activated by mitogenic stimuli and one of its main 
effectors, Akt, cooperates with MYC to suppress pro-apoptotic gene expression while 
simultaneously instructing the cell towards division (29). Given the important roles of both Akt 
and MYC in cancer pathology, there is an urgent need to understand the mechanism of cooperative 
signaling between these two regulators. 
In this report, we found that the transcriptional regulator CDCA7 was phosphorylated by Akt and 
this caused its disengagement from MYC and sequestration to the cytoplasm by binding to 14-3-
3. The binding of 14-3-3 to CDCA7 appeared to be competitive for MYC binding, as addition of 
recombinant 14-3-3 led to reduced co-precipitation of phospho-Thr163 CDCA7 and MYC. In 
addition, we found that this region harbored nuclear localization activity. Mutation of predicted 
consensus sites derived from the bipartite NLS domains of RB (16) and SWI5 (37) led to loss of 
nuclear localization of a large cargo protein. Mutation of two of these sites, Arg161 and Arg162, 
led to enhanced cytoplasmic localization of CDCA7, which was accompanied by increased 
phosphorylation of Thr163 and 14-3-3 binding.  
When CDCA7 was ectopically expressed with MYC there was a sensitization to serum-withdrawal 
apoptosis. Surprisingly, the (156-187)-CDCA7 mutation reduced serum-withdrawal induced 
apoptosis, suggesting that this protein was acting as a dominant negative and interfering with the 
pro-apoptotic function of MYC.  Conversely, knockdown of endogenous CDCA7 rescued MYC-
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expressing cells from apoptosis following serum withdrawal. These results argue that CDCA7 is 
an important co-factor in the ability of MYC to regulate target gene expression and, under 
physiological conditions, CDCA7 may be important for the normal regulation of MYC-target 
genes. On the other hand, dysregulation of this pathway becomes pro-apoptotic under 
pathophysiological conditions.  
Consistent with this, transformation of fibroblasts by MYC was also influenced by CDCA7. Co-
expression of CDCA7 reduced anchorage-independent colony growth, indicating that over-
expression of CDCA7 interferes with the process of MYC-transformation. Importantly, the (156-
187)-CDCA7 appeared to act as a dominant negative under these conditions, as this protein greatly 
reduced colony formation. These results suggest that CDCA7 influences MYC-induced 
transformation, with high level expression causing interference, possibly by increasing apoptosis 
within the forming colonies, while expression of (156-187)-CDCA7 interferes by disrupting the 
association of MYC with either endogenous CDCA7 or other factors that require full length 
CDCA7 for interaction. In support of this, knockdown of endogenous CDCA7 also reduced the 
transformation potential of MYC, again arguing that CDCA7 is required for MYC transforming 
activity. These observations are in general consistent with the earlier findings of Prescott and co-
workers (44), who found that CDCA7 rescued transformation by MYC containing a 
transformation-defective MYC-Box II deletion, supporting the hypothesis of a genetic link 
between CDCA7 and MYC.  While Prescott and coworkers found that CDCA7 co-expression did 
not significantly increase or decrease MYC-induced transformation (44), the difference between 
our experiments and those of Prescott and coworkers could be reflected by the levels of expression 
of MYC, CDCA7, or a combination of both. Future studies will examine if ectopic CDCA7 
expression reduces transformation as a direct result of increased apoptosis. 
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Interestingly, the cdca7 gene has itself been reported to be a target of MYC (22, 44). In our own 
experiments, overexpression of MYC in Rat1 cells caused a 2-5 fold increase in cdca7 mRNA, 
suggesting that a feed forward loop exists whereby MYC activation leads to elevated CDCA7. We 
hypothesize that growth factor signals use Akt activity to finely tune the activation of MYC 
through CDCA7, with loss of Akt activating the pro-death effects of CDCA7/MYC, tipping cell 
fate towards apoptosis.  
An important question remaining is the alteration of global gene expression caused by 
CDCA7/MYC interaction. The related protein JPO2 was shown to bind to SP1 sites of the MAOA 
gene via its C-terminal Zinc Finger domain (42). CDCA7 and JPO2 are 77% identical within this 
region, suggesting that CDCA7 may also bind to similar SP1 elements. MYC-binding E-box sites 
are preferentially enriched with SP1 elements across the genome (43), suggesting that CDCA7 and 
MYC might cooperate to regulate these genes. It also remains to be determined what role CDCA7 
plays in the context of cell fate determination during early development, where MYC expression 
is tightly regulated, and also the role that CDCA7 might have with other transcription factors in 
non-MYC expressing cells.  
In summary, we have identified a new target of Akt that is required for the pro-apoptotic and 
transformation properties of MYC. Akt phosphorylates CDCA7 within a 14-3-3 binding site, 
disrupting its interaction with MYC and resulting in CDCA7 transit from the nucleus to the 
cytoplasm. The fine-tuning of CDCA7 and MYC interaction by phosphorylation at Thr163 could 
represent an important physiological role for Akt, and one that becomes pathophysiological under 
conditions of an overactive Akt axis.  
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Chapter 3: CDCA7 Co-association and 14-3-3 Binding 
 
Introduction 
Since their discovery in 1967, 14-3-3 proteins have gained notoriety as being regulators of 
signaling pathways that effect a wide variety of cellular processes including apoptosis, 
metabolism, cell cycle regulation and general protein trafficking. 14-3-3 is a highly conserved 
protein which has been detected in all eukaryotic organisms to date but has yet to be identified in 
prokaryotes. This ~30KDa acidic polypeptide binds specific phosphoserine/threonine motifs 
(RSXpSXP or RXXXpSXP) on client proteins. 14-3-3 exerts its function by either inducing 
conformational change, providing scaffolding or by obstruction of key physical or sequence-
specific features of its target protein (Bridges and Moorhead, 2004). 14-3-3 proteins exist as either 
heterodimers in permutations of the seven 14-3-3 isomer families, or as homodimers of the same 
14-3-3 family. X-ray crystallography has shown that each monomer of 14-3-3 can concurrently 
bind a target motif on either a single client protein or on two separate proteins (Gardino et al, 
2006). Because of the phospho-dependent nature of 14-3-3 binding, these associations have been 
intimately linked to many of the key phospho-regulatory cascades that influence normal cell cycle 
progression and cell growth. Dysregulation of these pathways often lead to disease such as cancer 
and incriminate 14-3-3 in in the process (Morrison, 2009). 
14-3-3 and apoptotic/survival signalling 
The tug of war between apoptotic and survival signalling is at the heart of cell cycle control and 
the cell fate decision making process. 14-3-3 proteins are known to influence this fine balance by 
affecting the activity of proteins involved in proliferation and apoptosis. For example, 14-3-3 has 
been shown to localize the pro-apoptotic transcription factor FOXO1 to the cytoplasm by first 
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exposing its nuclear export sequence (NES) and then masking a nuclear important sequence 
(NLS). In this instance, apoptosis is inhibited by preventing the transactivation of pro-apoptotic 
genes by FOXO1. This inhibition of apoptosis is abolished when the FOXO1/14-3-3 complex is 
disrupted when stress signals result in the phosphorylation of FOXO1 by Jun-N-terminal kinase 
(JNK) (Donovan et al., 2002). 14-3-3 has also been shown to promote proliferation by influencing 
members of the mitogen activated protein kinase (MAPK) cascade. For example, maximal activity 
of C-Raf kinase depends on 14-3-3 mediated heterodimerization with B-Raf, resulting in the 
proliferative outcomes associated with the MAPK cascade (Rushworth et al., 2006). Mutations in 
BRAF have been found in human cancers, and are associated with constitutive 14-3-3 dependent 
heterodimerization of C-Raf and B-Raf proteins. It has been shown that 14-3-3 is therefore 
required for the transforming ability of B-Raf proteins (Wan et al, 2004).  
14-3-3 and tumor suppression 
The ability to supress cell-growth and cell-cycle progression in the event of DNA damage is an 
imperative step in tumor-suppression activity. 14-3-3 has been shown to be involved in this 
process. For example, upregulation of 14-3-3 by p53 and breast cancer type 1 susceptibility protein 
(BRCA1) results in the DNA-damage-induced cell-cycle checkpoint (Hermeking et al., 1997; 
Aprelikova et al., 2001). Expression of 14-3-3 by these tumor suppressor results in binding of the 
Cyclin-B1/Cdc2 complex and its cytoplasmic sequestration, leading to a halt of cell cycle 
progression thereby allowing DNA damage repair to take place (Chan et al., 1999). Loss of 14-3-
3 expression has been associated with tumors of the epithelium, most notably in breast cancer 
(Lodygin and Hermeking, 2006). Loss of 14-3-3 activity can occur by numerous means, including 
targeted ubiquitin-mediated degradation and hypermethylation of the 14-3-3 promoter (Umbricht 
et al., 2001).  
81 
 
14-3-3 as a cancer therapeutic target 
Epigenetic silencing of 14-3-3 is a phenomenon which takes place early in carcinogenesis and 
often occurs before any cancerous morphology is evident. This fact offers an opportunity for early 
detection of disease and recurrence in cancer patients by monitoring 14-3-3 methylation in various 
bodily fluids (Bhatia et al., 2003). This may prove to be a promising approach for cancer detection 
when considering that 14-3-3 downregulation via CpG hypermethylation has been detected in 
adenocarcinomas of the breast (96%), in hepatocellular carcinoma (89%), in lung cancer (83%) 
and endometroid endometrial adenocarcinoma (74%) (Ferguson et al., 2000; Moreira et al., 2004; 
Iwata et al., 2000).  
A promising therapeutic approach relies on the leveraging of methylation inhibitors to reverse 14-
3-3 silencing via CpG hypermethylation. The methyltransferase inhibitor 5-aza-2deoxycytidine 
(5-Azra) has been shown to reverse silencing of 14-3-3 via CpG hypermethylation and induce 
expression of 14-3-3 to pre-cancerous levels in vivo. Although different cell lines have exhibited 
unique sensitivities to 5-Azra, clinical trials focusing on cancer patients remain promising 
(Esteller, 2005).  
In examples where 14-3-3 activity is implicated in cancer initiation and progression, such as in the 
case of B-Raf/BRAF, targeted inhibition of 14-3-3 may prove to be an effective treatment strategy. 
This has been achieved by down regulation of 14-3-3 via siRNA, increasing the sensitivity of lung 
carcinomas, head and neck cancers and diffuse large B cell lymphomas to ionizing radiation and 
other apoptosis-inducing treatments (Fan et al., 2007, Maxwell et al., 2009 and Matta et al., 2010). 
In the almost half century since their discovery, 14-3-3 proteins have proven to play a crucial role 
in a wide array of cellular processes. These include apoptosis, cell growth and cell-cycle 
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progression. Although 14-3-3 proteins themselves posses no intrinsic catalytic activity, they serve 
as organizational nodes for signaling cascades that rely on serine/threonine kinases. An increased 
interest in epigenetics and methylation over the last ten years has broadened the scope of 14-3-3 
function and influence. Advances in proteomics and the ongoing mapping of the proteome has 
revealed the far-reaching implications of 14-3-3 via its 200 plus binding partners. There is no doubt 
that our understanding of 14-3-3 function will continue to expand over the coming years, especially 
as analysis of patient tumors begin to reveal the penetrance of 14-3-3 in cancer initiation and 
progression. Arming ourselves with this information will allow us to better design treatment 
options for cancer patients and screening techniques for early disease detection.   
What emerges from a study of 14-3-3 proteins is a recurring theme of bridging, or the bringing 
together of proteins that would otherwise not associate (Figure 3.1). In light of the fact that 14-3-
3 often facilitates homodimerization, we have yet to show whether this is the case between 
monomers of CDCA7. To date we have shown that CDCA7 physically interacts as a heterodimer 
with both Myc and 14-3-3 proteins in a phospho-dependent manner which is mediated by the 
kinase Akt. It is also well known that DNA binding proteins, most notably transcription factors, 
utilize homo and heterodimerization to impart specificity and control over DNA binding 
(Amoutzias et al., 2008). This line of reasoning is of interest because the related protein JPO2 was 
shown to bind to SP1 sites of the MAOA gene via its C-terminal Zinc Finger domain (Ou et al., 
2006). CDCA7 and JPO2 are 77% identical within this region, suggesting that CDCA7 may also 
bind to similar SP1 elements. In this chapter we ask the questions: does CDCA7 homodimerize 
with itself and if so, is this interaction dependent on 14-3-3 as bridging protein? Is there a 
possibility of a second 14-3-3 binding site within CDCA7? 
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Results 
 
CDCA7 Co-association – coimmunoprecipitation approach 
To investigate if CDCA7 homodimerizes, we first conducted a series of experiments using 
ectopically expressed proteins isolated from cells. Our initial approach was to express CDCA7 
from two plasmids – one containing an N-terminal FLAG epitope and the second an HA epitope 
tag. This allowed us to distinguish the two CDCA7 proteins following co-immunoprecipitation 
and immunoblotting. Thus, we first expressed pCMV10-3xHA-CDCA7 together with either empty 
vector or pCMV10-3xFLAG-CDCA7 in HEK293 cells. Following immunoprecipitation with anti-
FLAG bound agarose we resolved the proteins by SDS-PAGE and probed with anti-HA. Using 
this approach, we have shown that FLAG- tagged CDCA7 associates with HA- tagged CDCA7. 
Mutation of the T163 phosphorylation site or enforced/suppressed 14-3-3 binding (DE or KK R18 
peptide substitution respectively) did not alter CDCA7 association (Figure 3.2A). Association is 
reduced upon deletion of the C-terminal 260-371 region (Figure 3.2B), suggesting that the C-
terminal zinc-finger domain could play a role in in this protein-protein interaction. In contrast, 
deletion of the Myc-interacting region, Δ(156-187)-CDCA7, did not alter association with WT 
CDCA7 (Figure 3.3A). A surprising result of our work has been the consistent inhibition of Myc 
function by Δ(156-187)-CDCA7. The effect of this deletion on apoptosis and transformation is 
similar to the knockdown of endogenous CDCA7 expression by shRNA, suggesting that Δ(156-
187)-CDCA7 may be acting as a dominant negative by associating with endogenous CDCA7, 
preventing it from binding Myc and inhibiting any influence CDCA7 may have on Myc function. 
Next, we assayed other internal deletions, N- and C-terminal truncations to further refine the area 
of CDCA7 co-association. Of the truncations and deletions shown in figure 3.3A, the N-terminal 
truncation of amino acids 1-234 showed the most notable reduction in HA-CDCA7 co-
84 
 
immunoprecipitation. Figures 3.3 B and C further dissect the region flanked by amino acids 112 
and 234 by assaying internal deletion mutants and their ability to co-precipitate HA WT-CDCA7. 
Evidence of complete loss of association can be difficult to ascertain from western blots, especially 
considering that internal deletions may not completely target the region of interaction and may 
result in proportional reductions of association. Therefore, this data needs to be quantified to reveal 
subtle but significant changes in association when compared to a HA WT-CDCA7/FLAG WT-
CDCA7 interaction. This is achieved by quantifying the intensity of the HA WT-CDCA7 and 
FLAG CDCA7 signal in immunoprecipitation samples and calculating the HA:FLAG ratio of 
these signals. Specifically, this was accomplished using the Odyssey infrared scanner, which 
allows direct measurement of signal intensity which represents protein quantity. This data is then 
expressed as a percentage of HA WT-CDCA7/FLAG WT-CDCA7 association, which is defaulted 
to 100%. Figure 3.4 reveals that the internal deletions inclusive of amino acids 187-234 show a 
statistically significant reduction in association when compared to WT CDCA7. This data is 
summarized in a map illustrating the internal deletions responsible for a reduction in CDCA7 co-
association (Figure 3.5). 
 
CDCA7 Co-association – BioID approach 
Although coimmunoprecipitations are a general indicator of protein-protein interactions, there are 
some caveats which can render the technique impractical. It is important to consider a) the 
possibility of interactions occurring post lysis, leading to false-positive results b) the general 
difficulty involved in working with a milieu of soluble and insoluble proteins c) forced interactions 
due to over expression of ectopic proteins or conversely the insensitivity of antibodies to 
endogenous proteins leading to weak signals that are difficult to interpret. A recently developed 
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technique known as BioID aims to resolve most of these issues, and has become a powerful tool 
used to investigate novel protein-protein interactions. The technique involves the fusion of a 
protein of interest with a mutated biotin ligase (known as BirA*) isolated from Escherichia coli. 
Mutation of arginine 118 to glycine reduces BirA* affinity for bioAMP, resulting in early release 
of bioAMP and promiscuous biotinylation of proteins within ~ 10 nm (Kim et al., 2014). 
Biotinylated proteins can then be efficiently purified with streptavidin-agarose beads and identified 
by mass spectrometry, allowing for identification of novel protein-protein interactions (Figure 
3.6). This powerful approach has been used to identify the components of the mammalian nuclear 
lamina (Roux et al., 2012), cell junction complexes (Van Itallie et al., 2014) and constituents of 
centrosomes (Firat-Karalar et al., 2001). We have adapted this technique to study interactions 
between proteins of interest (POI) rather than unknown and novel interactions. In this case we 
have adapted the BioID protocol to further investigate CDCA7 co-association and to precisely map 
the area of interaction between CDCA7 monomers. Our protocol involves co-transfection of 
HEK293T cells with BirA*FLAG-WT-CDCA7 and a subset of FLAG-tagged CDCA7 mutants, 
biotin treatment followed by immunoprecipitation with FLAG-agarose beads and standard western 
blotting procedures (Figure 3.7). Samples transferred to membrane are probed with streptavidin-
IR (streptavidin conjugated to an infrared sensitive dye) and scanned by the LiCOR infrared 
imager to reveal levels of biotinylation on FLAG-CDCA7 proteins. Biotinylation of FLAG-
CDCA7 would suggest that protein-protein interactions have occurred, while loss of biotinylation 
due to truncation or deletions would reveal the location at which interactions are likely to take 
place. 
Using the original BioID method described by Roux and colleagues, we have been able to show 
for the first time that endogenous CDCA7 interacts with the ectopically expressed BirA*FLAG-
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WT-CDCA7 (Figure 3.8). This experiment also reveals that co-transfected FLAG-tagged CDCA7 
was also biotinylated by BirA*FLAG-WT-CDCA7.   
Next, as a proof of concept we employed our modified protocol as described above (Figure 3.7) to 
evaluate the extent to which an innocuous protein like GFP may interact with co-transfected 
FLAG-CDCA7. Figure 3.9 reveals that although co-transfected FLAG-CDCA7 was 
immunoprecipitated equally between BirA*GFP and BirA*FLAG-WT-CDCA7 co-transfections, 
only those transfected along with BirA*FLAG-WT-CDCA7 revealed any appreciable levels of 
biotinylation. These results indicate that promiscuous biotinylation by BirA* biotin ligase occurs 
at an acceptably low level. 
We attempted to map the area of interaction between BirA*FLAG-WT-CDCA7 and FLAG-
CDCA7 by repeating our modified protocol with a subset of FLAG-CDCA7 truncation and 
deletion mutants, similar to those used in figures 3.2 and 3.3 (Figure 3.10). Figure 3.11 reveals the 
quantified levels of biotinylation of these CDCA7 mutants and figure 3.12 illustrates these mutants 
on a binding map. As with our experiments investigating co-association via co-
immunoprecipitation, we decided to probe the region flanked by amino acids 187 and 234 with 
various deletion mutants targeting this region. Figure 3.13 shows that the area of interaction 
between CDCA7 monomers is between amino acids 187-234. These results are consistent with 
those gathered by the classical co-immunoprecipitation technique outlined above. This putative 
area of interaction is of interest because of secondary structure prediction that points to the 
presence of a helix and enrichment of leucine residues (Jones, 1999), a combination which is 
indicative of the classical leucine zipper motif involved in protein-protein interactions (Figure 
3.14) (Bridges and Moorhead, 2005). 
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Finally, we asked ourselves whether 14-3-3 binding with CDCA7 affects the co-association of 
CDCA7 monomers? We began this portion of our investigation by noting that the T163A mutation 
completely abolishes 14-3-3 association with CDCA7 but does not reduce CDCA7 co-association. 
The same is true of the KK CDCA7 substitution mutant, which relies on the mutated R18 peptide 
to replace T163 and to prevent 14-3-3 association (Figure 3.2).  Using the internal deletion mutants 
within and proximal to the CDCA7 co-association domain, we performed coimmunoprecipitations 
of FLAG CDCA7, HA CDCA7 and endogenous 14-3-3. As with the T163A mutation and KK 
substitution, deletion of amino acids 138-167 within CDCA7 completed abolished any interaction 
with 14-3-3, without impacting CDCA7 co-association (Figure 3.16 A and B). This loss of 14-3-
3 interaction is likely due to the loss of the T163 residue. However, in the case of deletion mutants 
targeting the putative CDCA7 co-association domain which keep T163 intact, there is a concurrent 
decrease between 14-3-3 association and CDCA7 co-association. This is statistically significant in 
the case of ∆187-204, ∆187-224 and ∆187-234 CDCA7 (Figure 3.16 A and B). In the case of 
deletions ∆187-194 and ∆187-214, although not statistically significant when quantified, there 
seems to be an objective restoration of 14-3-3 binding based on visual inspection of western blots.  
It remains to be seen whether 14-3-3 interaction and CDCA7 co-association are correlative or 
causative in nature.  
Investigating a Second 14-3-3 Binding Site 
It is well known that 14-3-3 exists as either homo or heterodimers involving combinations of the 
seven 14-3-3 family isoforms (Jones et al., 1995; Chaudhri et al., 2003). Although certain isomers 
prefer to either homo or heterodimerize, all 14-3-3 dimers have an affinity for a pair of pospho-
serine/residues centered around consensus sites I (RSX(pS/T)XP) or II (RX(F/Y)X(pS)XP) 
(Gardino et al., 2006). Crystal structure solutions show that each 14-3-3 monomer contains an 
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amphipathic ligand binding channel, allowing for 14-3-3 dimers to a) bind two identical/different 
motifs on the same client protein (usually >15 amino acid residues apart), or b) two 
identical/different motifs, each of which appears once on two identical/different proteins (Zhu et 
al., 2005; Obsil et al., 2001). In the former scenario, a single protein containing two 14-3-3 binding 
sites results in 30-fold greater affinity for binding then a protein displaying only one 14-3-3 site 
(Yaffe et al., 1997). The later scenario facilitates the coming together of two client proteins that 
would otherwise not associate as in the example of 14-3-3 mediated dimerization of B-Raf and C-
Raf (Figure 3.1) (Paul et al., 2012; Rushworth et al., 2006). This paradigm within which 14-3-3 
must operate is known as the ‘lynchpin’ hypothesis. The theory proposes that the conservation of 
one of the phospho-serine/threonine binding sites (the lynchpin residue) allowed the second 
residue to evolve and perhaps become the target of a novel kinase (Johnson et al., 2011). The 
evidence for the conservation of the lynchpin residue can be found in pre-2R-WGD invertebrate 
chordates dating back to the two rounds of whole-genome duplication that occurred approximately 
500 million years ago (Tinti et al., 2012; Huminiecki and Heldin, 2010). Due to the variable nature 
of the second site proposed by the lynchpin hypothesis, motifs outside of mode I and II must be 
considered when predicting 14-3-3 binding sites. Popular prediction tools such as Scansite or ELM 
(Eukaryotic linear motif database) do not take this into account and rely on a partial set of 
experimentally derived 14-3-3 binding sites (Obenauer, 2003; Puntervoll, 2003). Tinti and 
colleagues have recently developed an online tool known as ’14-3-3 Pred’ which includes not only 
modes I and II, but motifs which extend beyond the original predictors used by Scansite and ELM 
(Tinti et al., 2014; http://www.compbio.dundee.ac.uk/1433pred). Analysis of the human CDCA7 
coding sequence by ‘14-3-3 Pred’ (Figure 3.15A) suggests there may be four phospho-
serine/threonine residues within proximity of the CDCA7 co-association domain (a.a.187-234): 
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S185, T213, S231 and T234 (Madeira et al., 2015). Sequence alignment of human CDCA7 with 
Branchiostoma belcheri  or Ciona intestinalis, a pair of pre-2R-WGD organisms, reveals that four 
of these residues are in fact conserved (Figure 3.15B).  In light of our data which suggests that the 
CDCA7 co-association domain is within amino acids 187-234 (Figure 3.4, 3.11 and 3.13) it would 
be prudent of us to investigate the existence of such a secondary 14-3-3 binding motif. Doing so 
would allow us to gain more insights into if and how 14-3-3 may play a role in CDCA7 co-
association.   
Next we generated a series of mutations targeting the four 14-3-3 consensus residues predicted by 
‘14-3-3 Pred’ to assay their affects on 14-3-3 binding and CDCA7’s ability to co-associate with 
itself. As with earlier experiments these serine/threonine residues were mutated to an alanine to 
preclude any potential phosphorylation. These alanine mutations were then individually 
compounded with the T163A mutation. Transfection into HEK293 cells of these FLAG CDCA7 
mutants followed by immunoprecipitation with α-FLAG agarose allowed us to focus on three 
parameters: i) affect on 14-3-3 association with FLAG CDCA7 mutants (14-3-3/FLAG), ii) affect 
on phosphorylation of T163 in these novel mutants (pT163/FLAG) and iii) the amount of 14-3-3 
association as a product of any potential changes in T163 phosphorylation (14-3-3/pT163). Figure 
3.17 shows that although not all of the results were statistically significant, none of the point 
mutations in question completely abolished 14-3-3 binding or T163 phosphorylation in the manner 
that the T163A mutation yields. In the case of the T213A mutation, there is a statistically 
significant ~20% reduction in 14-3-3 association. Predictably, the T163A compound mutations 
completely abolished 14-3-3 interaction in every case.  Finally, phosphorylation of T163 remained 
unchanged in every case other then the S234A which may have produced a statistically significant 
increase of 30%. These results suggest that the S185, S231 and T234 consensus sites in question 
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do little to impact 14-3-3 binding to CDCA7. However, there was a marginal reduction in 14-3-3 
binding observed in the T213A mutant, resulting in ~20% less 14-3-3 coprecipitating with 
CDCA7.   
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Figure 3.1. Modes of 14-3-3/client interactions. 14-3-3 exists as a dimer and interacts with its 
target protein at either: a) two separate phospho-14-3-3 sites on the same target protein or b) two 
identical phospho-14-3-3 sites on a pair of target proteins (Paul et al., 2012). Adapted from Paul et 
al., 2012. 
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Figure 3.2. CDCA7 Co-association. A. HA-CDCA7 and FLAG-CDCA7 were co-transfected into 
HEK293 cells, and immunoprecipitated with α-FLAG agarose. Co-precipitating HA-CDCA7 was 
detected by HA immunoblotting. Mutation of the T163 phosphorylation site or enforced 14-3-3 
binding (by substituting T163 with the DE or KK R18 peptide) did not alter co-association. Arrow 
indicates the position of HA-CDCA7. B. CDCA7 co-association was reduced by deletion of the 
C-terminal zinc finger domain at amino acids 260-371.  
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Figure 3.3. Refining the area of CDCA7 co-association. A. HA-CDCA7 and various internal, 
N- and C-terminal deletion mutants of FLAG-CDCA7 were co-transfected into HEK293 cells, and 
immunoprecipitated with α-FLAG agarose. Co-precipitating HA-CDCA7 was detected by HA 
immunoblotting. Co-association was reduced most notably by the N-terminal deletion of amino 
acids 1-234 B. Deletions of increasing length between amino acids 187-234 were tested for their 
ability to co-associate with WT CDCA7. C. In order to further refine the area of co-association, 
deletions of constant length were used to scan the region between amino acids 187-234 to assay 
their ability to coprecipitate with WT CDCA7.  
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Figure 3.4. Quantification of CDCA7 co-association. Co-association of CDCA7 was quantified 
as a ratio of HA WT-CDCA7:FLAG CDCA7 in immunoprecipitated samples as visualized by 
western blots via the Odyssey LiCor scanner. Deletions within the region between amino acids 
187-234 resulted a statistically significant reduction of coimmunoprecipitated HA WT-CDCA7. 
Red bars indicate ratios < 50% of WT, green bars indicate ratios ≥ 50% of WT. n=2 for all samples 
except Δ187-194 where n=3. ** = P ≤ 0.01 and *** = P ≤ 0.001. Error bars represent standard 
deviation. 
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Figure 3.5. Mapping of CDCA7 co-association by immunoprecipitation. The area of 
responsible for CDCA7 co-association was mapped using the data in figure 3.4. Red bars indicate 
ratios < 50% of WT, green bars indicate ratios ≥ 50% of WT. Amino acid positions are indicated 
at top, while the grey area represents the area of interest between amino acids 187-234.  
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Figure 3.6. Summary of BioID. A) The BirA* fusion protein (blue) is transfected into HEK 293 
cells, associates with proximal/interacting proteins (orange) but does not associate with 
distance/non-interacting proteins (green, gray and black). B) When biotin is supplemented for 24 
hours, the BirA* fusion protein converts biotin into biotinyl-AMP (bioAMP) and prematurely 
releases it. The reactive bioAMP reacts with proximal/interacting proteins and tags them with 
biotin. C) Following cell lysis and solubilization, biotinylated proteins are captured on streptavidin 
conjugated beads and washed to purify out nonspecific interactors. D) Purified biotinylated 
proteins are then identified via mass spectrometric analysis. Modified from Roux et al. 2012. 
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Figure 3.7. Summary of classical and adapted method of BioID. We have adapted the classical 
BioID method, in yellow, by following biotin treatment with immunoprecipitation of the FLAG 
tagged protein of interest (POI) with α-FLAG agarose rather then streptavidin capture. Western 
blotting and probing with α-FLAG antibody and streptavidinIR allows one to identify the level of 
biotinylation on the FLAG tagged POI, and therefore infer the ability of the POI to interact with 
the BirA fusion protein. 
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Figure 3.8. BioID proof of concept. HEK293T cells were co transfected with BirA-FLAG-WT-
CDCA7 fusion protein and FLAG WT-CDCA7. Purification with streptavidin agarose followed 
by immunoblotting with α-FLAG and α-CDCA7 antibodies reveals that both ectopically expressed 
and endogenous CDCA7 are biotinylated by the BirA-FLAG-WT-CDCA7 fusion protein. * 
indicates possible endogenously biotinylated proteins. ** indicates a molecular weight of 55 kDa. 
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Figure 3.9. Adapted BioID protocol proof of concept. HEK293T cells were co-transfected with 
negative control BirA-GFP or BirA-FLAG-WT-CDCA7 fusion protein and one of several deletion 
mutants. Immunoprecipitation with α-FLAG agarose followed by western blotting and probing 
with streptavidinIR reveals the extent of FLAG-CDCA7 biotinylation by BirA fusion proteins.   
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Figure 3.10. Biotinylation of wild type CDCA7 and deletion mutants. HEK293T cells were co-
transfected with BirA-FLAG-WT-CDCA7 fusion protein and one of seven deletion mutants 
including internal, N- and C-terminal deletions. Immunoprecipitation with α-FLAG agarose 
followed by western blotting and probing with streptavidinIR reveals the extent of FLAG-CDCA7 
biotinylation by BirA fusion proteins. Top and bottom results were obtained from scanning the 
same membrane which was probed with secondary antibodies bound to 700nm and 800nm infrared 
dyes. 
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Figure 3.11. Quantification of FLAG CDCA7 biotinylation. Biotinylation of CDCA7 was 
quantified as a ratio of streptavidinIR:FLAG CDCA7 in immunoprecipitated samples as visualized 
by western blots via the Odyssey LiCor scanner. Red bars indicate ratios < 50% of WT, green bars 
indicate ratios ≥ 50% of WT. n=3 for all samples except Δ153-371, Δ112-137 and Δ138-164 where 
n=2. * =  P < 0.05. Error bars represent standard deviation. 
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Figure 3.12. Mapping of CDCA7 co-association by biotinylation. The area of biotinylation on 
variations of FLAG CDCA7 was mapped using the data in figure 3.11. Red bars indicate ratios < 
50% of WT, green bars indicate ratios ≥ 50% of WT. Amino acid positions are indicated at top, 
while the grey area represents the area of interest between amino acids 187-234. Yellow bars in 
WT CDCA7 indicate positions of all lysine residues with the percentage of missing lysine residues 
in truncation and deletion mutants indicated on the right. 
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Figure 3.13. Refining the area of biotinylation between amino acids 187-234. A) Two sets of 
internal deletions within the amino acids 187-234 region were co-transfected with BirA-FLAG-
WT-CDCA7 fusion protein into HEK293T cells. Biotinylation was visualized  after western 
blotting by probing with streptavidinIR via the Odyssey LiCor scanner. B) Biotinylation of 
CDCA7 was quantified as a ratio of streptavidinIR:FLAG CDCA7 in immunoprecipitated samples 
seen in A). The data was grouped into deletions inclusive of a.a.187-234 and a.a.205-234. The 
Δ187-234 group is significantly less biotinylated then WT CDCA7. Red bar indicates ratios < 50% 
of WT, green bar indicates ratios ≥ 50% of WT. n=5 for Δ187-234 deletion group and n=3 for 
Δ205-234 deletion group. * =  P < 0.05. Error bars represent standard deviation. 
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Figure 3.14. hCDCA7 secondary structure prediction. A) Prediction of hCDCA7 secondary 
structure by Psipred reveals a helix and a concentration of leucine residues (red circles) in the 
putative co-association domain (highlighted in green). http://bioinf.cs.ucl.ac.uk/psipred/. B) 
Leucine zipper motifs are known mechanism by which proteins can interact. Regularly spaced 
leucine residues within a helix interact with similar residues in the helix of the adjacent binding 
partner. (c)2012 Pearson Education Inc. 
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Figure 3.15. 14-3-3 pS/T motif prediction. A) Bioinformatic prediction of 14-3-3 pS/T motifs 
based on three different algorithms developed by Madeira et al., which are then cross referenced 
against confirmed sites in current literature and rated according to an average score of the three 
methods (Madeira et al., 2015). B) Protein conservation between human, Branchiostoma belcheri 
and Ciona intestinalis. T163, S185, S231 and T234 in human CDCA7 is conserved as possible 
targets of phosphorylation and may represent a second 14-3-3 phospho S/T site. Green arrow = 
T163 confirmed by our group (conserved), black arrow = conserved between humans and 
Branchiostoma belcheri or  Ciona intestinalis, red = not conserved.  
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Figure 3.16. CDCA7 Co-association and 14-3-3 Interaction. A) HA-CDCA7 and FLAG-
CDCA7 were co-transfected into HEK293 cells, and immunoprecipitated with α-FLAG agarose. 
Co-precipitating HA-CDCA7 and endogenous 14-3-3 were detected by immunoblotting. B) 
Quantification of HA CDCA7 and endogenous 14-3-3 coimmunoprecipitation shows that in the 
absence of 14-3-3, HA-CDCA7 still associates with FLAG CDCA7 (∆138-167).  However, in the 
case of ∆187-224 and ∆187-234 where both results are statistically significant, there is 
proportionate decrease in CDCA7 and 14-3-3 association. Dashed line indicates a 50% threshold. 
n=2 for all samples. * = P<0.05, ** = P ≤ 0.01 and *** = P ≤ 0.001. Error bars represent standard 
deviation. 
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Figure 3.17. Investigating secondary 14-3-3 binding sites on CDCA7. A) FLAG-CDCA7 and 
various mutants of 14-3-3 consensus pS/T residues were transfected into HEK293 cells, and 
immunoprecipitated with α-FLAG agarose. Co-precipitating endogenous 14-3-3 was detected by 
immunoblotting. B) Quantification of endogenous 14-3-3/FLAG, pT163/FLAG and 14-3-3/pT163 
in secondary site mutants reveals marginal decreases when compared to wild type. The single 
T163A and compound mutants completely abolishes 14-3-3 association with CDCA7 Dashed line 
indicates a 50% threshold. n=2 for all samples. * = P<0.05 and ** = P ≤ 0.01. Error bars represent 
standard deviation. 
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Figure 3.18. Hypothetical model of CDCA7 interactions and localization. CDCA7 monomers 
may associate in such a way that one monomer presents a T163 residue and nuclear localization 
signal (NLS), while masking the T163 residue and NLS on the opposing monomer, leaving only 
T213 exposed. For CDCA7 to bind 14-3-3, the exposed T163 residue must be phosphorylated. The 
sub-cellular localization of CDCA7 is then determined by the status of the exposed NLS. A) WT-
WT CDCA7 complexes are distributed throughout the cell depending on the phosphorylation state 
of T163. When phosphorylated, WT CDCA7 complexes are bound to 14-3-3, which masks the 
exposed NLS and sequesters the complex to the cytoplasm. B) When T163A CDCA7 associates 
with WT CDCA7, 14-3-3 cannot associate with the alanine residue nor the T213 residue alone. 
The NLS is exposed and therefore shuttles the complex to the nucleus. C) Deletion of the NLS at 
residues 156-187 also removes the otherwise exposed T163, therefore the complex is isolated in 
the cytoplasm despite not binding to 14-3-3. Because both monomers have their co-association 
domains present, the complex remains intact, thereby continuing to mask the NLS in the WT 
CDCA7 monomer. D) When a portion of the co-association domain is removed, there is a 
concurrent reduction of 14-3-3 interaction and CDCA7 co-association. Subcellular localization is 
unknown. 
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Figure 3.19. Hypothetical model of CDCA7 function mediated by Akt alone, or Akt and 
another kinase. 14-3-3 binding to CDCA7 can mediate its function by A) input from a single 
kinase such as Akt at T163, which is sufficient to disrupt CDCA7-Myc interaction and effect the 
activation of a subset of genes, or B) T163 and T213 need to be phosphorylated by different kinases 
to promote 14-3-3 binding and thus affecting various possible outcomes. 
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Discussion 
 
Secondary structure predictions based on the CDCA7 primary sequence suggest that the area 
between amino acids 187-234 may contain a helix and is enriched for leucine residues (Figure 3.14 
A). This prediction was obtained using PSIPRED, an online tool supplied by the Bioinformatics 
Group at the University College London. PSIPRED predicts secondary structures by first 
comparing input sequences with evolutionary related proteins in order to generate a position 
specific scoring matrix. This data is then processed by an artificial neural network that predicts 
secondary structure based on known crystal structures (Jones, 1999). Our results mentioned above 
(Figure 3.14 A) are of particular note because of the documented role that both helix structures 
and leucine residues play in protein-protein interactions (Jerome and Muller, 2001). We have used 
two complementary approaches to reveal that CDCA7 co-associates with itself. Using co-
immunoprecipitations of exogenously expressed WT-CDCA7 and various internal, N- and C-
terminal deletions we have mapped the region of this interaction to amino acids 187-234 (Figures 
3.2-3.5). However, a criticism of this approach suggests that over expression of proteins in vivo 
often results in forced interactions (Nan et al., 2015). This could be a product of stoichiometry or 
interaction post-lysis and therefore not an accurate representation of naturally occurring complexes 
in terms of levels, sub-cellular localization or temporal variances. Therefore, a means of taking a 
snapshot of interactions as they occur in the cell is required to overcome this criticism. BioID can 
achieve this by identifying proximal proteins which are biotinylated by the promiscuous biotin-
ligase BirA*. BirA* will only biotinylate proteins within a distance of ~10 nm (the average width 
of a protein) and only when cell culture media is supplemented with biotin. Washing away biotin 
prior to lysis prevents false-positives that may occur otherwise post lysis (Kim et al., 2014). 
Although biotinylation of proteins is not a direct indication of a protein-protein interaction, it can 
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at least suggest the presence of a complex of proteins which include the BirA* fusion protein and 
the protein of interest within ~10 nm. Using BioID we have replicated our co-immunoprecipitation 
study and confirmed that CDCA7 co-association in fact depends on the region between amino 
acids 187-234 (Figure 3.8-3.13). We have hesitated to use the term ‘dimer’ or ‘dimerization’ when 
describing this interaction simply because these studies do not preclude the possibility of two 
CDCA7 monomers exiting in a larger complex, yet still within the ~10 nm resolution of BioID. 
To be certain that a protein(s) can in fact form a dimer, it would have to be expressed in bacteria, 
purified and passed through a size exclusion column. The mass of the complex would indicate 
whether the protein exists as a monomer, or in a complex of multiples thereof. Alternatively, direct 
association can be assayed for by the same means we used to show a direct CDCA7-Myc 
interaction (Figure 2.1), that is to test for in vitro association of alternately tagged and purified 
proteins. These two methods generally rely on the expression and purification of the protein of 
interest in a bacterial host, which in most cases is an excellent means of producing large quantities 
of protein. However, our efforts using this approach yielded nominal levels of ectopically 
expressed CDCA7 in E. coli. This is can be explained by a phenomenon that results in inclusion 
bodies containing high concentrations of recombinant protein aggregates. A combination of high 
temperature, high concentration of induction compounds and expression via strong promoters can 
cause protein quality assurance mechanism to be overwhelmed. As a result, poorly folded proteins 
find themselves accumulating within inclusion bodies and are essentially of no use to researchers 
(Carrio and Villaverde, 2005). This setback forced us to rely on the methods described here, 
namely expression in HEK293 cells followed by co-immunoprecipitation studies and BioID.  
With the knowledge that CDCA7 interacts with the bridging protein 14-3-3 and that CDCA7 
monomers have the ability to associate, it was imperative for us to investigate whether 14-3-3 is 
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responsible for bringing CDCA7 together. The mechanism by which 14-3-3 can mediate such an 
interaction is outlined in figure 3.1 and is described above in detail. Our data reveals that CDCA7 
co-association does not depend on 14-3-3 to act as a bridging molecule. This is well illustrated in 
the T163A point mutation which completely abolishes 14-3-3 binding but not CDCA7 co-
association (Figure 3.2). However, when amino acids 187-234 are deleted from CDCA7 there is a 
significant drop in co-association and 14-3-3 binding despite T163 being intact (Figure 3.16 A and 
B). This result would suggest that either a) already existing complexes of CDCA7 (perhaps 
including other proteins) are acting as docking sites for 14-3-3, b) deletion of amino acids 187-234 
alters conformation of the pT163 binding site or c) deletion of amino acids 187-234 removes an 
unidentified second 14-3-3 binding site. Bioinformatic scans for 14-3-3 consensus sites within 
CDCA7 reveal 4 potential residues in the a.a.187-234 region of interest, with three of the sites 
being conserved over 500 million years (Figure 3.15 A and B) (Madeira et al., 2015). Our results 
indicate that mutation of T213 to alanine results in ~20% less 14-3-3 co-immunoprecipitation with 
CDCA7, and a complete abolishment when the T163A mutant is compounded with T213A (Figure 
3.17 A and B). This may suggest that T213 is a second, weaker site of 14-3-3 interaction which is 
not required for binding under our assay conditions. This makes way for the exciting potential that 
T213 could fall under the control of a kinase other than Akt (which phosphorylates T163). To that 
end, a Scansite search for consensus kinase sites at T213 suggests that Aurora B kinase may target 
that residue (Obenauer et al., 2003) which has been confirmed via mass spectrometry as being 
phosphorylated (Hornbeck et al., 2015). Aurora B kinase plays an important role during mitosis as 
part of the chromosomal passenger complex (CPC) which is required for cytokinesis to take place 
faithfully (Sampath et al., 2005). Confirmation of T213 phosphorylation by Aurora B kinase has 
yet to be established and would require a combination of: a) a custom antibody raised against 
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pT213, b) 2D-phosphotryptic mapping, c) in vitro kinase assays, d) experiments using Aurora B 
null cells and e) an Aurora B selective inhibitor such as AZD1152 (Bavetsias and Linardopoulos, 
2015).   
If 14-3-3 is not mediating the coming together of CDCA7 monomers, what other roles may it play 
in regulating CDCA7’s function? In most cases, being under the direct control of Akt kinase would 
warrant serious consideration, as Akt is known to regulate many critical functions of the cell 
(Fresno et al., 2004). In our published work from 2013 we showed that CDCA7 not only binds 14-
3-3 when T163 is phosphorylated by Akt, but that CDCA7 migrates to the cytoplasm in the process 
(Figure 2.5 and 2.6).  We showed that T163 is in fact found within a nuclear localization sequence 
between amino acids 156-187 (Figure 2.4). Is it possible that 14-3-3 binding to CDCA7 is 
mediating subcellular localization by binding T163 and masking the NLS in the process? There is 
precedent for exactly this function of 14-3-3 in the cytoplasmic localization of Cdc25. It has been 
shown that mutation of serine 287 to an alanine in Xenopus Cdc25 completely abolishes 14-3-3 
binding, resulting in nuclear accumulation of Cdc25 (Muslin and Xing, 2000). A threonine to 
alanine mutation at T163 of CDCA7 also causes nuclear accumulation and an inability to bind 14-
3-3 (Figure 2.3). It is important to consider that any explanation of how CDCA7 functions should 
take into account that it exists in a complex with another monomer of itself. All of the data that we 
have gathered to that end is in the context of one of the monomers existing as a wildtype molecule 
(HA CDCA7) while its counterpart bares the mutations in question (various forms of FLAG 
CDCA7). Therefore, in the example of T163A CDCA7, the loss of 14-3-3 binding and subsequent 
nuclear localization cannot be reversed by the wildtype threonine and what should be a masked 
NLS presented by the WT monomer. This is especially evident when considering that the T163A 
mutation does not alter CDCA7 co-association. What is even more striking is the fact that deletion 
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of the NLS at a.a. 156-187 (and loss of T163) prevents 14-3-3 binding, maintains co-association 
but reverses the nuclear targeting seen in the case of the T163A mutant. In this case, the WT 
CDCA7 monomer maintains its T163 residue and NLS, which may otherwise either bind 14-3-3 
or cause nuclear shuttling if the NLS is exposed. How is it that there is preference for one monomer 
of the CDCA7 complex to dictate 14-3-3 binding and sub-cellular localization? The answer may 
be found in a subtle variation in the way complexes of two proteins are generally depicted when a 
protein’s crystal structure has yet to be solved, which is usually side by side like beads on a string. 
Figure 3.18A depicts an arrangement of a WT-WT CDCA7 complex in such a way where 
monomer A presents a T163 residue and its NLS while masking the same structures on monomer 
B. This results in monomer B presenting only a T213 residue (the putative second 14-3-3 binding 
site, Figure 3.17) while occluding T213 on monomer A. This paradigm is depicted in Figure 3.18 
and elegantly allows for the four conflicting properties of CDCA7 to work in concert, that is 14-
3-3 binding at T163, the presence of a nuclear localization signal, CDCA7 co-association and a 
second 14-3-3 binding site at T213. 
The discovery that monomers of CDCA7 co-associate may reveal further insights into how Akt 
and potentially other kinases might mediate CDCA7 on a mechanistic level. Figure 3.19 outlines 
a hypothetical model whereby CDCA7 function is mediated through a single kinase (Akt) at T163, 
or by multiple kinases at T163 and T213. In the case of Akt acting alone, input from Akt is 
sufficient for 14-3-3 binding, shuttling to the cytoplasm and disruption of the CDCA7-Myc 
interaction. This results in a pro-survival outcome. CDCA7 function can also be mediated by 
phosphorylation via Akt at T163 and another kinase(s) at T213 to affect a variety of possible 
outcomes.  
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To date we have shown that CDCA7 not only interacts with another monomer of itself, but with 
Myc and 14-3-3 as well. The nexus of these interactions and understanding the conditions which 
determine their states are crucial to deciphering the exact means by which CDCA7 cooperates with 
its partners to affect proliferation, apoptosis or yet to be discovered processes. These conditions 
are myriad and should be explored further. For example, one must not overlook studying CDCA7 
in the context of: a) different points of the cell cycle, b) cell density and contact inhibition, d) 
stimulation with a variety of growth factors or e) experiments in different cell types.  
 
Materials and Methods 
 
Cell lines and cell culture 
HEK 293 and NIH 3T3 cells were obtained from the American Type Culture Collection and 
maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum 
and antibiotics at 37°C and 5% CO2.  
Transfections 
For transient expression of cDNA in HEK 293 cells, cells were plated onto 100-mm-diameter 
dishes at 80% confluency and transfected with 8 g of total plasmid using polyethylenimine (PEI) 
(Sigma-Aldrich #408727). 8 g of DNA was diluted with 1 mL of serum-free Opti-MEM 
(ThermoFisher Scientific #31985062). 24 g of PEI was added to the diluted DNA mix for a final 
ratio of 3:1 g PEI:g DNA. The mix was vortexed 10x and allowed to incubate at room 
temperature for 30 minutes. 3 mL of Dulbecco’s modified Eagle’s medium supplemented with 
10% fetal bovine serum was gently added to the transfection mix. The 4 mL total transfection mix 
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was then added to cells following aspiration. 7 hours later, transfection medium was removed and 
replaced with complete Dulbecco’s modified Eagle’s medium overnight. 
Antibodies and Reagents 
Mouse monoclonal M2 anti-flag (A2220), rabbit polyclonal anti-CDCA7 (HPA005565) and rat 
monoclonal anti-HA (3F10) and biotin (B4639) were purchased from Sigma-Aldrich. Streptavidin 
agarose (69203) was purchased from Millipore and StreptavidinIRdye 680 (926-68079) was 
purchased from Mandel. Mouse monoclonal anti-14-3-3 (SC-1657) was purchased from Santa 
Cruz. An anti-p-Thr163 CDCA7 rabbit polyclonal antibody was generated by Genscript 
Corporation (California).  
Cloning 
The CDCA7 coding region was ligated into the pCMV-HA-N mammalian expression vector 
(Clontech) to introduce an amino terminal HA epitope. The CDCA7coding region was ligated into 
the p3XFLAG-CMV10 mammalian expression vector (Sigma-Aldrich) to introduce an amino 
terminal FLAG epitope. Mutagenesis of p3XFLAG-CMV10-CDCA7 was performed using the 
QuikChange kit (Stratagene) and NEB Q5 Site Directed Mutagenesis Kit (E0554), and the various 
mutations were sequence-verified. Amino-terminal and internal deletions were created by 
introducing silent mutations coding for unique restriction sites, followed by digestion and re-
ligation.  Carboxyl terminal deletions were created by introducing stop codons.  All deletions were 
sequence verified. CDCA7 containing the 14-3-3-binding R18-peptide 
PHCVPRDLSWLDLEANMCLP or the control non-14-3-3-binding peptide 
PHCVPRDLSWLKLKANMCLP were created by ligating a double-stranded oligonucleotide to 
replace amino acids 139-164 of CDCA7 in the 3XFLAG-CMV10 vector.  
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The coding region for green fluorescent protein (GFP) and CDCA7 were ligated into the 
pcDNA3.1 MCS-BirA(R118G)-HA vector which was a gift from Kyle Roux (Addgene plasmid # 
36047) 
BioID 
HEK293 cells were plated at 50% confluency and transfected with the BirA* fusion proteins and 
p3XFLAG-CMV10-CDCA7 as per above. 18 hours later cell media was supplemented with 50 
 biotin and allowed to incubate at 37°C and 5% CO2 for 24 hours.. Following 3x washes with 
PBS, cells were harvested in T-X100 lysis buffer on ice as bellow. Samples were incubated with 
either 50 L of streptavidin agarose or anti FLAG agarose slurry and rotated overnight at 4°C. 
Samples where centrifuged and washed 3x with PBS prior to elution in sodium dodecyl sulfate 
sample buffer as per below. Lysates and immunoprecipitations were fractionated by SDS-PAGE, 
transferred to a PVDF membrane, blocked in Odyssey blocking buffer (Mandel, LIC-927-40100), 
and probed with a variety of primary antibodies or the streptavidinIR 700 dye. Primary antibodies 
were decorated with IR700 anti-mouse or rabbit and/or IR800 anti-mouse, rabbit or rat secondary 
antibodies (Li-Cor Biosciences) for 3 hours at room temperature and visualized using the infrared 
laser scanning (Odyssey, Li-Cor Biosciences).  
Cell Lysis, Immunoprecipitation, and Immunoblotting 
Cells were lysed in either RIPA lysis buffer (10mM NaPO4, pH 7.6, 150mMNaCl, 5mM EDTA, 
0.1% sodium dodecyl sulphate, 0.25% deoxycholic acid, 1% triton X-100, plus protease (Roche 
#88666) and phosphatase inhibitors (Roche #88667) or Triton X-100 lysis buffer (50mMHepes, 
pH 7.9, 250mMNaCl, 0.1% Triton X-100, 10% glycerol, plus protease and phosphatase inhibitors). 
Ten l of anti-FLAG M2 agarose conjugated beads (Sigma Aldrich) were added to lysates and 
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incubated overnight at 4°C. The beads were washed five times with lysis buffer, and proteins were 
eluted with 200 l of sodium dodecyl sulfate sample buffer and heated to 99°C for 5 min. Portions 
of the lysates prior to immunoprecipitation were also reserved and boiled with sodium dodecyl 
sulfate-containing sample buffer. Lysates and immunoprecipitations were fractionated by SDS-
PAGE, transferred to a PVDF membrane, blocked in Odyssey blocking buffer (Mandel, LIC-927-
40100), and probed with the appropriate antibody overnight at room temperature. Primary 
antibodies were decorated with IR700 anti-mouse or rabbit and/or IR800 anti-mouse, rabbit or rat 
secondary antibodies (Li-Cor Biosciences) for 3 hours at room temperature and visualized using 
the infrared laser scanning (Odyssey, Li-Cor Biosciences).  
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Chapter 4: CDCA7, 14-3-3 Association and the Cell Cycle 
 
Introduction 
The most important requisite which separates the living world from the inanimate is the ability to 
self-replicate and faithfully pass on proprietary genetic information from one generation to the 
next. This process as a whole is known as the cell cycle, and although it is cyclical, the endgame 
of the process is one of four outcomes: quiescence, senescence, apoptosis or mitosis. In order for 
a cell to enter a round of the cell cycle, it must cross a threshold between G1 and S phase known 
as the restriction point. It is the transition through this point which commits a cell to a round of 
DNA duplication. Control of the decision to transition from one phase to another is of great interest 
to molecular biologists, as it has been shown to be dysregulated in many cancers and serves as 
potential point for medical intervention. The importance of this critical juncture in the cell cycle is 
obvious as perhaps the three most studied proteins, Myc, the retinoblastoma protein pRB and p53, 
converge to control the restriction point (Santoni-Rugiu et l., 2000). Therefore, an intimate 
understanding of cell cycle and its components can be invaluable when studying cell cycle 
progression, proliferation and aberrations which can lead to disease. 
In previously published work we have identified cell division cycle associated protein 7 (CDCA7) 
as physically interacting with the transcription factor Myc (Gill et al., 2013). We have mapped the 
domains of CDCA7-Myc interaction and have discovered that Akt phosphorylates CDCA7 near 
this contact region, leading to loss of its association with Myc, binding to 14-3-3 proteins and 
exclusion from the nucleus. Co-expression of CDCA7 with Myc sensitized cells to serum-
withdrawal induced apoptosis and this pro-apoptotic activity required the Myc-binding region. 
Short hairpin RNAi-mediated knockdown of CDCA7 rescued cells from MYC-dependent 
apoptosis following removal from serum. Although this data implicates cooperation between Myc, 
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CDCA7 and Akt as affecting apoptosis, it does not address the possibility of a concurrent affect 
on the cell cycle. It is important to note that CDCA7’s (cell division cycle associated protein 7) 
name sake is derived from its periodic expression during the G1/S phase transition of the cell cycle 
(Osthus et al., 2005). Therefore, we have sought to investigate any possible affects CDCA7 may 
have on the cell cycle, and how if any influence Myc and Akt may have on that outcome. What 
follows is a review of the most pertinent information regarding the cell cycle, its progression, 
inhibition and how it may be altered in disease. 
Cyclin-dependent kinases  
The very term ‘cell cycle’ suggests the reoccurrence of a series of events in an orderly fashion, the 
control of which is commissioned to a set of serine/threonine kinases known as cyclin-dependent 
kinases (Cdks) (Morgan, 1995). Cdks were discovered in the early 1970’s by Lee Hartwell, a 
milestone in molecular biology which would eventually earn him the Nobel Prize. Using early 
methods of genetic screening, Hartwell was able to isolate a family of genes which, when mutated, 
halted the cell cycle of the common baker’s yeast when cultured at elevated temperatures (Hartwell 
et al., 1970). He termed these genes cell division cycle, or CDC genes, which were quickly shown 
to be conserved amongst eukaryotes and the driving force behind what is known as the cell cycle 
engine. CDC genes code for kinases known as cyclin-dependent kinase, of which there are five 
that are active during the cell cycle; during G1 (CDK4, CDK6 and CDK2), S (CDK 2), G2 and M 
(CDK1) and CDK7 during the entire cycle (Morgan, 1995). The activity of these kinases hinges 
on the availability of cyclins, which activate Cdks when the proteins form a heterodimeric complex 
(Hunt, 1991). Although Cdk levels do not fluctuate during the cell cycle, it is the periodic rise and 
fall in cyclin protein levels which are responsible for the cycle’s division of phases. 
Phosphorylation of Cdks subunits can either positively or negatively modulate the activity of these 
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kinases (Arellano and Moreno, 1997). The exact set of Cdk targets has not been completely 
catalogued as the phosphorylation cascades initiated by these kinases bifurcate at many points. 
The most well-known Cdk target is the mammalian retinoblastoma susceptibility protein, pRB, 
which works to regulate progression from G1 to S and has been shown to be the central node of 
the restriction point. When in its underphosphorylated state, pRB exerts its function by binding the 
transcription factor E2F, preventing the transactivation of genes that are critical for S phase (see 
below) (Zhou and Elledge, 2000). Progression through the restriction point is highly dependent on 
cell type, environment and context; largely owing to the spectrum of requirement for homeostatic 
tissue renewal. Although entry into S phase may be initiated differently between cell types, one 
criteria must always be realized and that is the activation of Cdks (Massague, 2004).   
Cyclins  
Cyclins exert their influence on Cdks by forcing them into an active conformation upon binding, 
effectively establishing a binary system in which the Cdk is the inactive catalytic subunit that relies 
on the activating subunit that are cyclins. The periodic fluctuation of cyclin protein levels via 
programmed synthesis and degradation guarantees a finite window for Cdk activation. The 
irreversibility of ubiquitin mediated proteolysis of cyclins guarantees the one-way direction of the 
cell cycle. To date, sixteen mammalian cyclins have been discovered, A, B1, C, D1-3, E, F, G1 
and 2, H, I, K, T1 and T2. Cyclin D activates Cdks 4/6 in early G1 while cyclin E activates Cdk 2 
in mid G1. During mid S phase, cyclin A associates with Cdk2 but also activates Cdk1 in G2. 
Finally, cyclin B associates with Cdk1 while the cycle transitions to M phase (Johnson and Walker, 
1999). Although the cell cycle is in theory a continuously revolving door, an opportunity for the 
cycle to initiate must exist. This is made possible by the fact that unlike other cyclins, cyclin D 
levels do not fluctuate during the cycle, but are constantly synthesized so long as growth factors 
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are present. This disconnect from the rhythm of the cell cycle allows cells to integrate information 
and growth cues from its environment. As growth factors activate receptor tyrosine kinases, the 
Ras/Raf/Mek/Erk cascade is initiated and results in the activation of downstream transcription 
factors such as c-Jun and c-Myc, which transactivate the cyclin D gene and thus provides a link 
between extracellular inputs and the initiation of the cell cycle (Kerkhoff and Rapp, 1998; Johnson 
et al., 1996). Cyclin D is responsible for activating Cdks 4 and 6 which promote the transition 
through the restriction point via the molecular switch that is the pRB node (in addition to Cyclin 
E/Cdk 2 hyperphosphorylation of pRb), committing the cell to a round of the cell cycle.  
Cyclin-dependent kinase inhibitors 
The forward progression of the cell cycle can be attributed to the cooperative nature of Cdks and 
cyclins, however in the event that the cell requires a halt in the cycle it turns to cyclin-dependent 
kinase inhibitors (CKIs) to complete this task. CKIs can be recruited in a number of situations such 
as in the event of DNA damage or when required to enter a state of post-mitotic terminal 
differentiation. Their exact mode of influence has been difficult to interpret because the inventory 
of CKIs remains constant between cells, however they are differentially regulated depending on 
the stimuli or cell type (Ekholm and Reed, 2000). CKIs are categorized into one of two families 
depending on their structure and affinity: the INK4 family consists of p15, p16, p18 and p19, and 
the Cip/Kip family is composed of p21, p27 and p57 (Carneo and Hannon, 1998). 
INK4 CKIs are specific in their affinity, as they only inactivate G1 Cdks 4 and 6 by binding them 
before they complex with cyclin D, thus preventing activation of the kinase. INK4 binding of Cdks 
4 and 6 occurs via a concave cleft in the CKI which is composed of ankryin repeats. This forces 
the Cdks into an inactive conformation, further inhibiting their catalytic function and a promotes 
arrest of the cycle in G1 (Russo et al., 1998, Brotherton et al., 1998). The best example of a INK4 
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inhibitor’s effect on the cell cycle is the induction of p15 by the antiproliferative factor TGFβ, 
thereby preventing progression through G1 via inhibition of Cdks 4 and 6 (Massague and Wotton, 
2000).  
Cip/Kip inhibitors are considered to be broad spectrum CKIs as they inhibit both cyclin-Cdk 1 and 
cyclin-Cdk2. The ability to inhibit both cyclin-Cdk complexes establishes a unique mode of 
regulation known as CKI exchange (discussed below), that allows CKIs to be sequestered away 
from targets when cell cycle progression is required. Inhibition by Cip/Kip proteins is achieved by 
binding both units of the cyclin-Cdk heterodimeric complex and invasion of the kinases substrate 
binding pocket (Russo et al., 1996). p21 is arguably the most studied of the Cip/Kip family as it is 
integral to the DNA damage response mediated by p53 at the G1/S checkpoint.  Upon DNA 
damage, the transcription factor p53 becomes stabilised and induces the expression of p21 and 
thus promotes G1 arrest by binding cyclin E-Cdk2, which is one of the critical kinases that 
promotes progression through the restriction point by phosphorylating pRB. 
The pRB-E2F pathway 
The induction of cyclin D by c-Jun and c-Myc via the Ras/Raf/Mek/Erk cascade is the first step in 
entering the cell cycle. Accumulation of cyclin D in G1 encourages the activation of Cdks 4 and 
6, of which the primary target is the retinoblastoma susceptibility protein pRB. pRB plays a critical 
role in the progression of the cell cycle through G1 by being the central node in the molecular 
switch that is the restriction point. pRB is known to bind numerous proteins when in its active and 
underphosphorylated state, most notably the transcription factor E2F which is rendered ineffective 
by virtue of being in complex with pRB. E2F transcription factors are responsible for regulating 
the expression of key proteins that are essential for the progression of the cell cycle, most notably 
cyclin E. Upon phosphorylation and inactivation of pRB by cyclin D-Cdk 4/6, E2F dissociates 
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from pRB and is allowed to transactivate the cyclin E gene. Build up in cyclin E levels promotes 
association with and activation of Cdk2, whose primary substrate is also pRB (Johnson and 
Walker, 1999). By further phosphorylating pRB, cyclin E-Cdk2 works to maintain pRB in a 
hyperphosphorylated and inactive state, thereby establishing a positive feedback loop that allows 
E2F to transactivate other important genes for DNA replication; such as those coding for cyclin A 
or DNA polymerase. Cyclin E-Cdk 2 also phosphorylates histone H1, an important event in the 
rearrangement of chromatin during genome replication (Stevaux and Dyson, 2002). However, to 
suggest that progression through the restriction point is as simple as phosphorylating pRB would 
be overlooking the importance of c-Myc in the transition from G1 to S phase. 
Myc and G1/S transition 
The induction of the transcription factor c-Myc occurs rapidly in early G1 upon mitogen 
stimulation, with proteins levels reaching their peak in G1 but dropping to lower steady-state 
concentrations in proliferating cells (Campisi et al., 1984). Although Myc has been convincingly 
linked to promoting proliferation, the exact set of gene targets that link Myc to mitogen stimulation 
and the cell cycle apparatus is still being investigated. Despite this, it is now known that Myc 
promotes the transition through the restriction point by both indirect and direct means. As eluded 
to above, Myc induces the transcription of cyclin D through the Ras/Raf/Mek/Erk cascade, 
promoting progression in three ways: a) by activating Cdks 4 and 6, resulting in cyclin E induction, 
b) sequestration of the Cip/Kip inhibitors p21 and p27 by cyclin D-Cdk 4/6 away from cyclin E-
Cdk 2, promoting the activation of Cdk2 and c) Myc transactivates the phosphatase cdc25, which 
relieves the inhibitory phosphorylation of Cdk2 on Thr 14/Tyr 15 (Bartek and Lukas, 2001). The 
former is made possible by the fact that Cip/Kip inhibitors can bind to pre-existing cyclin-Cdk 
complexes and have dual specificities for cyclin D-Cdk 4/6 and cyclin E-Cdk 2, unlike their INK4 
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counterparts. This mechanism is known as CKI exchange and is important in regulating the G1/S 
transition. The process relies on the accumulation of cyclin D-Cdk 4 which recruits Cip/Kip 
inhibitors (p27 for example) away from cyclin E-Cdk2, allowing for the activation of the liberated 
cyclin E-Cdk2 kinase. The freeing of cyclin E-Cdk 2 from Cip/Kip inhibition and relief of 
inhibitory phosphates on Cdk 2 by cdc25, allows for the ubiquitination and proteasome-mediated 
degradation of p27. This complex series of events commits the cell to enter S phase, which 
eventually results in the resetting of the molecular switch via the induction of INK4 inhibitors p16 
and p15 (Ekholm and Reed, 2000). 
The cell cycle and cancer 
With increasing levels of cell cycle regulations comes many opportunities for dysregulation 
promoting unrestrained cell growth. Normal cells are receptive to their environmental cues and are 
able to integrate them such that internal checks and balances ensure the timely and accurate 
progression of the cell cycle. Cells that have stepped outside of these controls are able to bypass 
the G1 restriction point and proliferate in the absence of external growth cues. Over expression of 
the oncogene cyclin D promotes pRB phosphorylation and G1/S progression, while deletion or 
mutation of tumor suppressors such p53, pRB or CKIs results in unchecked cell growth resulting 
in an elevated risk of tumor formation.  
There have been numerous examples of altered Cdk expression in cancer. For example, 
overexpression of Cdk4 by amplification has been identified in melanoma, sarcoma and glioma 
(Wolfel et al., 1995), while overexpressed Cdks 1 and 2 have been identified in a subset of colon 
adenomas (Yamamoto et al., 1998). Point mutations have also been reported to result in selective 
growth advantage in cells carrying the R24C mutation within CDK4, due to the mutant protein’s 
inability to bind the INK4 inhibitor p16. This results in constitutive activation of CDK4 in certain 
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lung cancers, lymphomas and familial melanoma (Peyressatre et al., 2015). 
Cyclin D seems to be the most frequently altered cyclin in human cancers, not surprisingly since 
cyclin D allows cells to integrate environmental cues in order to initiate the cell cycle. 
Translocation of the cyclin D gene next to the immunoglobulin heavy chain locus enhancer region 
causes cyclin D1 overexpression in centrocytic B-lymphocytes and is often a sign of poor 
prognosis (Weisenburger et al., 1987). Overexpression, amplification or both of Cyclin E has been 
identified in acute lymphoblastic and myeloid leukemias as well as in some cases of breast and 
colon cancer (Vermeulen et al., 2003). 
Inhibitors of the cell cycle are also found to be dysregulated in cancer. CKIs are commissioned to 
restrain cell growth by preventing the phosphorylation of pRB, therefore they are considered to 
function as tumor suppressors. Due to the specificity of p16 for cyclin D, any alterations in function 
would have a severe impact on the restriction point’s ability to modulate the cell cycle. p16 has 
indeed been found to be altered in cancers, by means of point mutations, deletions or silencing by 
hypermethylation (Kamb, 1998). Deletions are the most common alterations affecting p16 levels 
and are found in 20-30% of acute lymphoblastic leukemias, 40-60% of nasopharyngeal, biliary 
tract and pancreatic tumors as well as in 50% of gliomas and mesotheliomas (Hall and Peters, 
1996).  
Loss of gene expression may be a result of events other than gene deletion. In colorectal 
carcinomas, p27 loss has been attributed to an increased rate of proteasome dependent degradation 
(Pagano, 1997), while p21 expression is affected due to its transcriptional regulation by p53. 
Considering the fact that p53 is the most frequently mutated gene in human cancer, it is of no 
surprise that the p21 mediated DNA damage checkpoint is sidestepped when p53 is inactivated 
(Deng et al., 1995). 
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Although the components of the cell cycle machinery are often dysregulated in cancer, their 
substrates can also fall victim to molecular pathology. The restriction point governing the 
transition from G1 to S phase converges on pRB, the most important substrate of cyclin D-Cdk4/6. 
When pRB function is altered, cell cycle progression proceeds unchecked and results in 
uncontrolled cell growth. pRB is commonly mutated in lung cancer and retinoblastoma, the cancer 
from which it derives its name (Hall and Peters, 1996). Alterations in pRB can be a result of 
deletions or mis-sense mutations that cause absence of pRB, truncation or a non-functional protein. 
Inactivation of pRB can also result from binding of tumor virus proteins such as human 
papillomavirus E7, adenovirus E1A and simian virus 40 (Vermeulen et al., 2003).  
The above examples demonstrate that studying cancer requires an intimate knowledge of the cell 
cycle and its regulators. It is estimated that approximately 90% of human cancers acquire 
alterations in at least one component of the pRB molecular switch, so it is of no surprise that 
current efforts in drug development seek to target components of the cell cycle machinery. New 
insights into cancer pathophysiology have shifted the focus of drug development from brutish 
attempts to kill tumor cells towards more sophisticated methods that target the cell cycle 
machinery. These approaches include induction of checkpoint mechanisms in hopes of 
encouraging cytostasis or apoptosis, or inducing arrest of cancerous cells in phases of the cell cycle 
that render them susceptible to other treatments.  
The most attractive approach to date is the targeting of Cdks by either indirect or direct means. 
Cdk activity can be indirectly inhibited by focusing on Cdk regulators by either overexpressing 
CKIs, administrating synthetic peptides that mimic CKIs, decreasing cyclin levels, targeted 
degradation of Cdks and manipulating the phosphorylation states of Cdks and their regulators. 
However, the most successful strategy to date has been the direct targeting of Cdks by inhibiting 
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their kinase activity. These methods focus on the disruption of ATP binding sites rather than the 
inhibition of protein-protein interactions between Cdks and their activating cyclin cohorts 
(Senderowicz and Sausville, 2000; Mcdonald and el Deiry, 2000).  
Flavopiridol is a first-generation pan-Cdk inhibitors which shows specificity for Cdk1, 2 and 4. 
The compound is a synthetic analogue of an alkaloid found in Dysoxylumbinectariferum, a plant 
native to India, and was discovered as a powerful growth inhibitor of lung and breast cancer cell 
lines. Flavopiridol has gone through numerous phase II and III clinical trials, but unfortunately has 
yet to live up to the early expectations placed in Cdk inhibitors (Byrd et al., 2007). Despite 
setbacks, second generation Cdk inhibitors are currently in either advanced pre-clinical testing or 
clinical trials. Three particular classes of Cdk inhibitors are showing promise, as they are more 
potent and/or drug-like then their predecessors: a) broad spectrum Cdk inhibitors targeting Cdks 
1, 2, 4, 6, 7 and 9. b) inhibitors specific for cdk4/6 or cdk2 and c) inhibitors specific for Cdks in 
addition to off target kinases that may synergistically enhance anti-tumor activity (Malumbres et 
al, 2007). Most recently, Palbociclib became the first Cdk 4/6 specific inhibitor to be approved for 
cancer treatment (Rocca et al., 2017).  Our understanding of the genetic nature of cancer and the 
cell cycle and the ability to genotype the tumours of patients will enhance our ability to develop 
drugs and insure the most effective treatment. For example, foreknowledge of the status of p53 or 
pRB would aid in the selection of therapies which take advantage of the cells ability to arrest the 
cell cycle. 
The concept of the cell cycle has long fascinated biologists, and though the end product is blatantly 
obvious, the means by which one cell becomes two has only until recently, remained a mystery. 
Described here is only a distilled outline of the most important aspects of the pRB molecular switch 
and the DNA damage checkpoint that converges at the restriction point. Our growing 
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understanding of the mechanisms which regulate the cell cycle have expanded our insights into its 
dysregulation and the tenacious beast that is cancer. The restriction point between the G1/S 
transition and the mechanisms that control it have proven to be a crucial node in both tumorigenesis 
and cancer therapy. Although the basics behind the cell cycle have been solved, advances in high-
throughput technologies and computing capabilities promise to broaden our knowledge to new 
levels. An expanding repertoire of cell cycle signalling networks means greater opportunities to 
intervene in tumorigenesis by rational drug design. 
 
The following data reveals the implications of CDCA7 on cell cycle distribution and proliferation 
rates. We have investigated the links between these phenotypic profiles with the expression of key 
components of the cell cycle via qPCR, ChIP and promoter assays. We have shown that expression 
of CDCA7 in Rat1 and HEK293 cells results in the increase of the proportion of cells in the G2/M 
phase of the cell cycle (Figure 4.3-4.5). In addition, we have shown that Rat1 cells expressing 
various versions of CDCA7 results in different proliferation rates (Figure 4.6). Preliminary data 
suggests that CDCA7’s effect on cell cycle distribution and growth rates may be attributed to 
alterations in expression of Cyclin D1, Cyclin B1, BAX and other known Myc targets (Figure 4.7 
and 4.8). Finally, in light of CDCA7’s physical interaction with Myc and cooperation in activating 
a Myc reporter (Figure 4.1 and 4.2), we hypothesize that CDCA7 directly cooperates with Myc in 
altering the expression of key Myc-dependent cell cycle components in a manner that is controlled 
by Akt. This may occur either directly by influencing Myc promoter occupancy or by competing 
for Myc binding with other known Myc binding partners. 
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Results 
 
CDCA7 cooperates with Myc to activate a Myc E-Box reporter 
We have identified CDCA7 as being a Myc binding partner (Gill et al., 2013). To answer whether 
CDCA7 alters Myc’s ability to transactivate an E-box promoter, we transfected a Myc-luciferase 
reporter containing a canonical E-box (CACGTG) into HEK293 cells that stably expressed 
doxycycline-inducible CDCA7. Myc reporter activation was positively correlated with increasing 
amounts of doxycycline and CDCA7 expression. Activation was highest in cells expressing the 
KK variant of CDCA7, which does not bind the 14-3-3 adaptor protein and is localized in the 
nucleus. Conversely, the DE variant of CDCA7 that forces binding to 14-3-3 and sequestration in 
the cytoplasm away from Myc, resulted in the poorest activation of the Myc reporter (Figure 4.1A). 
To determine if this activity was dependent on CDCA7’s ability to bind Myc, we infected Rat1 
cells that were stably expressing Myc with a retrovirus containing an empty vector, CDCA7 or the 
non-Myc binding Δ(156-187)CDCA7. Western blots confirming this expression can be seen in 
figure 4.1B. Measurement of luciferase activity suggests that activation of the reporter was 
dependent on Myc’s ability to bind CDCA7, as the non-Myc binding Δ(156-187) CDCA7 resulted 
in less activation then even native Rat1 cells (Figure 4.1C).  
CDCA7 expression increases Myc occupancy at the BAX promoter 
Next, we asked whether CDCA7 and Myc co-associate on chromatin to alter Myc-dependent gene 
expression. We have previously shown that expression of T163A CDCA7 results in significant 
increases in Myc-dependent apoptosis (Gill et al., 2013) and we have data indicating that CDCA7 
expression causes an increase in BAX mRNA (Figure 4.9), which is a pro-apoptotic Myc target 
gene (Dang, 1999; Robson et al., 2011). Thus, we preformed chromatin immunoprecipitations 
from Rat1 clones stably expressing wildtype CDCA7 or T163A CDCA7. This showed that during 
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serum-starvation conditions, a condition which sensitizes CDCA7 expressing cells to apoptosis, 
CDCA7 expression elevates both Myc and RNAPII occupancy at the BAX promoter (Figure 4.2). 
These results were further enhanced when expressing T163A CDCA7, which is localized almost 
exclusively to the nucleus and undergoes greater amounts of Myc-dependent apoptosis. This data 
is the first to demonstrate that CDCA7 can associate with chromatin, and supports the hypothesis 
that CDCA7 modulates Myc-dependent gene expression.  
CDCA7 expression alters cell cycle progression  
Propidium iodide is a fluorescent molecule which can intercalate with DNA in a stoichiometric 
fashion and therefore alert users to DNA content as cells progress through the cell cycle. This 
principle is the basis for fluorescence based flow cytometry. The use of both propidium iodide and 
antibodies conjugated to fluorescent molecules is a powerful method that allows users to track 
protein content or post translational modifications (such as phosphorylation) as cells progress 
through the cell cycle. We have used flow cytometry to analyze the cell cycle distribution of Rat1 
or Rat1-Myc cells expressing WT CDCA7 or Δ(156-187) CDCA7. Our results indicate that cells 
expressing CDCA7 in 10% serum conditions show larger population of cells occupying the G2/M 
phase of the cell cycle. This ratio is marginally increased with coexpression of ectopic Myc. 
Expression of the non-Myc binding Δ(156-187) CDCA7 abrogates this shift towards G2/M phase 
(Figure 4.3A). Expression of T163A CDCA7 in 0% serum also resulted in fewer cells within G2/M 
compared to WT CDCA7 (Figure 4.3B). 
To further investigate the affects of CDCA7 on cell cycle progression, we synchronized HEK293 
cells transiently expressing CDCA7 in G2/M phase with 100 ng/ml Nocodazole (a microtubule 
inhibitor) for 18 hours. These cells were then allowed to re-enter the cell cycle and were collected 
at various time points for cell cycle analysis via flow cytometry. Figure 4.4 shows that Nocodazole 
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did in fact synchronize a large portion of cells in G2/M (untransfected and transfected cells), 
however analysis of FLAG positive gated-cells indicates that expression of FLAG-CDCA7 
prevents those cells from entering G2/M and may in fact result in a noticeable population of 
apoptotic cells (sub-G1 cells). What remains unknown is the status of T163 phosphorylation during 
progression through the cell cycle. To shed light on this we repeated cell synchronization in the 
same fashion, followed by staining with propidium iodide and α-pT163 CDCA7 prior to flow 
cytometry. Figure 4.5A indicates that T163 appears to be phosphorylated in those cells which are 
synchronized in G2/M. Upon release and progression through the cell cycle, phosphorylation of 
T163 becomes almost undetectable as the majority of cells progress back into G1 phase. This result 
was replicated at the protein level when lysates from the same cells used for flow cytometry were 
lysed and subjected to western blot analysis (Figure 4.5B). Finally, this result is reinforced when 
both negative and positive phospho-T163 cells are depicted on the same histogram (gathered via 
flow cytometry). In figure 4.5C cells negative for T163 phosphorylation are indicated by the left 
gate, while positive cells are bound by the right gate. Upon synchronization in G2/M with 
Nocodazole, there are two distinct populations of cells representing phospho-T163 negative and 
positive cells. However, upon 2 hour release into the cell cycle, the positive phospho-T163 signal 
is no longer detectable. Although the sensitivity of flow cytometry and infrared-based western 
blotting can differ (depending on the set of antibodies being employed), the results in both cases 
suggest that phosphorylation of T163 is occurring primarily during G2/M and drops considerably 
as cells cycle out of G2/M and into G1.  
CDCA7 phosphorylation at T163 occurs in the nucleus 
With the knowledge that T163 is phosphorylated during to G2/M phase, we sought to identify the 
subcellular localization of phospho-T163 CDCA7 upon G2/M synchronization. In our experience, 
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cell synchronization with nocodazole often resulted in cells which are far less adherent and 
amenable to microscopy. This could be attributed to the toxic nature of nocodazole, which can act 
as a pro-apoptotic agent during prolonged incubation. Therefore, we were forced to use RO-3306 
as a substitute for nocodazole, with greater success in regard to cell adherence during fixing and 
mounting protocols. RO-3306 is a non-toxic reversible Cdk1 inhibitor with the ability to 
synchronize cells in G2/M in the µM range (Vassilev, 2006). Figure 4.6A shows that when 
HEK293 cells are synchronized in G2/M with RO-3306, there is a complete absence of T163 
phosphorylation. However, 60 minutes after release from synchronization, T163 phosphorylation 
appears striking, and punctate within the nucleus. Next, we investigated the striking subcellular 
localization of pT163 CDCA7 and asked whether it correlated with similar, and typical localization 
of centrosomes during mitosis (Dahm et al., 2007). We repeated synchronization of HEK293 and 
HeLa cells with RO-3306 and visualized phospho-T163 CDCA7, endogenous CDCA7, the 
centrosomal marker protein γ-Tubulin and the Akt activation marker phospho-S473 Akt. Figure 
4.6B shows that 60 minutes post release from RO-3306 synchronization, phospho-T163 CDCA7 
colocalizes with γ-Tubulin at the same punctate regions in HEK293 cells as seen in figure 4.6A. 
In HeLa cells released from RO-3306 synchronization, endogenous CDCA7 also colocalize with 
γ-Tubulin (Figure 4.6C top). In these same cells, phospho-T163 CDCA7 was seen to colocalize 
with activated Akt as indicated by the presence of phospho-S473 Akt (Figure 4.6B bottom), in the 
same punctate manner seen in previous results. Finally, these results were recapitulated in HEK293 
cells transfected with FLAG-CDCA7 as well as NIH3T3 cells stably expressing FLAG-CDCA7 
(Figure 4.7).  
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CDCA7 alters proliferation rates 
To evaluate whether CDCA7’s effect on the cell cycle translates into altered growth rates, we have 
measured proliferation rates using a colorimetric assay based on the reduction of XTT (2,3-bis-(2-
methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) via the membrane-electron 
transport chain. Color intensity of the reaction product is directly proportional to the quantity of 
cells being assayed. Therefore, cell proliferation rates can be tracked as a function of color intensity 
as cells are assayed over multiple time points. We employed this assay to test the proliferation 
rates of Rat1 cells stably expressing CDCA7 (Figure 4.8A). The most intriguing observation from 
these results is the differential growth rates produced by the various iterations of CDCA7, 
suggesting that CDCA7 may play a direct role in cell proliferation. More specifically, the gradient 
in growth rates may be a result of CDCA7’s ability to bind 14-3-3, as we have shown that DE 
CDCA7 constitutively binds 14-3-3 while T163A and KK CDCA7 cannot bind 14-3-3. When cells 
were maintained in media supplemented with 2 % FBS for 6 days, only Rat1 cells expressing DE 
CDCA7 (constitutively bound to 14-3-3) showed a growth advantage over Rat1 control cells 
(Figure 4.8B). Conversely, WT CDCA7 and KK CDCA7 (cannot bind 14-3-3) exhibited the 
slowest growth rates. When cells were maintained in 5% FBS, cells expressing WT CDCA7 saw 
an improvement in growth rates over cells expressing KK and T163A CDCA7, indicating that 
perhaps only WT CDCA7 has an ability to affect growth rates in response to serum concentrations.  
CDCA7 alters the expression of Myc target genes involved in the cell cycle 
We have accumulated data which suggests that expression of CDCA7 affects Myc-dependent 
apoptosis, cell cycle distribution and proliferation, and therefore decided to probe the expression 
profiles of Myc target genes that are involved in these processes (Dang, 1999; Robson et al., 2011). 
After an initial screen of a large subset of genes via qPCR (data not shown), we identified INS, 
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BAX and CyclinB1 expression as being upregulated and INK4B as being suppressed in Rat1 cells 
stably expressing CDCA7 (Figure 4.9A). Induction of CDCA7 by doxycycline, resulted in similar 
upregulation of INS and suppression of INK4B expression (Figure 4.9B) while in cells stably 
expressing shRNA targeting CDCA7, the opposite trend was observed when compared to a 
scrambled shRNA control (Figure 4.9C). These results would indicate that the mRNA products of 
the INS and INK4B genes are positively and negatively (respectively) affected by CDCA7 
expression. The INS gene encodes for the peptide hormone insulin which is crucial for the 
metabolism of carbohydrates, proteins and fats. Insulin exerts its function by initiating a signaling 
cascade which includes the activation of Akt (Lee et al., 2009), the same kinase which is 
responsible for phosphorylating CDCA7 at T163. The INK4B gene encodes a protein known as 
p15INK4B which is known to inhibit G1 progression by sequestering CDK4 or CDK6 away from 
cyclin D, thereby preventing CDK activation (Krimpenfort et al., 2007). It is possible that the 
compounded effects of increased INS expression and decreased INK4B expression are aiding in 
the transition of cells from G1 into G2/M as we see a larger population of cells in G2/M when 
expressing CDCA7.  
Next, we probed the expression of cyclin D1 and B1. These genes were chosen because of their 
importance in the progression of the cell cycle. Cyclin D1 is responsible for allowing cells to 
transition through G1 phase by complexing with CDK4, phosphorylating the retinoblastoma 
protein (pRB) and thereby allowing the E2F transcription factor to transactivate genes required for 
transition into S phase (Matsushime et al., 1992). Cyclin B1 is known to be a positive regulator of 
mitosis as it complexes with CDK1 and encourages G2/M transition by phosphorylating and 
activating 13S condensin to promote chromosome condensation (Kimura et al., 1998). We asked 
if cells expressing CDCA7 show a shift in cell population towards G2/M, then how might these 
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genes be affected? We used qPCR with pools stably expressing CDCA7 that were synchronized 
by starvation for 18 hours and then stimulated with the addition of FBS. In the case of Cyclin D1 
(Figure 4.10A), we observed a marginal increase in Cyclin D1 message in cells expressing WT 
CDCA7, while cells expressing T163A CDCA7 contained approximately 30% less Cyclin D1 
mRNA compared to controls cells upon release from starvation conditions. qPCR for Cyclin B1 
message resulted in a more pronounced affect upon release from starvation (Figure 4.10B). 
Expression of WT or T163A CDCA7 yielded approximately 40% and 50% (respectively) 
increases in Cyclin B1 mRNA. Whether CDCA7 is directly responsible for the changes in mRNA 
levels reported here is unknown, there is also the possibility that any affects might be indirect. For 
example, increased levels of cyclin B1 may simply be a product of the larger population of cells 
found in G2/M when CDCA7 is expressed (Figures 4.3-4.5). Finally, we decided to test CDCA7’s 
ability to affect the activation of a Cyclin D1 promoter via luciferase assay (Figure 4.10C). In both 
cases where WT or T163A CDCA7 was stably expressed in Rat1 cells, activation of the Cyclin 
D1 reporter was approximately 50% lower when compared to control cells. The reduction of 
Cyclin D1 promoter activity seen in figure 4.10C may explain the reduction in mRNA levels seen 
in figure 4.9. 
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Figure 4.1. Myc activity is regulated by CDCA7. A. (n=3) HEK293 cells stably expressing 
doxycycline-inducible CDCA7 and the indicated mutations were transfected with a Myc-reporter 
plasmid and treated with doxycycline for 24 hours as indicated, and luciferase activity was 
determined after normalization with b-gal. P values were calculated using WT CDCA7 as the 
comparison population. B. Rat1 cells stably expressing Myc were infected with retrovirus 
containing empty vector, CDCA7 or ∆(156-187) CDCA7. C. (n=5) After selection for 6 days, a 
Myc-reporter plasmid was transfected and luciferase was measured after 24 hours. * = P<0.01 
when compared to 0 µg/ml DOX for each transfection. Error bars represent standard deviation. 
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Figure 4.2. ChIP analysis of CDCA7 at the BAX promoter. A. Rat1-Myc cells stably expressing 
either empty vector, WT CDCA7 or T163A CDCA7 were cross-linked, lysed and chromatin 
sheared by sonication. Anti-RNAPII, anti-Myc or anti-FLAG-CDCA7 antibodies were used to 
precipitate protein-DNA complexes. Following reversal of cross-links, DNA was isolated using a 
commercial kit (Millipore) and quantified by qPCR. The amount of DNA precipitated was 
measured against DNA isolated by a non-specific IgG control. * = P<0.05, ** = P≤0.01, N=3. 
Error bars represent standard deviation. 
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Figure 4.3. CDCA7 promotes G2/M transition. A. (left) Cell cycle distribution of Rat1 or Rat1-
Myc cells stably expressing CDCA7 or ∆(156-187) CDCA7 maintained in media supplemented 
with 10% FBS. (right) G2/M:G1 Ratio summary for 3 – 5 independent experiments, normalized 
to the G2/M:G1 ratio of Rat1 cells. B. (top) Cell cycle distribution of Rat1 cells stably expressing 
CDCA7 and maintained in media containing 0% FBS for 18 hours. (bottom) Quantified cell cycle 
data over three experiments. Average cell population gated for G1, S and G2/M. * = P<0.05, ** = 
P ≤ 0.01 and *** = P ≤ 0.001. Error bars represent standard deviation. 
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Figure 4.4. CDCA7 prevents cells from synchronizing in G2/M. HEK293 cells transiently 
expressing FLAG-CDCA7 were synchronized in G2/M with 100 ng/ml of Nocodazole for 18 hours 
and then released as indicated. Top row of histograms represents cell cycle profiles of all cells 
stained with propidium iodide, with red representing gating for G1 and G2/M cells by Modfit. 
Bottom row of histograms represents cell cycle profile of cells positively stained with α-FLAG 
antibody, as gated by Modfit. 
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Figure 4.5. T163 CDCA7 is phosphorylated in G2/M. A. HEK293 cells transiently expressing 
FLAG-CDCA7 were synchronized in G2/M with 100 ng/ml of Nocodazole for 18 hours and then 
released as indicated. Top row of histograms represents cell cycle profiles of all cells stained with 
propidium iodide. Bottom row of histograms represents cell cycle profile of cells positively stained 
with α-pT163 CDCA7 antibody. B.  Lysates and immunoprecipitations were generated from cells 
in A and subjected to western blotting. Membranes were probed with α-FLAG, α-14-3-3 and α-
pT163 CDCA7 antibodies. This data was quantified via the Odyssey infrared scanner and is 
depicted below (averaged over 3 experiments). C. Total cell population distribution from A at 0 
and 2 hours post release from Nocodazole synchronization. Left gate indicates phospho-T163 
negative cells, right gate indicates phospho-T163 positive cells as per staining with α-pT163 
CDCA7 antibody. Error bars represent standard deviation. 
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Figure 4.6 CDCA7 T163 phosphorylation is localized to centrosomes. HEK293 and HeLa cells 
were treated with 10 μM RO-3306 for a minimum of 18 hours in order to synchronize cells in 
G
2
/M phase. Cells were washed three times with PBS and released in RO-3306 free media before 
being fixed and mounted for immunofluorescence microscopy or FLOW cytometry. A. HEK 293 
cells synchronized with RO-3306 (top, cell cycle distribution) for 18 hours show no 
phosphorylation of endogenous T163 CDCA7 (bottom). Phosphorylation of T163 becomes 
evident at 60 minutes post release. B. pT163 CDCA7 is localized to centrosomes as indicated by 
the centrosomal marker protein γ-Tubulin (Dahm et al., 2007). C. Similar results were 
recapitulated in HeLa cells that were synchronized for 24 hours and released for 40 minutes (top) 
or synchronized for 20 hours and released for 50 minutes (bottom). Activated Akt (pS473) 
colocalizes with pT163 CDCA7.  
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Figure 4.7 CDCA7 T163 phosphorylation in transfected cells is localized to specific areas of 
the nucleus. HEK293 and NIH3T3 cells were synchronized in G
2
/M phase with 10 μM RO-3306 
for 18 hours. Cells were washed three times with PBS and released in RO-3306 free media before 
being fixed and mounted for immunofluorescence microscopy. HEK293 cells were transiently 
transfected with FLAG-WT CDCA7. NIH3T3 cells are stably expressing FLAG-WT CDCA7. 
Although FLAG WT-CDCA7 is evenly distributed throughout the cell, pT163 appears punctate 
and localized to DNA, likely at centrosomes as in figure 4.6.  
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Figure 4.8. Generation of Rat1 pools stably expressing CDCA7 and their XTT growth assays 
profiles. A. Rat1 cells were infected with retrovirus containing an antibiotic selection marker and 
cDNA of various forms of flag tagged CDCA7. After two weeks of selection, lysates were 
generated from antibiotic resistant pools and probed with anti-flag antibody to confirm expression 
of CDCA7. B. Cells from pools depicted in A. were plated in triplicate in 96-well plates at 2000 
cells/well and were allowed to grow for 6 days in media containing 2% or 5% FBS. Samples were 
assayed each day at the same hour. P values for each time point are indicated below graphs, where 
p<0.05 is highlighted, N=3. Error bars represent standard deviation. 
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Figure 4.9. qPCR analysis of Myc target genes. A. mRNA was analyzed by qPCR in Rat1 cells 
stably expressing CDCA7 vs Rat1 expressing empty vector (Control). The primers for CDCA7 
detected ectopic CDCA7, which was 5 fold above control Rat1 cells. B. Rat1 cells stably 
expressing doxycycline-inducible CDCA7 were treated with doxycycline for 18 hours and mRNA 
for INS and INK4B was measured by qPCR. C. Rat1 cells expressing either scrambled shRNA or 
CDCA7- targeted shRNA were isolated and mRNA for INS and INK4B was measured by qPCR. 
* = P<0.05, ** = P ≤ 0.01 and *** = P ≤ 0.001.  Error bars represent standard deviation. 
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Figure 4.10. qPCR analysis of Cyclin D1 and B1. mRNA levels of Cyclin D1 A. and Cyclin B1 
B. was analyzed by qPCR in Rat1 cells stably expressing CDCA7 vs Rat1 expressing empty vector 
(Control). Pools were starved in 0.1% FBS for 18 hours at which point 10% FBS was added back 
for 5 hours. C. Cyclin D1 promoter assay via a luciferase reporter was conducted with Rat1 cells 
stably expressing CDCA7 vs empty vector. Cells were plated at equal densities and kept in media 
supplemented with 10% FBS for 24 hours. * = P<0.05, ** = P≤0.01, N=3 in A and B, N=2 in C. 
Error bars represent standard deviation. 
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Discussion 
 
In the studies outlined above, we have shown that cooperation between CDCA7 and Myc results 
in altered cell cycle distribution with a shift of cell populations towards G2/M phase, while 
expression of WT CDCA7 prevents cells from synchronizing in G2/M. Cell cycle data also shows 
that phosphorylation of T163 occurs in G2/M and it likely occurs in proximity to centrosomes. 
Proliferation assays have revealed that growth rates vary depending on the form of CDCA7 that is 
expressed which results in growth rates which may be correlated with CDCA7’s ability to bind 
14-3-3. For example, forced binding of 14-3-3 resulted in the quickest proliferation rates, while 
lack of binding resulted in the slowest rates. The phenotypic results summarized here broadens the 
scope of CDCA7’s influence on major cellular process including not only apoptosis, but cell cycle 
progression and proliferation. In this chapter, we have also sought to better understand the extent 
to which CDCA7 might be directly involved in Myc-mediated gene expression. We have shown 
that CDCA7 enhances Myc’s ability to activate a reporter that contains a canonical E-box promoter 
element. ChIP experiments verify that CDCA7 binds to chromatin and promotes increased Myc 
occupancy of the BAX promoter, which is a proapoptotic Myc target gene. Finally, expression of 
CDCA7 alters the mRNA levels of Myc target genes that are involved in cell cycle progression, 
proliferation and apoptosis. 
As our group reported in 2013, CDCA7 directly interacts with Myc and potentiates Myc-dependent 
apoptosis (Gill et al. 2013). What was unknown at the time was whether CDCA7 interacts with 
DNA directly or indirectly via its association with Myc. This scenario is likely as CDCA7 and 
JPO2 share a high degree of homology in their C-terminal cysteine rich regions, which in JPO2 
has been shown to confer DNA binding ability (Goto, 2006). Here we have established that 
CDCA7 expression enhances the activation a Myc E-box reporter and that this activation is 
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dependent on CDCA7’s interaction with Myc (Figure 4.1C).  Based on these results, we surmised 
that CDCA7 may enhance the promoter occupancy of Myc at target genes involved in apoptosis. 
We chose to specifically focus on the BAX promoter, as this well-known pro-apoptotic Myc target 
gene has been shown to be involved in Myc-mediated apoptosis upon serum withdrawal (Mitchell 
et al., 2000). Activation of the PI3K pathway has also been shown to suppress the translocation of 
BAX to the mitochondria, and therefore promoting survival (Tsuruta et al., 2002). Using chromatin 
immunoprecipitation followed by qPCR, we have shown that expression of WT CDCA7 does in 
fact increase Myc occupancy of the BAX promoter (Figure 4.2). This is further enhanced by the 
expression of T163A CDCA7, which when co-expressed with Myc in Rat1 cells results in 
hypersensitivity to apoptosis upon serum withdrawal (Gill et al., 2013). Finally, expression of 
CDCA7 also increases BAX mRNA levels by approximately 2.5 times over empty vector 
expression alone, perhaps as a product of increased Myc occupancy at the BAX promoter. These 
results are the first to implicate CDCA7 in a known apoptotic pathway involving the Myc target 
gene BAX, and may shed light on how CDA7 is involved in Myc-mediated apoptosis.  
The G2/M distribution of cells expressing CDCA7 (figure 4.3) may also be a reflection of Myc 
target genes influenced by CDCA7 (Figure 4.9 and 4.10). In particular, we have evidence showing 
that expression of CDCA7 increases mRNA levels of Cyclin B1 while decreasing mRNA levels 
of p15INK4B. These two proteins are of considerable note because of their roles in G2/M progression 
and commitment to mitosis. Cyclin B1 is critical in initiating mitosis by promoting chromatin 
condensation and works by activating Cdk1, and in doing so forms the mitosis promoting factor 
(MPF) (Sciortino et al., 2001; Chang et al., 2003). The CDK inhibitor p15INK4B is known to arrest 
cells in G1 by inhibiting Cyclin D/Cdk 4/6 and are induced via the MAPK pathway (Carneo and 
Hannon, 1998). The simultaneous upregulation of Cyclin B1 and down regulation of p15INK4B may 
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explain the preponderance of CDCA7 expressing cells occupying G2/M phase. However, at this 
point one cannot rule out the possibility that this mRNA profile is simply a result of cells being 
encouraged into G2/M by some other means and is simply a normal reflection of cells in this state. 
This line of reasoning may also extend to the reduction of Cyclin D1 promoter activity seen upon 
CDCA7 expression (Figure 4.10C). Cyclin D1 is expressed via Myc during G1 and promotes G1/S 
transition. It is possible that the reduction of Cyclin D1 promoter activity is due to: a) CDCA7 
expressing cells occupying G2/M or b) CDCA7’s association with Myc represses Cyclin D1 
expression directly or by altering Myc promoter occupancy and specificity to the Cyclin D1 
promoter.  
One of the most surprising results from our investigation into cell cycle progression is the fact that 
CDCA7 T163 phosphorylation occurs strictly in G2/M and in proximity to centrosomes (Figure 
4.5-4.7). This is revealing in light of two recent publications that implicate mutations in CDCA7 
as being correlated with immunodeficiency-centromeric-instability-facial anomalies syndrome 
(ICF) (Thijssen et al., 2015; Wu et al., 2016). CpG hypomethylation in juxtacentromeric DNA is 
a hallmark of ICF and is used as a diagnostic indicator for the syndrome. These hypomethylated 
sequence have been shown to correlate with chromosomal abnormalities in interphase as well as 
mitotic missegregation (Tuck-Muller et al., 2000; Gisselsson et al., 2005). It remains to be seen 
whether there is a relationship between ICF onset or progression and T163 phosphorylation at 
centrosomes. Interestingly, the four mutations within CDCA7 that are associated with ICF occur 
in the C-terminal zinc finger domain (Thijssen et al., 2015) which we believe may impart DNA 
binding ability on CDCA7. Could these mutations prevent CDCA7 from localizing to 
juxtacentromeric DNA, thus preventing methylation of juxtacentromeric DNA? Could 
phosphorylation of T163 in proximity to centrosomes play a part in mitotic missegregation seen 
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in ICF? Our lab is currently generating the mutations in question in order to investigate their effect 
on CDCA7 localization, T163 phosphorylation and DNA binding ability. We will also investigate 
how these mutations affect cell cycle progression, cell proliferation and apoptosis.  
Materials and Methods 
 
Cell lines and cell culture 
HEK 293, Rat1 and 3T3 cells were obtained from the American Type Culture Collection and 
maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum 
and antibiotics at 37°C and 5% CO2. Rat1-MYC cells were obtained by stable transfection of Myc 
and selection in 600 g/ml G418 and 20% fetal bovine serum. Clones expressing both wild-type 
and mutant CDCA7 were established using the Tet-ON advanced inducible gene expression 
system from Clontech. Specifically, stable clones expressing a tet-induced transactivator (rtTA) 
were obtained by stable transfection of Rat1 and Rat1-MYC cells, respectively, with pIREShyg3-
rtTA, followed by selection in 200g/ml hygromycin. Subsequently the rtTA-Rat1 and rtTA-Rat1-
MYC cells were co-transfected with a 100:1 ratio of pTRE-tight-3xFLAG-CDCA7 plasmid and 
linearized puromycin plasmid, followed by selection in 2g/ml puromycin. All Rat1-MYC derived 
inducible lines were maintained in 20% fetal bovine serum while Rat1-CDCA7 derived inducible 
lines were maintained in 10% fetal bovine serum. Rat1 pools stably expressing CDCA7 were 
generated via viral infection as per Clontech’s protocol, followed by selection in 200g/ml 
hygromycin. 
Transfections 
For transient expression of cDNA in HEK 293 and Rat1 cells, cells were plated onto 100-mm-
diameter dishes at 80% confluency and transfected with 8 g of total plasmid using 
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polyethylenimine (PEI) (Sigma-Aldrich #408727). 8 g of DNA was diluted with 1 mL of serum-
free Opti-MEM (ThermoFisher Scientific #31985062). 24 g of PEI was added to the diluted DNA 
mix for a final ratio of 3:1 g PEI:g DNA. The mix was vortexed 10x and allowed to incubate at 
room temperature for 30 minutes. 3 mL of Dulbecco’s modified Eagle’s medium supplemented 
with 10% fetal bovine serum was gently added to the transfection mix. The 4 mL total transfection 
mix was then added to cells following aspiration. 7 hours later, transfection medium was removed 
and replaced with complete Dulbecco’s modified Eagle’s medium overnight. 
Transfection of cDNA for stable integration and expression in Rat1 cells was accomplished using 
Lipofectamine 2000 (Life Technologies #11668019) and serum free Opti-MEM (ThermoFisher 
Scientific #31985062) according to manufacture’s protocol. Briefly, Rat1 cells were plated onto 
100-mm-diameter dishes at 80% confluency and transfected with 5 g of plasmid using 
Lipofectamine 2000 (Invitrogen) following the manufacturer’s protocol. Transfection medium was 
removed and replaced with complete Dulbecco’s modified Eagle’s medium overnight. 
Virus Production and Infections 
The ORF of CDCA7 was cloned into the Clontech retroviral vector set (Clontech #631516) and 
expressed in DH5α E. coil, from which cDNA was purified for use in transfections. This cDNA 
was transfected into Clontech Ecopack 2-293 cells (Clontech #631507) for virus production 
according to manufacture’s protocols. Virus collected from Ecopack 2-293 was used in infections 
of Rat1 or 3T3 cells according to manufacture’s protocols. Following 24-48 hour incubation 
periods, stable pools were selected using the appropriate antibiotic as dictated by the viral vector. 
Briefly, 3X-FLAG-CDCA7 or CDCA7 with various mutations were cloned into the pQCXIH 
retroviral vector (Clontech) upstream of an IRES sequence and the hygromycin resistance gene. 
Either empty pQCXIH or pQCXIH-CDCA7-IRES-Hygro retroviral vectors were transfected into 
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the ecotropic-envelope protein packaging cell line EcoPack 2-293 (Clontech). Viral particles were 
collected 48 hours later and concentrated using Retro-X concentrator (Clontech).  
Antibodies and Reagents 
Mouse monoclonal M2 anti-flag (A2220) and rabbit polyclonal anti-CDCA7 (HPA005565) were 
purchased from Sigma-Aldrich.  Rabbit polyclonal anti-CDCA7 (Ab69609) was purchased from 
Abcam.  Mouse monoclonal anti-14-3-3 (SC-1657) and 9E10 mouse monoclonal anti-MYC (SC-
40) were purchased from Santa Cruz. Rabbit polyclonal anti-Myc (5605) was purchased from Cell 
Signaling Technologies.  An anti-p-Thr163 CDCA7 rabbit polyclonal antibody was generated by 
Genscript Corporation (California).  
qRTPCR 
Total RNA was purified and cDNA synthesized using NEB’s ProtoScript® M-MuLV First Strand 
cDNA Synthesis Kit. Up and down regulation of genes of interest were performed using SA 
Bioscience’s RT² SYBR® Green qPCR Master mix and Applied Biosystems’ 7500 Fast RT-PCR 
system.  
Cloning 
The CDCA7coding region was ligated into the p3XFLAG-CMV10 mammalian expression vector 
(Sigma-Aldrich) to introduce an amino terminal FLAG epitope. Mutagenesis of p3XFLAG-
CMV10-CDCA7 was performed using the QuikChange kit (Stratagene) and NEB Q5 Site Directed 
Mutagenesis Kit (E0554), and the various mutations were sequence-verified. Amino-terminal and 
internal deletions were created by introducing silent mutations coding for unique restriction sites, 
followed by digestion and re-ligation.  Carboxyl terminal deletions were created by introducing 
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stop codons.  All deletions were sequence verified. CDCA7 containing the 14-3-3-binding R18-
peptide PHCVPRDLSWLDLEANMCLP or the control non-14-3-3-binding peptide 
PHCVPRDLSWLKLKANMCLP were created by ligating a double-stranded oligonucleotide to 
replace amino acids 139-164 of CDCA7 in the 3XFLAG-CMV10 vector.  
Cell Lysis, Immunoprecipitation, and Immunoblotting 
Cells were lysed in either RIPA lysis buffer (10mM NaPO4, pH 7.6, 150mMNaCl, 5mM EDTA, 
0.1% sodium dodecyl sulphate, 0.25% deoxycholic acid, 1% triton X-100, plus protease (Roche 
#88666) and phosphatase inhibitors (Roche #88667) or Triton X-100 lysis buffer (50mMHepes, 
pH 7.9, 250mMNaCl, 0.1% Triton X-100, 10% glycerol, plus protease and phosphatase inhibitors). 
Ten l of anti-FLAG M2 agarose conjugated beads (Sigma Aldrich) were added to lysates and 
incubated overnight at 4°C. The beads were washed five times with lysis buffer, and proteins were 
eluted with 200 l of sodium dodecyl sulfate sample buffer and heated to 99°C for 5 min. Portions 
of the lysates prior to immunoprecipitation were also reserved and boiled with sodium dodecyl 
sulfate-containing sample buffer. Lysates and immunoprecipitations were fractionated by SDS-
PAGE, transferred to a PVDF membrane, blocked in Odyssey blocking buffer (Mandel, LIC-927-
40100), and probed with the appropriate antibody overnight at room temperature. Primary 
antibodies were decorated with IR700 anti-mouse or rabbit and/or IR800 anti-mouse, rabbit or rat 
secondary antibodies (Li-Cor Biosciences) for 3 hours at room temperature and visualized using 
the infrared laser scanning (Odyssey, Li-Cor Biosciences).  
Microscopy 
Rat1, NIH3T3 or HEK 293cells were plated at 80% confluency on no. 1 glass coverslips. 
Following the desired treatment, the coverslips were washed twice in PBS and then fixed and 
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permeabilized in 3:1 methanol:acetic acid for 25 minutes. The coverslips were then washed three 
times in PBS followed by blocking in 1% BSA in PBS. Primary antibodies at varying 
concentrations were applied for 1.5 hours in a humidified chamber at room temperature.  
Coverslips were washed three times in PBS prior to applying secondary antibodies for 2 hours in 
a humidified chamber at room temperature and in the dark. The slips were washed three times in 
PBS before mounting with Invitrogen’s ProLong Gold antifade reagent with DAPI. The slides 
were viewed on an Olympus microscope and images were taken via a QImaging 2000R camera 
and Q-Capture pro software.  
XTT Proliferation Assay 
Cells were plated at 2000 cells/well in triplicate within a 96 well plate for 24-48 hours. 10 mg of 
XTT (Sigma Aldrich #X4626) was dissolved in 20 ml of PBS containing 2 ml of DMEM 
(containing 10% fetal bovine serum). A 1/10 dilution of 10 mM PMS (N-methyl dibenzopyrazine 
methyl sulfate, Sigma Aldrich #P13401) was made in the 0.5 mg/ml XTT solution. Cells were 
washed three times with 37°C PBS, followed by addition of 100 μl of the XTT/PMS solution, 
including addition to blank wells as a control. Cells are incubated for 2 hours at 37°C and 5% CO2 
and then read at 490 nm using a spectrophotometer. This is repeated every day, making an effort 
to keep all actions and volumes constant. 
Cell Synchronization and Flow analysis 
Synchronization of cells was accomplished with either 50 ng/ml Nocodazole (Sigma Aldrich 
#M1404) or 10 μM RO-3306 (Sigma Aldrich #SML0569) in DMEM containing 10% FBS for 18 
hours. Cells were then washed three times with PBS and either collected for analysis or released 
to progress through the cell cycle by add back of DMEM containing 10% FBS for a predetermined 
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length of time. Cells were collected by trypsinization, centrifuged at 2000g and washed three times 
with PBS. 70% ethanol was prechilled to -20°C and added dropwise while vortexing to 300 μl, 
and then incubated at -20°C for 20 minutes. Cells were centrifuged at 2000g for 10 minutes 
followed by decanting of supernatant. Cells were resuspended by vortexing in 350 μl of PBS 
containing 500 μg/ml RNase A (ThermoFisher #12091021) and 40 μg/ml propidium iodide 
(ThermoFisher #P3566) and incubated at 37°C for 30 minutes. Counter staining with α-FLAG M2 
(1/1000) and α-pT163 (1/1000) antibodies was performed prior to propidium iodide staining and 
followed immediately by staining with IR700 anti-mouse or rabbit and/or IR800 anti-mouse or 
rabbit secondary antibodies (As per Cell Signalling Technology 
https://www.cellsignal.com/contents/resources-protocols/flow-cytometry-protocol-(flow)/flow). 
Data was gathered with the BDFacscalibur system coupled with BD CellQuest Pro software and 
analyzed with ModFit LT. 
Reporter Assay 
The MYC and D1 promoters were cloned into vectors supplied by Promega (#E6661) and 
transfected into HEK293 and Rat1 cells. 24 hour-48 hours cells were collected and processed 
through Promega’s Luciferase Assay System (#E4030) as per the supplied protocol.  
ChIP 
Genomic DNA was isolated from Rat1 cells stably expressing Myc and variants of CDCA7 using 
Millipore EX-ChIP (#17-371) and used as sample for immunoprecipitations as per manufacture’s 
protocols. Mouse monoclonal M2 anti-flag (Sigma Aldrich #A2220), 9E10 mouse monoclonal 
anti-MYC (Santa Cruz #SC-40) and anti-RNA polII (Abcam #ab26721) were used for 
immunoprecipitation from sheared genomic DNA samples. 
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Chapter 5: Concluding Discussion and Future Directions 
 
Discussion 
 
At the onset of this research project, our goal was to learn as much as we could about CDCA7 and 
how it may be involved in processes mediated by the transcription factor Myc. We were optimistic 
in this regard because prior to our investigation others had shown that JPO2, a protein closely 
related to CDCA7, directly interacts with Myc (Huang et al., 2005) and has DNA binding abilities 
(Goto et al., 2006). To that end, our initial bioinformatic analysis indicated that CDCA7 may be a 
target of Akt phosphorylation at T163 and may associate with 14-3-3. This piqued our interest 
because our lab was uniquely positioned to investigate 14-3-3 and the PI3K pathway as this was 
the subject of previous projects produced by our group (Matitau and Scheid, 2008; Moon et al., 
2008; Sephton et al., 2009). Of particular interest was the possibility that CDCA7 may be involved 
in Myc-mediated apoptosis because it had been shown that activation of the PI3K pathway could 
suppress Myc-mediated apoptosis upon serum withdrawal (Kauffmann-Zeh et al., 1997). 
Therefore, if CDCA7 was in fact a target of Akt and did associate with Myc, we might be able to 
shed some light on the paradox of Myc-mediated apoptosis. The specifics behind the dual signal 
model of Myc function has evaded researchers since Evan and colleagues first described this 
paradox in 1992. The model proposes that Myc drives proliferation while simultaneously priming 
cells for apoptosis. Cell death is kept at bay in the presence of growth factors, which promotes 
survival via the PI3K pathway among others. Upon growth factor withdrawal, the priming of 
apoptosis is realized and cell death is initiated (Evan et al., 1992). Investigating if and how CDCA7 
is implicated in this model would be the foundation of this research project (chapter II), which 
would ultimately bifurcate into many unexpected lines of questioning (chapters III and IV).  
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Our publication in 2013 confirmed that CDCA7 associated with Myc and was in fact 
phosphorylated by Akt to regulate Myc-dependent apoptosis and tumorigenesis (Gill et al., 2013). 
Phosphorylation of T163 by Akt results in binding of 14-3-3 and masking of a nuclear localization 
signal, thus sequestering CDCA7 in the cytoplasm and away from nuclear-Myc. Although this 
model affords us a general and valuable understanding of CDCA7 on a molecular level, it does not 
explain how CDCA7’s relationship with Myc can affect apoptosis or tumorigenesis. The data 
presented in chapter IV attempts to elucidate these unknown mechanisms. We have added the 
following to our understanding of CDCA7 and its relationship to Myc: CDCA7 potentiates the 
activation of an E-box element, enhances Myc’s occupancy of the BAX promoter and can enhance 
or repress Myc target gene expression. These results suggest that CDCA7 confers DNA binding 
specificity or selectivity to Myc and can drive the expression of genes involved in apoptosis. We 
have for the first time not only implicated CDCA7 in Myc-dependent apoptosis, but we have 
revealed the means by which CDCA7 sensitizes cells to apoptosis in the absence of growth factors. 
CDCA7 is therefore a prime candidate for being involved in the dual signal model of Myc function 
proposed by Evan in 1992. According to this model, Myc would drive proliferation in the presence 
of growth factors, which has the effect of stimulating the PI3K pathway. Subsequent activation of 
Akt would result in phosphorylation of CDCA7 at T163, 14-3-3 binding and sequestering of 
CDCA7 in the cytoplasm. In its 14-3-3 bound state, CDCA7 would be prevented from interacting 
with Myc and therefore decrease Myc driven expression of BAX by reducing occupancy at the 
BAX promoter. Withdrawal of serum would result in a reduction of CDCA7 phosphorylation at 
T163, dissociation from 14-3-3 and shuttling to the nucleus where CDCA7 and Myc can cooperate 
to express proapoptotic genes such as BAX. This hypothesis is strengthened by the fact that the 
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T163A CDCA7 mutant cannot be phosphorylated, does not bind 14-3-3, is primarily nuclear and 
sensitizes cells to apoptosis greater than WT CDCA7.  
In addition to affecting Myc-dependent apoptosis, our research indicates that CDCA7 may also 
influence cell cycle progression and proliferation rates. As with apoptosis, CDCA7’s influence on 
these processes might be a product of targeted gene expression. We have shown that expression of 
CDCA7 results in an increase of cells in G2/M phase. This shift is further exaggerated by 
coexpression of CDCA7 and Myc while being abolished with the expression of the non-Myc 
binding mutant ∆(156-187) CDCA7. This cell cycle profile may be a result of the simultaneous 
increase in Cyclin B1 mRNA and decrease in p15INK4B mRNA levels upon expression of CDCA7. 
Expression of Cyclin B1 is known to be required for chromatin condensation during mitosis while 
the CDK inhibitor p15INK4B promotes arrest in G1 (Sciortino et al., 2001; Chang et al., 2003; 
Carneo and Hannon, 1998). It is important to note that Cyclin B1 is a confirmed target of Myc 
transactivation, while p15INK4B is known to be actively repressed by Myc (Menssen and 
Hermeking, 2002; Wiese et al., 2013). It is possible that expression of CDCA7 is shifting cell cycle 
distribution towards G2/M by influencing Myc’s role in the expression of Cyclin B1 and p15INK4B. 
This is supported by the fact that the non Myc binding mutant ∆(156-187) CDCA7 is insulated 
from changes in cell cycle distribution. What remains unknown is if and how this mutant affects 
the expression of Cyclin B1 and p15INK4B. While it is possible that the cell cycle distribution seen 
here is a product of the up and down regulation of Cyclin B1 and p15INK4B respectively, the inverse 
may also be true. The mRNA profiles of these two genes may simply be a product of cells 
predominantly occupying G2/M. If the latter is the case, then CDCA7 is still likely to be 
responsible for the change in cell cycle distribution upon its expression. Careful consideration 
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should be placed into selecting other possible Myc target genes which are involved in G2/M 
transition and assay them for changes in expression. 
We have shown that phosphorylation of CDCA7 at T163 is a critical event in regulating its 
subcellular localization and availability to Myc. This knowledge extends from our research 
published in 2013, which probed the nature of T163 phosphorylation in asynchronous cells treated 
by various means which activate the PI3K pathway. In chapter IV of this thesis, we relied on the 
synchronization of cells by either nocodazole or RO-3306 in G2/M phase as a means of not only 
studying cell cycle progression but to accentuate various effects of CDCA7 expression. This 
broadened the scope of our knowledge regarding the spatial and temporal nature of T163 
phosphorylation. Using flow cytometry after synchronization in G2/M, we have established that 
CDCA7 is phosphorylated at T163 exclusively in G2/M. We have also established that phospho-
T163 CDCA7 colocalizes with the centrosomal protein marker γ-Tubulin and activated Akt 
(phospho-S473) to produce a pronounced punctate topography. This colocalization is presumably 
in the vicinity of centrosomes. The spatial and temporal nature of T163 phosphorylation should be 
of interest to those studying immunodeficiency-centromeric-instability-facial anomalies syndrome 
(ICF). Thijssen, Wu and colleagues have recently identified four mutations within CDCA7’s C-
terminal zinc finger as being directly correlated with ICF (Thijssen et al., 2015; Wu et al., 2016). 
Molecular hallmarks of ICF include hypomethylation of juxtacentromeric DNA which can result 
in chromosomal abnormalities in interphase as well as mitotic missegregation leading to 
chromosomal instability (CIN) (Tuck-Muller et al., 2000; Gisselsson et al., 2005). It is well known 
that CIN can be a result of improper mitotic spindle formation arising from centrosome 
dysfunction, improper centrosomal biogenesis or abnormal centrosome number (Vitre and 
Cleveland, 2012). The fact that phosphorylation of CDCA7 at T163 occurs during mitosis and 
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within the vicinity of centrosomes may warrant further investigation as it pertains to CIN and ICF. 
It is also worth noting that centromeric aberrations and CIN are indicative of various types of 
cancer, including chronic myeloid leukemia (CML) which Osthus and colleagues identified as 
harboring elevated CDCA7 mRNA levels (Giehl et al., 2005; Osthus et al., 2005). Finally, Nam 
and colleagues have recently shown that activation of the PI3K-Akt pathway via oncogenic 
hepatocyte growth factor receptor signaling induces centrosome amplification and CIN (Nam et 
al., 2010). These data points suggest that CDCA7 may play a role in disease development which 
extends beyond the reach of Myc’s influence.  
Chapter III of this thesis focused on dissecting the details behind CDCA7 co-association. Using a 
complement of experiments including co-immunoprecipitations of endogenous and ectopic protein 
as well as BioID, we have identified that CDCA7 co-associates at amino acids 187-234. We have 
also investigated the possibility that CDCA7 contains a second 14-3-3 binding site which may be 
involved in mediating co-association of CDCA7. Bioinformatics suggest that four phospho-
serine/threonine residues within proximity of the CDCA7 co-association domain (a.a.187-234) 
conform to predicted 14-3-3 binding sites. These residues are S185, T213, S231 and T234 
(Madeira et al., 2015). Sequence alignment of human CDCA7 with Branchiostoma belcheri or 
Ciona intestinalis reveals that 3 of the 4 predicted sites are in fact conserved and may lend credence 
to the lynchpin hypothesis of 14-3-3 binding. The theory proposes that the conservation of one of 
the phospho-serine/threonine binding sites (the lynchpin residue) allowed the second residue to 
evolve and perhaps become the target of a novel kinase (Johnson et al., 2011). The data outlined 
in chapter III identifies T213 as a potential second 14-3-3 binding site, as mutation of threonine 
213 to alanine resulted in approximately 20% less 14-3-3 co-immunoprecipitating with CDCA7. 
Deletion of the a.a. 187-224 region (inclusive of T213) resulted in approximately 80% less 14-3-
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3- binding and CDCA7 co-association. However, the T213A point mutation’s effect on co-
association is currently unknown and needs to be assayed. At present, we are certain that CDCA7 
co-associates either via a larger complex or perhaps directly via protein-protein interactions 
between monomers of CDCA7. What role CDCA7 co-association or dimerization may play in its 
function or regulation thereof remains a mystery. However, this should not be overlooked as there 
is precedent for Akt mediated homodimerization in regulating the function of proteins (Kolliputi 
and Waxman, 2009; Han et al., 2013).  
In chapter I, we identified seven research objectives that served as a framework for our 
investigation into CDCA7. We have successfully addressed these objectives, and in doing so raised 
new questions based on our broadened understanding of CDAC7. The following is a summary of 
those objectives and our findings: 
Research Objective 1 - Investigate Consensus Sites within CDCA7’s Amino Acid Sequence 
We have confirmed the existence of an Akt phosphorylation site, 14-3-3 binding site and nuclear 
localization signal within CDCA7.  
Research Objective 2 - Does CDCA7 Interact with the Oncogene Myc? 
CDCA7 interacts with Myc at a.a. 156-187 in CDCA7. 
Research Objective 3 - Map the Subcellular Localization of CDCA7 
CDCA7 subcellular localization is dynamic and depends on T163 phosphorylation and 14-3-3 
binding. Phosphorylation of CDCA7 at T163 enforces 14-3-3 binding, masking of the nuclear 
localization signal and results in cytoplasmic sequestration of CDCA7. 
Research Objective 4 - How Does CDCA7 Affect Apoptosis and Proliferation? 
CDCA7 potentiates Myc dependent apoptosis and reduces proliferation rates.  
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Research Objective 5 - Does CDCA7 Exist as a Monomer or a Homodimer? 
CDCA7 has the ability to co-associate either via larger complexes containing other proteins or 
directly via protein-protein interactions between monomers. 
Research Objective 6 - How Does CDCA7 Affect Gene Expression? 
CDCA7 activates an E-box promoter in a Myc-binding dependent manner. CDCA7 can enhance 
or repress the expression of Myc target genes and increases Myc occupancy at the BAX promoter. 
Research Objective 7 - How Does CDCA7 Affect the Cell Cycle? 
CDCA7 causes cells to shift towards G2/M phase and phosphorylation of CDCA7 at T163 was 
observed exclusively in G2/M. Finally, phosphorylation of CDCA7 at T163 was observed in 
mitotic cells, colocalized with the centrosomal marker protein γ-Tubulin and activated Akt 
(phospho-S473) near centrosomes.  
 
The research outlined in this thesis solidifies CDCA7 as an important node in PI3K pathway 
convergence on Myc-mediated apoptosis and tumorigenesis. CDCA7 functions by influencing 
Myc target gene expression and has the ability to influence the cell cycle, albeit by an unknown 
mechanism. Figure 5.1 summarizes our findings and outlines our current understanding of 
CDCA7’s involvement in the dual-signalling model of Myc dependent apoptosis It is our hope that 
the data presented here will serve those who continue to research CDCA7 and diseases such as 
cancer and immunodeficiency-centromeric-instability-facial anomalies syndrome.  
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Figure 5.1. Hypothetical model of CDCA7’s contribution to the dual signal model of Myc 
mediated apoptosis. In the presence of growth factors, such as the tissue culture media 
supplemented with serum, receptor tyrosine kinases initiate the activation of the PI3K/Akt 
pathway. This allows activated Akt to phosphorylate CDCA7 in the nucleus, resulting in the 
disassociation of CDCA7 from Myc, binding of 14-3-3 at pT163 and subsequent localization to 
the cytoplasm. This event results in Myc’s inability to drive the transactivation of the pro-apoptotic 
BAX gene, and therefore proliferation in favored. CDCA7 and 14-3-3 are both depicted as 
monomers for simplicity. 
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Future Directions 
 
The following is a list of unanswered questions and future directions which will aid in 
understanding the function and regulation of CDCA7: 
1.  CDCA7 and regulation of Myc-target genes – we have presented a limited scope of CDCA7’s 
influence on Myc target genes. We opted to probe Myc target genes which are known to be 
involved in apoptosis and proliferation. The results we obtained were satisfactory, however 
employing high throughput qPCR arrays on a large number of Myc target genes would be far more 
informative. This data could subsequently be used to select promoters for ChIP analysis. Finally, 
qPCR and ChIP should be performed using various mutants of CDCA7 not included in this study. 
These include the co-association mutant ∆(187-234) CDCA7 and the proapoptotic T163A CDCA7 
mutant.  
2. Is CDCA7 co-association direct or via a complex? Direct protein-protein interactions between 
monomers of CDCA7 can be assayed in vitro using purified proteins either from a bacterial or 
mammalian host. Although we have attempted this strategy, quantities of purified proteins must 
be substantially improved before one can draw any conclusions. 
3. What causes CDCA7 to shift cells towards G2/M? Our study has revealed that CDCA7 causes 
a shift towards G2/M phase, while upregulating expression of Cyclin B1 and downregulating 
expression of p15INK4B. What remains unknown is whether this mRNA profile causes the reported 
change in cell cycle distribution or is simply a product as such. Investigating means by which 
CDCA7 affects the cell cycle could prove to be important as deregulated cell cycle progression is 
a common theme in cancer onset and progression. 
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4. Use BioID to identify novel binding partners of CDCA7 – We have successfully employed 
BioID as a means of assaying association of CDCA7 monomers. It would be tremendously 
valuable to employ this technique in conjunction with mass spectrometry to identify novel binding 
partners of CDCA7. The initial stages of this investigation have begun in our lab, and will continue 
to be a focus going forward. 
5. Investigate the CDCA7 mutations reported in immunodeficiency-centromeric-instability-facial 
anomalies syndrome (ICF) – Thijssen and colleagues have identified 4 homozygous variants of 
CDCA7 in ICF patients, each containing missense mutations within the c-terminal z-finger 
domain. These include R274C, R274H, G294V and R304H (Thijssen et al., 2015). It would be 
prudent of us to generate these mutations in and test their affect on various properties of CDCA7 
including but not limited to: T163 phosphorylation, DNA binding ability, subcellular localization, 
apoptosis and proliferation. It would also be of interest to obtain ICF B-cells that are commonly 
used when investigating ICF and to use these a model for experiments focusing on ICF. 
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